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Pancreatic neuroendocrine neoplasms (PNENs) are biologically and clinically 
heterogeneous neoplasms in which pathogenic alterations are often indiscernible. 
Treatments for PNENs are insufficient in part due to lack of alternatives once current 
options are exhausted. Despite previous efforts to characterize PNENs at the molecular 
level, there remains a lack of molecular subgroups and molecular features with clinical 
utility for PNENs. In this work, I describe the identification and characterization of four 
molecularly distinct subgroups from primary PNEN specimens using whole-exome 
sequencing, RNA-sequencing and global proteome profiling. A Proliferative subgroup 
with molecular features of proliferating cells was associated with an inferior overall 
survival probability. A PDX1-high subgroup consisted of PNENs demonstrating genetic 
and transcriptomic indications of NRAS or HRAS activation. An Alpha cell-like subgroup, 
enriched in PNENs with deleterious MEN1 and DAXX mutations, bore transcriptomic 
similarity to pancreatic α-cells and harbored proteomic cues of dysregulated metabolism 
involving glutamine and arginine. Lastly, a Stromal/Mesenchymal subgroup exhibited 
increased expression and activation of the Hippo signaling pathway effectors YAP1 and 
WWTR1 that are of emerging interest as potentially actionable targets in other cancer 
types. Whole-genome and whole-transcriptome analysis of PNEN metastases identified 
novel molecular events likely contributing to pathogenesis, including one case 
presumably driven by MYCN amplification. In agreement with the findings in primary 
PNENs, four of the metastatic PNENs displayed a substantial Alpha cell-like subgroup 
signature and all harboured concurrent mutations in MEN1 and DAXX. Collectively, the 
identified subgroups present a potential stratification scheme that facilitates the 
identification of therapeutic vulnerabilities amidst PNEN heterogeneity to improve the 
effective management of PNENs. 
Keywords:  pancreatic neuroendocrine neoplasms; whole-genome sequencing; 
whole-exome sequencing; RNA-sequencing; proteomic profiling 
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Chapter 1.  
 
Introduction to pancreatic neuroendocrine 
neoplasms 
Neuroendocrine neoplasms (NENs) are a group of rare but heterogeneous 
tumours arising from neuroendocrine cells that can be found within dedicated endocrine 
tissues and diffusely throughout the body (Oronsky et al., 2017). The endocrine 
compartment of the pancreas, the islets of Langerhans, (Figure 1.1) is an example of 
dedicated endocrine tissue from which pancreatic NENs (PNENs) can arise. The history 
of NENs began in the mid-to-late 19th century with the repeated post-mortem 
observations of atypical masses in the small intestine. In contrast to the aggressive 
behaviours typically seen with carcinomas, these masses had no or low-grade invasion 
into the surrounding tissues and were referred to as “benign carcinomas” by the German 
physician and pathologist Siegfried Oberndorfer (Modlin et al., 2004). These “benign 
carcinomas” were rarely observed, and as such the indications and characteristics of 
these tumours remained cryptic until an entity-defining publication by Oberndorfer in 
1907 (Modlin et al., 2004). In his seminal paper, Oberndorfer proposed that these rare 
growths belong to a novel disease entity and coined the term “karzinoide”, now referred 
to as carcinoid, to describe their “carcinoma-like” characteristics while distinguishing 
them from the classical carcinomas with highly aggressive clinical behaviours (Modlin et 
al., 2004; Oberndorfer, 1907). Nearly a decade later, it was found that carcinoid tumours 
shared biochemical properties with a neuroendocrine cell type in the small intestine, 
specifically in their ability to reduce silver salts (ie. argentaffin). This similarity suggested 
neuroendocrine cells as the likely cells-of-origin of carcinoid tumours (Modlin et al., 
2004) and marked the first evidence supporting the probable neuroendocrine origin of 
carcinoid tumours. 
Subsequent to the discoveries of small intestinal carcinoid tumours, tumours of 
similar clinical and biochemical behaviours were observed in other organs such as the 
stomach and pancreas (Feyrter, 1938). It is now recognized that tumours can originate 
from neuroendocrine cells found throughout the body (Oronsky et al., 2017). Despite 
their rather short history since discovery, the terminologies for these neuroendocrine 
2 
cell-derived neoplasms have gone through considerable modifications. For the purpose 
of this thesis, they are generically referred to as NENs, which include any neoplasms 
with neuroendocrine differentiation. 
 
Figure 1.1. The exocrine and endocrine components of the pancreas. 
The pancreas consists of an exocrine component, acinar and duct cells, and an endocrine 
component, islets. The islets are scattered throughout the pancreas and are clusters of different 
cell types that secrete various hormones for maintaining body homeostasis. The image was 
adapted from the original work by OpenStax College, obtained from the public domain Wikimedia 
(under the license CC BY 3.0). 
Among NENs of different primary sites, those arising from the gastrointestinal 
(GI) tract and the pancreas were typically combined in earlier studies and referred to as 
gastroenteropancreatic NENs (GEP-NENs) due to the anatomical proximity and similar 
cells of origins of these organs (Modlin et al., 2008). However, it was later recognized 
that PNENs differed from extrapancreatic NENs in their responses to therapies (Kulke et 
3 
al., 2011), warranting separate assessments and considerations for PNENs (Kunz, 
2015). Since PNENs have been analyzed separately from other NENs in the last decade 
only, studies focusing solely on PNENs have been limited; many of the early studies 
included PNENs as part of a study on NENs of all sites or GEP-NENs. Our knowledge of 
PNENs has therefore lagged and there is a dire need for the clinical, biological, and the 
integrated understanding of this under-studied disease to facilitate clinical management 
of PNENs. In this chapter, an abundance of background information referenced and 
introduced relates to NENs in general or GEP-NENs. Where applicable, studies or 
results specific to PNENs are indicated. 
1.1. Incidence and prevalence of PNENs 
NENs are considered rare neoplasms accounting for ~1.5% of new cancer 
diagnoses, but the annual incidence of NENs increased 6.4-fold while the incidence of 
all malignancies remained stable between 1973 and 2012 (Dasari et al., 2017). This 
rising NEN incidence has largely been due to expanded availability of advanced imaging 
technologies and has led to increased diagnosis of early-stage diseases, suggesting the 
prevalence of NENs is higher than originally expected despite their low incidence (Dasari 
et al., 2017; Hallet et al., 2015). Indisputably, due to their typically slow-growing nature, 
the prevalence of NENs has exceeded those of esophageal, gastric, pancreatic and 
hepatobiliary cancers (Yao et al., 2008). For PNENs, the annual incidence increased 
substantially from less than 0.2 to 0.84 per 100,000 individuals in the United States 
between 1973~2012 (Dasari et al., 2017) and from 0.1 to 0.6 per 100,000 individuals in 
Canada (Ontario) between 1994~2009 (Hallet et al., 2015). The proportion of metastatic 
disease among new diagnoses, however, decreased during the period while more 
patients presented with localized disease, supporting the hypothesis that increased 
detection of early-stage disease is leading to higher incidence (Dasari et al., 2017; Hallet 
et al., 2015). 
1.2. Evolution of cancer classification in PNENs 
A cancer classification system not only divides a cancer type into classes based 
on similar presentations and anatomical locations but also aids in providing prognostic 
and therapeutic implications for a given class to facilitate clinical management (Carbone, 
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2020). Our initial paucity and recent exponential gain of knowledge of PNENs is perhaps 
best represented by the numerous attempts to devise a classification system, initially for 
NENs and more recently for PNENs specifically, over the course of the past 6 decades. 
 Classification of NENs based on embryological origin 
Establishment of a cancer classification system relies on, and is built upon, prior 
clinical observations and evidence, which were seemingly lacking during the early years 
following the first recognition of NENs. The first classification system for NENs was 
proposed by Williams and Sandler in 1963, 56 years after Oberndorfer coined the term 
“karzinoide” (Modlin et al., 2004). In their paper, Williams and Sandler suggested that 
NENs could be grouped based on the embryological origin of the organ from which a 
NEN arose from. This stratified NENs into foregut, midgut and hindgut NENs (Figure 
1.2). Their recommendation was based on the observations that NENs could vary in 
histological structures, frequency of cells being argentaffin, secretion of 5-
hydroxytryptophan (5-HTP) and accompanying carcinoid syndrome in patients (Williams 
and Sandler, 1963). Formulated on the combination of these characteristics, NENs 
arising from the foregut (eg. bronchus, stomach and pancreas), midgut (eg. mid-
duodenum, cecum and mid-transverse colon), or hindgut (eg. descending colon and 
rectum) were found more similar to those arising from organs of the same embryological 
origin than those that differed (Williams and Sandler, 1963). Although this classification 
system is now considered superficial, it was a pioneering effort to classify NENs based 
on histopathology, which remains the foundation for the current NEN classification 
system established by the World Health Organization (WHO). 
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Figure 1.2. Embryological classification of NENs. 
The carcinoid tumours first identified by Siegfried Oberdorfer in 1907 in the small intestine were 
subsequently found in other organs and later classified by Williams and Sandler in 1963 based on 
embryological origins. The foregut, midgut and hindgut carcinoid tumours were found to differ in 
frequencies of being argentaffin, accompanying carcinoid syndrome and 5-HTP and histological 
presentations. Note that a recent study identified a greater proportion of small intestinal NENs 
with carcinoid syndrome compared to NENs of the lungs or other primary sites (Halperin et al., 
2017). Image of the gut was adapted from the original work by Mikael Häggström, obtained from 
the public domain Wikimedia Human body diagrams (under the license CC0). 
 Earlier editions of the WHO classification of PNENs 
The WHO classification system is currently the only clinically relevant and 
standardized classification for PNENs. Its antecedent, the International Histological 
Classification of Tumours (IHCT), commenced in 1967 and primarily relied on 
histological examinations (Sobin, 1981) which later incorporated immunohistochemical 
(IHC) assessments in the subsequent edition (Sobin, 1989). The first and second 
editions of IHCT on GI cancer were published in 1976 and 1990, respectively. The later 
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edition improved on a few key cancer types, including GEP-NENs (still referred to as 
carcinoids at the time) for which the IHC assessments of hormones (eg. gastrin, 
somatostatin, pancreatic polypeptides) superseded the traditional silver staining in 
subclassifying GEP-NENs (Jass et al., 1990) (Table 1.1). 
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Confined to pancreas 
No perineural invasion 
No angioinvasion 
< 2 cm in diameter 
< 2 mitotic rateb or < 2% Ki67 
 
Uncertain Behaviour 
Confined to pancreas 
At least one of: perineural invasion, angioinvasion, > 
2cm in diameter, 2-10 mitotic rate or > 2% Ki67 
 
WDEC 
Local invasion and/or metastases 
PDEC 






< 2 mitotic rate 
or  
≤ 2% Ki67 
NET-G2 




> 20 mitotic rate 
or 
> 20% Ki67 
LC or SC 
MANEC 






< 2 mitotic rate 
or 
< 3% Ki67 
NET-G2 




> 20 mitotic rate 
or 
> 20% Ki67 
NEC 
LC or SC type 
MiNEN 
≥ 30% are 
NE cells 
aThe hyperplasia/dysplasia class from the WHO 2010 classification referred to pre-neoplastic lesions and is excluded 
from this table. bMitotic rate: number of mitotic cells / 10 high power fields. IHC: immunohistochemistry, NE: 
neuroendocrine, NEN: NE neoplasm, NEC: NE carcinoma, NET: NE tumour, GEP-NEN: gastroenteropancreatic NEN, 
PNEN: pancreatic NEN, MANEC: mixed adeno-neuroendocrine carcinoma, MiNEN: mixed neuroendocrine-
nonneuroendocrine neoplasm, WDET: well-differentiated endocrine tumour, WDEC: well-differentiated endocrine 
carcinoma, PDEC: poorly-differentiated endocrine carcinoma, LC: large cell, SC: small cell, WHO: World Health 
Organization. 
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Ten years later, the WHO Classification of Tumours project replaced and 
continued the mission of the IHCT in standardizing cancer classifications based on 
histopathology with the addition of molecular genetics to facilitate clinical management 
(Kleihues and Sobin, 2000). This refreshed classification system also included the first 
WHO classification section dedicated to PNENs (published in 2004). The 2000/2004 
WHO classification system proposed to classify PNENs based on histological 
differences, prognostic markers and stage of the disease into three groups: well-
differentiated endocrine tumour (WDET), well-differentiated endocrine carcinoma 
(WDEC) and poorly-differentiated endocrine carcinoma (PDEC); this classification was 
similarly proposed for other GEP-NENs. For PNENs, WDETs were those confined to the 
pancreas and were further subclassified into benign or tumours of uncertain behaviour 
based on size, proliferative potential, and presence of vascular and perineural invasions. 
WDECs were NENs with evidence of gross local invasion and/or metastases, while 
PDECs were those of poorly-differentiated histology and high proliferative potential 
(Heitz et al., 2004) (Table 1.1). The criteria implemented in this system, however, 
overlapped largely with cancer staging (eg. local invasion and distant metastasis), and 
the intrinsic ambiguities associated with WDETs of uncertain behaviour could potentially 
lead to confusions between clinicians and pathologists. Updates to the WHO 
classification for GEP-NENs were therefore proposed to address these concerns (Rindi 
et al., 2014). 
In 2010, a new edition of the WHO classification for GEP-NENs was published 
and similarly implemented the histological differentiation and proliferative potential 
criteria of its predecessor. However, it also proposed major rectifications, including the 
use of “neuroendocrine” instead of “endocrine” to better reflect the biological nature of 
NENs. Therein, GEP-NENs were grouped into five classes: 1) neuroendocrine tumour 
(NET)-G1, 2) NET-G2, 3) neuroendocrine carcinoma (NEC)-G3, 4) mixed adeno-
neuroendocrine carcinoma (MANEC), and 5) hyperplastic/dysplastic neoplasm. The term 
“carcinoma” implies poorly-differentiated histology and NECs may be of small cell or 
large cell type (Rindi et al., 2010). The term “NENs” was used as a generic term to refer 
to both NETs and NECs, and this usage is adopted throughout this thesis. 
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Among the five classes, NET-G1/2 and NEC-G3 were defined according to 
proliferative potential (based on Ki67 or mitotic index), while MANEC and 
hyperplastic/dysplastic neoplasm (Rindi and Solcia, 2007) were defined based on 
histological and morphological assessments (Table 1.1). The grading-based grouping of 
the first three classes proved to be prognostically significant, however, it was later 
determined inadequate due to a Ki67 categorization gap between NET-G1 (≤ 2% Ki67 
index) and NET-G2 (3–20% Ki67 index) and the assumption that all NECs-G3 were 
poorly-differentiated and with high proliferative potential (Rindi et al., 2014). These 
limitation and assumption were particularly evident for NENs in the pancreas, where the 
histological differentiation status is highly correlated with responses to different therapies 
(Inzani et al., 2018). 
 Current classification system 
Subsequently in 2017, the WHO classification was updated for PNENs to include 
a NET-G3 class to accommodate well-differentiated PNENs (ie. PNETs) with a 
proliferative potential greater than the G2 range. The grading threshold of NET-G1 was 
also increased from ≤ 2 to < 3% Ki67 index (Lloyd et al., 2017). In addition, the updates 
in the 2017 classification system included removal of the hyperplastic/dysplastic class 
and redefinition of MANEC into mixed non-neuroendocrine-neuroendocrine neoplasm 
(MiNEN) that encompasses NENs with substantial neuroendocrine and non-
neuroendocrine components (Table 1.1). 
At the time of writing this thesis, the release of the new edition of the WHO 
Classification of Tumours series has commenced, with the first volume published in 
2019 covering cancers of the GI tract including GEP-NENs. In this most up-to-date 
version, GEP-NENs are classified similar to the 2017 WHO classification for PNENs, 
and no specific changes were proposed for PNENs. This 2017/2019 WHO classification 
of PNENs has been widely adapted, and the works that will be introduced in the 
subsequent chapters of this thesis are based on the criteria and terminologies of this 
updated classification system. That is, PNENs are divided based on their histological 
differentiation into well-differentiated PNETs and poorly-differentiated PNECs, where 
PNETs may be further classified into G1-3 based on proliferative potential and PNECs 
may be of small-cell type (PNEC-SC) or large-cell type (PNEC-LC) (Table 1.1). 
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 Cancer staging system 
In addition to the WHO classification, it is worth mentioning that PNENs are 
TNM-staged like other cancer types as of 2009 using the American Joint Committee on 
Cancer (AJCC) 7th edition staging system (Kulke et al., 2010a). The TNM staging 
describes the size (T), and evidence of local spread (N) and distant metastasis (M) of 
any given tumour to aid with its clinical management. This TNM staging system is used 
complementarily to the WHO classification system for clinical management. 
1.3. Clinical heterogeneity 
A major hurdle in the management of PNENs is clinical heterogeneity, where 
patients present with a wide spectrum of clinical manifestations and the neoplasms have 
variable characteristics and responses to therapies. Although NENs were initially 
described as “benign carcinoma” due to their usually indolent clinical nature, disease-
related mortality has become evident, especially in patients with PNENs diagnosed in a 
metastatic setting or eventually becoming metastatic (Hallet et al., 2015; Niederle et al., 
2010). Indeed, patients with PNENs have among the shortest median overall survival 
time (3.6 years) compared to patients with NENs in general (9.3 years), but the 5-year 
overall survival probabilities for patients with PNENs have been reported to range from 
26% to 100% depending on various clinical phenotypes (Halfdanarson et al., 2008; Yao 
et al., 2008). Variables such as the spread of the disease at the time of diagnosis, the 
spectrum of symptoms patients present with, the underlying hereditary cancer 
syndromes leading to predisposition of PNENs and the variable responses to treatments 
all contribute to the often unpredictable disease prognosis and behaviours of PNENs. 
 Functional vs nonfunctional PNENs 
PNENs can be clinically defined as functional or nonfunctional, which is 
independent from their WHO classification designation. Functional PNENs are found in 
patients presenting with hormonal syndromes resulting from the hypersecretion of one or 
more amines or peptides by the neoplasms. In comparison, nonfunctional PNENs do not 
result in specific hormonal syndromes and are more clinically silent but account for the 
majority of PNEN incidences (Halfdanarson et al., 2008) (Table 1.2). Functional PNENs 
are named according to the hormone they secrete in excess, and the most common 
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functional PNENs are insulinomas and gastrinomas with hypersecretion of insulin and 
gastrin, respectively (Halfdanarson et al., 2008; Ito et al., 2012). Each of these 
hormones, when secreted in excess, leads to a particular syndrome often with 
nonspecific manifestations. For example, a patient with insulinoma may suffer from 
hypoglycemia due to excessive insulin secretion by the neoplasms (Hofland et al., 
2020a). Hypersecretion of more than one hormone in functional PNENs is rare and has 
only been observed in metastatic cases (Crona et al., 2016). 
Table 1.2. The proportional of functional vs nonfunctional PNENs in reported 
cohorts. 
 Proportion of all PNENs 
Functional PNENs  
Insulinoma 30-45% 
Gastrinoma 16-30% 
VIPoma < 10% 
Glucagonoma < 10% 
Nonfunctional PNENs 25-100% 
Data adapted from (Halfdanarson et al., 2008). The data had originally been compiled by Halfdanarson et al. from 25 
prior studies. For functional PNENs, only the four most common types are shown. VIP: vasoactive intestinal peptide. 
The indication of whether a PNEN is functional or nonfunctional is strictly defined 
within the clinical setting: nonfunctional PNENs may still be secretory, but their 
secretions do not result in clinically significant syndromes (Ito et al., 2012). This 
functional status indication is important from a clinical perspective, as the resultant 
hormonal syndrome often needs to be controlled concurrent with the anti-cancer 
regimen directed at the PNENs (Ito et al., 2012). Yet, despite functional PNENs causing 
hormonal syndromes, the prognoses of functional PNENs are typically better than 
nonfunctional PNENs (Wang et al., 2011a). For instance, patients with benign 
insulinomas have a 10-year overall survival rate of 78%, while patients with 
nonfunctional PNENs have a 5-year overall survival rate of 26-58% (Halfdanarson et al., 
2008). The reasons behind this survival difference are not entirely known but may be 
partly attributed to a greater proportions of functional PNENs (insulinomas in particular) 
being benign and most nonfunctional PNENs becoming only symptomatic and detected 
at later disease stage (Cloyd and Poultsides, 2015; Halfdanarson et al., 2008; Vinik et 
al., 2010). 
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 Hereditary cancer syndromes 
The vast majority of PNENs are sporadic, but it has been well-established that a 
few hereditary cancer syndromes can lead to predisposition of, and contribute to, up to 
10% of PNENs (de Wilde et al., 2012). These syndromes are the consequences of 
germline alterations to tumour suppressor genes menin 1 (MEN1), von Hippel-Lindau 
tumour suppressor (VHL), TSC complex subunit 1/2 (TSC1/2) and neurofibromin 1 
(NF1) that result in a multitude of hyperplastic/neoplastic growths in certain organs 
(Alexakis et al., 2004) (Table 1.3). The degrees to which PNENs contribute to the 
mortality of the patients with these hereditary cancer syndromes among various 
manifestations are not well-known, but the presence of PNENs was associated with an 
inferior survival outcome in patients with multiple endocrine neoplasia type I (MEN1) 
syndrome (Jensen et al., 2008), suggesting PNENs contribute, at least partially, to the 
mortality of patients presenting with these hereditary cancer syndromes. 
Table 1.3. Hereditary cancer syndromes leading to predisposition of PNENs. 
Hereditary cancer syndrome Affected gene Prevalence 
among population 
Frequency of PNENs 
in affected individuals 
Multiple endocrine neoplasia type I MEN1 1-10 / 100,000 60% 
Von Hippel-Lindau syndrome VHL 2-3 / 100,000 < 20% 
Neurofibromatosis type I NF1 1 / 3,000-4,000 < 10% 
Tuberous sclerosis complex TSC1/2 1 / 10,000 Rare 
Data adapted from (Alexakis et al., 2004; Ito et al., 2012; de Wilde et al., 2012). 
Multiple endocrine neoplasia type I syndrome 
MEN1 syndrome is a rare autosomal dominant condition that results from 
germline alterations in the MEN1 gene and is characterized by hyperplastic/neoplastic 
growths in the parathyroid, enteropancreatic tissues and pituitary. PNENs are evident in 
more than 60% of MEN1 patients. And similar to sporadic PNENs, MEN1-associated 
PNENs may be functional or nonfunctional, with the latter constituting the majority of 
observations (Ito et al., 2012; Jensen et al., 2008). 
Von Hippel-Lindau syndrome 
Von Hippel-Lindau (VHL) syndrome is also a rare autosomal dominant condition. 
Patients with VHL syndrome harbour germline alterations in the VHL genes and typically 
present with multiple tumours and/or cysts of various phenotypes. PNENs are observed 
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in less than 20% of patients with VHL syndrome, but nearly all VHL syndrome-
associated PNENs are nonfunctional (Alexakis et al., 2004; Ito et al., 2012; Jensen et al., 
2008). 
Neurofibromatosis type I 
Neurofibromatosis type I (NF1) disorder results from germline alterations in the 
NF1 gene and is a relatively common condition compared to MEN1 and VHL (Alexakis 
et al., 2004). Common clinical manifestations of NF1 include disorders of the nervous 
system such as benign or malignant tumours of the central and peripheral nervous 
systems. Only up to 10% of patients with NF1 disorder develop PNENs, and these 
PNENs can be functional or nonfunctional (Ito et al., 2012; Jensen et al., 2008).  
Tuberous sclerosis complex 
Tuberous sclerosis complex (TSC) is an autosomal dominant condition and 
occurs as a results of germline alterations in the TSC1 or TSC2 genes. Patients with 
TSC often present with hamartomas and neoplasms in multiple organs (Alexakis et al., 
2004; Ito et al., 2012; Jensen et al., 2008). Pancreatic involvement is not common in 
patients with TSC, but PNENs are the most common pancreatic lesion in patients with 
TSC and may be functional or nonfunctional (Ito et al., 2012; Larson et al., 2012). 
 Treatments and responses 
Clinical management of PNENs is complicated by multiple factors such as the 
functional status, the spread of the disease and the WHO classification. All of these 
contribute to the clinical behaviour of PNENs and thus largely dictate the optimal 
treatment regimen for each patient. In general, removal of tumour mass is the mainstay 
when feasible, and a surgical resection with curative intent is standard for localized 
PNENs. For metastatic cases, cytoreductive surgery and/or liver-directed therapies may 
be recommended to target the primary and secondary lesions, respectively (Kunz, 
2015). For progressive, unresectable, metastatic and/or symptomatic PNENs, systemic 
treatments are administered, where the particular therapeutic agents considered depend 




PNECs are generally treated differently from PNETs due to historically observed 
differences in treatment responses between NENs of different histological differentiation. 
In most cases, NECs are treated similarly regardless of their primary sites, while 
different targeted treatments are recommended for NETs depending on their primary 
sites (Kunz, 2015). The current standard systemic treatment for NECs is cisplatin with 
etoposide, which had originally been administered for patients with small cell lung 
cancer, a type of lung NEC (Strosberg et al., 2010). This combination achieved an 
excellent response rate in patients with NECs (67% overall tumour regression rate) but 
dreadful response rate in patients with NETs (7% overall tumour regression rate) 
(Moertel et al., 1991). A retrospective study of GEP-NECs-G3 (2010 WHO classification) 
found increased median overall survival time in patients treated with a combination of 
platinum-based agent (cisplatin or carboplatin) and etoposide (11 months; 95% CI of 
9.4-12.6 months) versus patients under best supportive care (1 month; 95% CI of 0.3-1.8 
months). Of note, a lower response rate to the treatment combination was observed in 
GEP-NECs-G3 with <55% Ki67 index (15% vs 42%), though GEP-NECs-G3 with <55% 
Ki67 index were associated with a slightly better survival outcome compared to >55% 
Ki67 index (Sorbye et al., 2013). However, this study did not examine or distinguish the 
histological differentiation status of the specimens. Among PNENs, NETs-G3 often have 
<55% Ki67 index, whereas most NECs have >55% Ki67 index (Basturk et al., 2015; 
Tang et al., 2016). While randomized clinical trials specifically for PNECs are lacking, the 
greater response rate to platinum-based therapy observed in GEP-NECs-G3 with >55% 
Ki67 index likely suggests a similarly differential response rate to cisplatin-based therapy 
in PNECs vs PNETs-G3. 
PNETs 
Systemic therapies for PNETs are administered to control tumour growth and/or 
symptoms, where the latter are mostly attributed to the functional status of the tumour. 
For the purpose of this thesis, only tumour-controlling therapeutic agents for PNETs are 
discussed. 
Somatostatin analogues 
Somatostatin (SST) is a cyclic peptide that binds to somatostatin receptors 1~5 
(SSTR1~5) and regulates the release of multiple hormones, many of which cause 
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hormonal syndromes in patients with functional NENs (Günther et al., 2018). Given the 
inhibitory role of SST in releases of hormones and abundant expression of SSTRs on 
NEN cells, SST was expected to be of therapeutic value in patients with functional 
NENs. Due to the extremely short half-life of SST (< 3 minutes), attempts were made to 
synthesize SST analogs (SSAs) suitable in clinical settings (Lamberts et al., 1996). 
Octreotide was the first SSA introduced and has been used in the clinics since the 1980s 
(Kunz, 2015). Another SSA, lanreotide, was later approved and showed similar efficacy 
as octreotide but with easier administration (O’Toole et al., 2000). SSAs inhibit SSTR2/5 
and elicit clinical benefits in patients with functional NENs by suppressing their levels of 
circulating hormones such as insulin and glucagon thereby alleviating the associated 
symptoms (Kvols et al., 1987; Lamberts et al., 1996; O’Toole et al., 2000). Considering 
their clinical benefits and historical success, SSAs are the mainstays for alleviating 
functional syndromes in patients with functional NENs (Hofland et al., 2020b; Kunz, 
2015; Li et al., 2020).  
In addition to their suppressive effects on hormone secretion, SSAs were found 
to elicit antitumour effects. In a randomized, double-blind phase 3 trial involving patients 
with metastatic nonfunctional enteropancreatic NETs, treatment with lanreotide improved 
progression-free survival compared to treatment with placebo (median survival time not 
reached vs 18.0 months). Among the patients with metastatic nonfunctional PNETs (n = 
91), multivariate analysis showed improved progression-free survival rate in those 
treated with lanreotide vs placebo (hazard ratio of 0.58; 95% CI of 0.32~1.04) (Caplin et 
al., 2014). 
Building upon the abundance of SSTRs on the NEN cell surface, radiolabeled 
SSAs have been exploited for targeted therapy. This approach, called peptide receptor 
radionuclide therapy (PRRT), uses SSAs chelated with radionuclide to introduce 
localized radiation to SSTR-positive NEN cells (Hofland et al., 2020b). Two radiolabeled 
SSAs, 90Y-DOTATOC and 177Lu-DOTATATE, were investigated in several clinical trials 
and showed survival benefits in patients with metastatic SSTR-positive NENs 
(Brabander et al., 2017; Imhof et al., 2011). A phase 3 trial involving midgut NETs found 
increased progression-free survival (65.2% vs 10.8% at month 20) in patients treated 
with 177Lu-DOTATATE compared to octreotide (Strosberg et al., 2017). A phase 3 trial 
investigating the efficacy of 177Lu-DOTATATE in locally advanced or metastatic NETs-
G2/3 is still in recruitment phase at the time of writing (CinicalTrials.gov Identifier: 
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NCT03972488). While no randomized, prospective trial of PRRT exists for patients with 
PNENs, PRRT has been used for the treatment of metastatic SSTR-positive NENs in 
Europe since the 1990s (Kunz, 2015). A retrospective analysis of 68 patients with 
metastatic SSTR-positive PNETs treated with 177Lu-DOTATATE reported a disease 
control rate (sum of partial response, minor response and stable disease) of 81% 
(Ezziddin et al., 2014), suggesting patients with SSTR-positive PNENs are likely to 
benefit from PRRT. 
Chemotherapies 
Cytotoxic agents are considered for the treatment of advanced stage PNETs, 
and a combination of an alkylating agent and an antimetabolite is used. Historically, the 
combination of streptozocin and fluorouracil was used for the treatment of advanced 
PNENs (Moertel et al., 1992). However, due to limited response rate and toxicity, 
capecitabine plus temozolomide (Cap/Tem) has become the combination of choice for 
patients with advanced PNETs (Kunz, 2015). No phase 3 trials involving Cap/Tem have 
been conducted in patients with PNENs, but preliminary results from a recent phase 2 
trial (ClinicalTrials.gov Identifier: NCT01824875) involving patients with unresectable or 
metastatic PNETs-G2/3 suggested that treatment with Cap/Tem was favoured over 
temozolomide alone in improving progression-free survival (22.7 vs 14.4 months; HR = 
0.58) and overall survival (median overall survival not reached vs 38 months) with a 
response rate of 33% (Kunz et al., 2018; Li et al., 2020). 
Targeted therapies 
Aside from SSAs and cytotoxic agents, two molecularly targeted therapeutic 
agents have been approved for the treatment of advanced stage PNETs: everolimus and 
sunitinib. Targeted therapeutic agents exploit certain molecular vulnerabilities such as 
dysregulated signaling pathways to preferentially distress the tumours growth and/or 
viability. Everolimus is an inhibitor of the mechanistic target of rapamycin kinase (MTOR) 
that suppresses the PI3K/AKT/mTOR signaling pathway (Bhaoighill and Dunlop, 2019). 
A phase 3 trial involving patients with unresectable or metastatic PNETs-G2/3 showed 
increased progression-free survival (11 vs 4.6 months; HR = 0.35) but no overall survival 
benefit in patients treated with everolimus vs placebo. The authors remarked that the 
clinical benefits of everolimus treatment in patients with advanced PNETs were primarily 
stabilization or minor shrinkage of the tumours (Yao et al., 2011). Sunitinib is an inhibitor 
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of receptor protein-tyrosine kinases, among which include vascular endothelial growth 
factor receptors (VEGFRs) that induce angiogenesis (Roskoski, 2007). In a phase 3 trial 
involving patients with unresectable or metastatic PNETs of any grade, sunitinib 
treatment similarly increased progression-free survival (11.4 vs 5.5 months; HR = 0.42) 
compared to placebo treatment (Raymond et al., 2011). Although everolimus and 
sunitinib were shown to improve progression-free survival in patients with advanced 
PNETs, the tumour response rate to either agent was dismal (5% and 9.3%, 
respectively) suggesting these agents only provide therapeutic benefits in a small subset 
of patients with PNETs (Raymond et al., 2011; Yao et al., 2011). 
1.4. Molecular heterogeneity 
As with the evolution of their classification, our growing understanding of the 
molecular alterations underlying PNENs has revealed the highly heterogeneous nature 
of their molecular landscapes. Earlier studies identified potential driver genes 
contributing to PNEN development from investigating hereditary cancer syndromes 
(described in Section 1.3.2). These studies led to the identification of MEN1, VHL, NF1 
and TSC1/2 as putative driver genes in PNENs (Mafficini and Scarpa, 2019; Pipinikas et 
al., 2019). However, only less than 10% of PNENs are associated with cancer hereditary 
syndromes (de Wilde et al., 2012), and PNENs have a low tumour mutation burden 
(TMB; 0.82 mutations per megabase with a range of 0.04~4.56, compared to 2.64 with a 
range of 0.65~28.2 in pancreatic ductal adenocarcinoma [PDAC]), suggesting there are 
other molecular alterations beyond gene mutations that contribute to PNEN etiology and 
pathogenesis (Banck et al., 2013; Jiao et al., 2011; Scarpa et al., 2017). Omic 
approaches have become increasingly popular in molecular characterization studies 
over the past decade due to advancing technologies and declining costs. Accordingly, 
microarray and high-throughput sequencing technologies have been exploited to 
characterize the genome, epigenome and transcriptome of PNENs in attempts to identify 
clinically relevant molecular alterations. The results of these studies have culminated in 
the identification of recurrently altered genes, dysregulated signaling pathways and 
chromosomal anomalies among PNENs (Cao et al., 2013; Hong et al., 2020; Jiao et al., 
2011; Lawrence et al., 2018; Missiaglia et al., 2010; Roldo et al., 2006). More recently, 
different molecular subtypes of PNENs with prognostic implications were identified and 
described by separate groups (Cejas et al., 2019; Chan et al., 2018; Lawrence et al., 
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2018), including one study that compared patient PNENs with neoplasms from a 
genetically engineered mouse model with spontaneous PNEN development 
(Sadanandam et al., 2015). 
 Early biological studies using mouse models 
Early pathogenesis studies of PNENs were enabled by the development of the 
RIP-Tag mouse model by Douglas Hanahan during the 1980s. Hanahan created a 
fusion construct RIP-Tag by combining rat insulin promoter with SV40 large T antigen 
(Tag) and injected the fusion construct into mouse embryos. The resultant RIP-Tag litter 
had heritable tumour formations in the pancreas and died at an age of 9~12 weeks. The 
pancreatic lesions were confirmed as insulinomas and NECs (then-called “islet cell 
carcinomas”) that arose from transformed pancreatic β-cells (Hanahan, 1985). This 
mouse model provided the first evidence supporting the capability of pancreatic β-cells 
to give rise to PNENs. Subsequently, various genetically engineered mouse models 
provided evidence that PNENs may arise from the endocrine compartment of the 
pancreas depending on the genetic alterations introduced and the cells of targeted 
expression. Glucagonomas could arise from expression of Tag or deletion of tumour 
suppressor genes RB transcriptional corepressor 1 (Rb1) and transformation related 
protein 53 (Trp53) in pancreatic α-cells (Efrat et al., 1988; Glenn et al., 2014), and 
insulinomas could arise from β-cell-specific deletion of Men1 (Bertolino et al., 2003a). 
Interestingly, heterozygous Men1 mice developed PNENs with varying biochemical and 
histological characteristics including insulinomas, glucagonomas, NECs, as well as 
PNETs expressing both insulin and glucagon (Bertolino et al., 2003b). Recently, the 
insulinoma-associated 1 (Insm1) gene was linked to the development of metastatic 
nonfunctional PNENs using the RIP-Tag mouse model, suggesting pancreatic endocrine 
cells may give rise to functional and nonfunctional PNENs (Kobayashi et al., 2019). 
The RIP-Tag mouse was an exemplary model to elucidate not only the 
development of PNENs but also the progression of cancer in general, as it sustained a 
spectrum of pre-malignant and malignant lesions and showcased a continuum of 
progressive lesions reminiscent of cancer progression (Hanahan, 1985; Hanahan and 
Folkman, 1996). Hence, studies using this model system led to the identification of 
several cancer hallmarks (Hanahan and Folkman, 1996; Hanahan and Weinberg, 2000, 
2011). Using histological, temporal and statistical assessments of the pancreatic lesions 
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from the RIP-Tag model, Hanahan proposed two distinct pre-cancerous stages,  
hyperplastic and angiogenic, between normal islets and PNENs. It was found that ~50% 
of the islets in RIP-Tag mice became hyperplastic with hyperproliferation (Teitelman et 
al., 1988), possibly driven by aberrant insulin-like growth factor 2 (Igf2) gene expression 
(Christofori et al., 1994, 1995). Only a small percentage (1~2%) of the hyperplastic islets 
became angiogenic with evidence of neovasculatures and ultimately developed into 
PNENs upon loss of E-cadherin (Perl et al., 1998). Elevated expression of insulin growth 
factor 1 receptor (Igf1r) could accelerate the development of the PNENs (Lopez and 
Hanahan, 2002). The “angiogenic switch” was required for the progression of 
hyperplastic islets into adenomas that subsequently progressed into PNENs (Folkman et 
al., 1989). Treatment of RIP-Tag mice with sunitinib inhibited tumourigenesis and 
stabilized established tumours improving survival outcomes (Casanovas et al., 2005; 
Pietras and Hanahan, 2005). However, similar to the treatment outcomes in patients, 
tumour progression eventually ensued in RIP-Tag mice treated with sunitinib, and the 
tumour regrowth accompanied increased invasive and metastatic potentials (Pàez-Ribes 
et al., 2009). 
While these mouse models provided possible etiology and pathogenesis of 
PNENs, they are not fully representative of PNENs found in patients. The genetic 
modulations introduced into the genetically engineered PNEN mouse models are only 
observed in subsets of patient PNENs. For instance, transformation driven by Tag was 
primarily mediated through inhibition of Rb1 and Trp53 (Ali and DeCaprio, 2001), and 
alterations to tumour suppressor genes RB1 and tumor protein p53 (TP53) are common 
in PNECs but rare in PNETs among patients (Yachida et al., 2012), though the cyclin 
dependent kinases 4 and 6 (CDK4; CDK6) that act downstream of RB1 were found to be 
overexpressed or amplified in a subset of PNETs (Tang et al., 2012). Moreover, the 
majority of murine PNEN models give rise to functional PNENs, while most sporadic 
PNENs in patients are nonfunctional (Halfdanarson et al., 2008). Most murine PNENs 
also do not fully recapitulate patient PNENs (Yu, 2016), and the human and murine 
endocrine pancreas are different in structures and cell-type proportions (Dolenšek et al., 
2015). A microarray-based study of mRNA and miRNA identified three subtypes among 
patient PNENs, only two of which were observed among PNENs found in RIP-Tag mice 
(Sadanandam et al., 2015). Careful extrapolation of PNEN etiology from murine models 
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is therefore warranted, and recent interests in the molecular underpinnings of patient 
PNENs have shifted towards direct investigations using patient specimens. 
 Recurrently mutated genes in PNENs 
DNA-sequencing studies of sporadic PNENs have identified a few recurrently 
mutated genes and mutational differences between PNETs and PNECs (Table 1.4). 
Using whole-exome sequencing (WES) and Sanger sequencing, Jiao et al. (2011) 
identified recurrent somatic gene mutations in MEN1, death domain associated protein 
(DAXX), ATRX chromatin remodeler (ATRX), and genes of the PI3K/AKT/mTOR 
pathway (including TSC2, phosphatase and tensin homolog [PTEN] and 
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [PIK3CA]) in 
44.1%, 25%, 17.6% and 14% of 68 PNETs-G1/2, respectively. The identified mutations 
in MEN1, DAXX and ATRX were mostly inactivating, suggesting their tumour 
suppressive roles. The mutations in DAXX and ATRX were mutually exclusive and 
collectively affected 42.6% of the sequenced specimens. Later, Scarpa et al. (2017) 
performed whole-genome sequencing (WGS) on 98 sporadic PNETs and similarly 
identified somatic mutations affecting MEN1, DAXX/ATRX and the PI3K/AKT/mTOR 
pathway (including PTEN and DEPDC5 [DEP domain containing 5, GATOR1 
subcomplex subunit]) in 36.7%, 33.7% and 9.2% of sequenced specimens, respectively. 
Each sequenced specimen on average harboured 23.5 somatic coding mutations. 
Interestingly, 17% of the sequenced PNETs harboured germline pathogenic mutations 
affecting putative tumour suppressor genes including MEN1, VHL, mutY DNA 
glycosylase (MUTYH), checkpoint kinase 2 (CHEK2) and BRCA2 (BRCA2 DNA repair 
associated), all coupled with somatic loss of heterozygosity (LOH) and resulted in 
biallelic loss of the respective gene (Scarpa et al., 2017).  
Another study performed targeted sequencing of 637 genes among 42 PNETs 
and identified 52.4%, 11.9% and 7.1% of the sequenced specimens with mutations in 
MEN1, DAXX/ATRX and PTEN, respectively (Lawrence et al., 2018). A WES or targeted 
sequencing study of 65 PNETs from the previously mentioned phase 3 everolimus trial 
(Section 1.3.3) revealed mutations in MEN1, DAXX/ATRX and genes of the 
PI3K/AKT/mTOR pathway in 43.1%, 38.5% and 10.8% of the specimens (Yao et al., 
2019). Targeted sequencing of cancer-related genes in 96 tumour samples from 80 
patients with metastatic PNETs who had received prior treatments revealed 56.3%, 
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40%, 25%, 25% and 12.5% of the cohort with mutations in MEN1, DAXX, ATRX, TSC2 
and PTEN, respectively (Raj et al., 2018). In addition, 7.5% of the cohort harboured 
mutations in BRAF (B-Raf proto-oncogene, serine/threonine kinase), two of which 
resulted in p.V600E, an activating variant commonly associated with melanoma and 
colorectal cancer (Cantwell-Dorris et al., 2011). Notably, this cohort had a median TMB 
of 2.95 mutations per megabase, substantially higher than a TMB of 0.82 reported by 
other studies, possibly due to prior treatments (Raj et al., 2018). 
While there were differences in the recurrence of mutations affecting MEN1, 
DAXX/ATRX and genes of the PI3K/AKT/mTOR pathway between cohorts and studies, 
the results from all studies support that these genes are recurrently altered in PNETs. 
The majority of the PNETs included in the above sequencing studies were nonfunctional. 
Analyses of insulinomas alone, however, did not identify recurrent mutations affecting 
any of these genes. In fact, few somatic coding mutations (average of 3.7-10.7 per 
specimen) were identified among insulinomas, but a recurrent hotspot mutation affected 
the YY1 transcription factor (YY1) gene. This hotspot mutation resulted in a p.T372R 
variant and was found in 15.4-32.6% of insulinomas (Cao et al., 2013; Cromer et al., 
2015; Hong et al., 2020; Lichtenauer et al., 2015; Wang et al., 2017). 
Table 1.4. Recurrently mutated genes in PNENs. 






MEN1 NETs 38-56% 5% 
(Jiao et al., 2011; 
Lawrence et al., 
2018; Raj et al., 
2018; Scarpa et al., 
2017; Yao et al., 
2019) 
DAXX/ATRX NETs 11-58% - 
(Jiao et al., 2011; 
Lawrence et al., 
2018; Raj et al., 
2018; Scarpa et al., 
2017; Yao et al., 
2019) 
YY1 (p.T372R)a Insulinomas 15-33% - 
(Cao et al., 2013; 
Cromer et al., 2015; 
Hong et al., 2020; 
Lichtenauer et al., 
2015; Wang et al., 
2017) 
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NETs 7-43% - 
(Jiao et al., 2011; 
Lawrence et al., 
2018; Raj et al., 
2018; Scarpa et al., 
2017; Yao et al., 
2019) 
RB1 NECs 71% - 
(Yachida et al., 
2012) 
TP53 NECs 57-60% - 
(Vijayvergia et al., 
2016; Yachida et 
al., 2012) 
KRAS (activating) NECs 28-30% - 
(Vijayvergia et al., 
2016; Yachida et 
al., 2012) 
MUTYH NETs - 5% 
(Scarpa et al., 
2017) 
CHEK2 NETs - 4% 
(Scarpa et al., 
2017) 
BRCA2 NETs - 1% 
(Scarpa et al., 
2017) 
CDKN1B NETs - 1% 
(Scarpa et al., 
2017) 
VHL NETs - 1% 
(Scarpa et al., 
2017) 
aIn YY1, only hotspot mutations resulting in p.T372R  have been reported. bIncludes DEPDC5, PIK3CA, PTEN and 
TSC2. 
Sequencing studies involving PNECs are scarce. A targeted sequencing study of 
9 cancer-related genes identified activating KRAS (KRAS proto-oncogenes, GTPase) 
mutations, inactivating TP53 mutations and inactivating RB1 mutations in 28.6%, 57.1% 
and 71.4% of 7 PNECs, respectively. None of the 11 PNETs also included in the study 
had mutations in these three genes suggesting genetic distinctions between PNETs and 
PNECs (Yachida et al., 2012). In another study that performed targeted sequencing of 
50 cancer-related genes among 23 NECs of various primary sites, 60.1% and 30.4% of 
the specimens harboured mutations in TP53 and KRAS, respectively (Vijayvergia et al., 
2016). Together, these findings suggest genetic distinctions between PNETs and 
PNECs, where PNECs are genetically more similar to extrapancreatic NECs than to 
PNETs. 
In addition to single nucleotide variations (SNVs) or small insertions and 
deletions (Indels) that affect local sequences, a few structural variations (SVs) with 
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predicted functional impacts were reported in PNETs. These included rearrangements 
leading to inactivation of MTAP (methylthioadenosine phosphorylase; 4.1%), ARID2 (the 
AT-rich interaction domain 2; 5.1%), SMARCA4 (SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, subfamily a, member 4; 3.1%) and KMT2C 
(lysine methyltransferase 2C; 3.1%). Gene fusions involving EWSR1 (EWS RNA binding 
protein 1) were found in three PNETs, where two were due to in-frame fusion with the 
BEND2 (BEN domain containing 2) and another with FLI1 (Fli-1 proto-oncogene, ETS 
transcription factor) (Scarpa et al., 2017). The latter is common in Ewing’s sarcoma 
(Sankar and Lessnick, 2011).  
MEN1 
MEN1 encodes a ubiquitously expressed scaffold protein with predominant 
nuclear localization (Guru et al., 1998) and has been associated with transcriptional 
regulation, cellular signaling and DNA repair (Agarwal, 2017). The mutations in MEN1 
observed among PNETs were largely inactivating mutations suggesting MEN1 poses 
inhibitory roles on PNET development, but the mechanisms by which it suppresses 
tumourigenesis from the endocrine pancreas remain elusive. In the context of PNENs 
and the endocrine pancreas, MEN1 indirectly regulates the gene expression of cell cycle 
inhibitors, cyclin dependent kinase inhibitor 1B (CDKN1B) and cyclin dependent kinase 
inhibitor 2C (CDKN2C), through histone H3 (H3) lysine 4 trimethylation at the CDKN1B 
and CDKN2C promoter regions (Karnik et al., 2005). Loss of CDKN2C was found in 
67.3% of 61 PNENs from patients with MEN1 syndrome (Conemans et al., 2018). The 
Wnt signaling pathway inhibits proliferation of mouse PNEN cells, and MEN1 interacts 
with members of the Wnt signaling pathway, including catenin beta 1 (CTNNB1) and 
transcription factor 3 (TCF3), and regulates the expression of Wnt pathway target gene 
axin 2 (AXIN2) (Chen et al., 2008). MEN1 likely also regulates the PI3K/AKT/mTOR 
pathway as it inhibits the activation of AKT serine/threonine kinase 1 (AKT1) by 
preventing its translocation from cytoplasm to the plasma membrane during growth 
factor stimulation (Wang et al., 2011b). Hotspot activating mutations in KRAS are found 
in nearly all PDACs but are virtually nonexistent in PNETs (Jiao et al., 2011). MEN1 was 
found to act downstream of KRAS and assumed an anti-proliferative role thereby 
suppressing pancreatic endocrine cell proliferation upon KRAS activation (Chamberlain 
et al., 2014). 
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DAXX and ATRX 
The mutually exclusive occurrence of inactivating mutations in DAXX and ATRX 
among PNETs suggested their cooperative roles in suppressing PNET development. 
DAXX and ATRX coordinately deposit histone H3 variant H3.3 (H3.3) at telomeric and 
pericentric heterochromatin in a replication-independent manner (Drané et al., 2010; 
Goldberg et al., 2010; Lewis et al., 2010; Wong et al., 2010). Both DAXX and ATRX as 
well as telomeric H3.3 deposition are required to suppress the alternative lengthening of 
telomere (ALT) pathway. ALT is a homologous recombination (HR)-dependent but 
telomerase-independent mechanism that promotes cancer cell immortality (Clynes et al., 
2015). Loss of DAXX or ATRX protein expression is associated with chromosomal 
instability (CIN) in PNETs (Marinoni et al., 2014). Analysis of 41 PNETs using 
fluorescence in situ hybridization revealed 61.0% with ALT, all of which harboured 
mutation in DAXX/ATRX and/or lost nuclear localization of DAXX/ATRX (Heaphy et al., 
2011). Three independent studies of PNETs congruously reported the prognostic utility 
of ALT in PNETs where ALT positivity was associated with reduced disease-free 
survival, larger tumour size and higher WHO grade (Kim et al., 2017b; Marinoni et al., 
2014; Singhi et al., 2017). A subsequent study using an international cohort of over 600 
nonfunctional PNETs showed loss of DAXX/ATRX staining or ALT positivity was 
independently associated with reduced recurrence-free survival. The 5-year recurrence-
free survival rates were 40% for DAXX/ATRX-loss and 42% for ALT-positive subsets 
compared to 85% and 86% in the opposed subsets, respectively (Hackeng et al., 2021). 
PI3K/AKT/mTOR pathway 
The PI3K/AKT/mTOR pathway is involved in numerous cellular processes 
including stress adaptation, cell proliferation and regulation of bioenergetics for cell 
growth and survival. The pathway is dysregulated in multiple cancer types and is a target 
of interest among PNETs (Porta et al., 2014). A few somatic mutations in genes of the 
PI3K/AKT/mTOR pathway were identified and collectively affected 7~14% of sequenced 
PNETs (Jiao et al., 2011; Lawrence et al., 2018; Scarpa et al., 2017). In addition to gene 
mutations, microarray analysis comparing PNENs to normal islets identified reduced 
TSC2 expression in the tumours. IHC analysis of TSC2 and PTEN showed lower levels 
of these proteins in PNENs compared to islets, and PNENs with lower TSC2 or PTEN 
IHC scores were associated with poor clinical outcomes (Missiaglia et al., 2010). IHC 
positivity of phosphorylated MTOR and phosphorylated ribosomal protein S6, markers 
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indicative of PI3K/AKT/mTOR pathway activation, were also associated with 
clinicopathological characteristics of poor clinical outcomes (Komori et al., 2014). 
However, there is currently no data to support whether aberrant activation of 
PI3K/AKT/mTOR pathway leads to susceptibility to the MTOR inhibitor everolimus in 
PNENs (Yao et al., 2019). 
DNA damage repair 
There have been few but consistent reports supporting alterations in DNA 
damage response and repair pathways among PNETs. Sanger sequencing of 35 kinase 
genes among 36 PNENs identified somatic mutations affecting the ATM serine/threonine 
kinase gene (ATM) in 5.6% of the specimens (Corbo et al., 2012). ATM as well as 
BRCA2, CHEK2 and MUTYH, described above in which germline mutations were found 
among PNETs, are involved in DNA damage response and repair pathways. The ATM-
CHEK2 pathway is stimulated in response to DNA double stranded breaks to activate 
checkpoint responses that facilitate DNA repair and cell survival (Smith et al., 2010b). 
BRCA2 acts downstream of CHEK2 and regulates the HR repair of DNA double 
stranded breaks (Bahassi et al., 2008; Thorslund and West, 2007; Yang et al., 2002). 
MUTYH is a DNA glycosylase involved in base excision repair pathway that prevents 
G:C>T:A transversion, and germline mutations in MUTYH lead to colorectal polyposis 
(Al-Tassan et al., 2002; Shinmura et al., 2000). In addition to regulation of ALT, DAXX, 
ATRX and H3.3 were recently associated with DNA damage repair. DAXX, ATRX and 
their coordinated deposition of H3.3 were required during extended DNA repair 
synthesis at exogenously induced DNA double stranded breaks (Juhász et al., 2018). 
Together, these findings point to potentially defective DNA damage response pathways 
in some PNETs. PNECs frequently harboured mutations in TP53 and RB1, which can 
also lead to elevated DNA damage. Deletion of RB1 results in increased double 
stranded breaks due to reduced HR-mediated and non-homologous end-joining-
mediated DNA damage repairs (Cook et al., 2015; Marshall et al., 2019). TP53 has been 
connected to various DNA damage repair mechanisms including base excision repair 
and HR-mediated repair (Williams and Schumacher, 2016). MUTYH is transcriptionally 
regulated by TP53 and potentially mediates the tumour suppressor functions of TP53 
(Oka et al., 2014), suggesting potential molecular similarities between certain PNETs 
and PNECs despite distinctions in recurrently mutated genes between the two entities. 
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 Copy number variations in PNENs 
Chromosomal alterations in PNETs have been investigated by a few studies and 
used to identify copy number variation (CNV)-based subtypes associated with 
clinicopathological characteristics (Table 1.5). A single nucleotide polymorphism (SNP) 
array study of 15 PNETs identified recurrent loss of chromosomes 1 (40%), 3 (46.7%), 
11 (53.3%) and 22 (40%) and recurrent gain of chromosomes 5 (46.7%), 7 (60%), 12 
(46.7%), 14 (53.3%), 17 (53.3%) and 20 (46.7%). Recurrent LOH of 11q was observed 
in 46.7% of the analyzed PNETs. While the sample size was small, the PNETs with 
more than four chromosomal gains/losses had larger tumour size (5.4 cm vs 2.3 cm) 
compared to those with four or less chromosomal gains/losses (Nagano et al., 2007). In 
their study of 98 PNETs, Scarpa et al. (2017) similarly used SNP array for copy number 
analysis and identified four discrete groups based on unsupervised clustering of 
chromosomal arm copy number patterns. Approximately one third of the cohort had 
limited CNV events, and the other two thirds had a recurrent pattern of either whole 
chromosomal loss or gain. A small subset of PNETs with recurrent chromosomal gain 
formed a polyploid group and was associated with a higher somatic mutation rate with 
an average of 1.98 mutations per megabase compared to an average of 0.82 mutations 
per megabase across the cohort. Among the recurrent chromosomal loss regions across 
the sequenced cohort were 11q13.1 and 9q21.3 that included MEN1 and CDKN2A, 
respectively (Scarpa et al., 2017). A separate study analyzing somatic CNVs from WGS 
or WES data of 127 nonfunctional PNETs similarly identified three groups either with 
limited CNV events or recurrent chromosomal gain or loss. The group with limited CNV 
events was associated with a better relapse-free survival and fewer cases with 
mutations in DAXX/ATRX compared to the other two (Table 1.5; Hong et al., 2020). 
Lawrence et al. (2018) also identified three CNV-based groups from targeted 
sequencing data of 637 genes from 42 PNETs. One group (Group 1) was characterized 
with recurrent pattern of LOH affecting chromosomes 1, 2, 3, 6, 8, 10, 11, 16, 21 and 22 
and PNETs with lymphovascular invasion and MEN1 mutation. The two other groups 
had limited CNV events, where Group 2 contained PNETs with MEN1 mutation and LOH 
affecting chromosome 11 while Group 3 PNETs did not harbour MEN1 mutation and had 
higher MEN1 mRNA expression (Table 1.5; Lawrence et al., 2018). Unsupervised 
clustering of CNV events also identified three groups among 65 PNETs from the phase 3 
everolimus trial introduced in Section 1.3.3. Two of the three groups displayed LOH in 
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chromosomes 1, 2, 3, 6, 8, 10, 11, 15, 16, 21 and 22 and contained mostly PNETs 
harbouring MEN1 mutation with high CIN score. Patients of these two groups with 
recurrent LOH also had a better overall survival probability (Yao et al., 2019). 
Despite nonfunctional PNETs being consistently categorized into three CNV-
based groups, clustering of CNV events among 84 insulinomas revealed only a group 
with limited CNV events and another with recurrent chromosomal gain. The hotspot YY1 
p.T372R was more common among insulinomas with limited CNV events (59% vs 7%), 
while the majority of insulinomas with chromosomal gains harboured amplification of 
TSC1/2 (Table 1.5). No difference in relapse-free survival was observed between the 
two insulinoma groups (Hong et al., 2020). 
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primary-2 











High PDX1 expression 
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specimens 
Type B 
High PDX1 expression 
Few ALT+ specimens 
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chromosomes 1, 2, 3, 6, 8, 
10, 11, 16, 21, 22 
Enriched in specimens 
with mutant MEN1 and 
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Enriched in specimens 
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Group 2 
Limited CNV with recurrent 
LOH affecting 
chromosome 11 
Enriched in specimens 
with mutant MEN1. 
Group 3 
Contained specimens of 
variable aneuploidy 
Variable clinical outcomes 
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with TSC1/2 amplification 










Clustered with α-cells 
IHC positivity for ARX but 
not PDX1 
Enriched in specimens 
with mutant MEN1 
β-like 
Clustered with β-cells 








Majority of specimens 
were positive for ARX IHC 
Enriched in specimens 
with mutant MEN1 and 
DAXX/ATRX 
Reduced DFS compared 
to the other two subtypes 







Few mutant MEN1 or 
DAXX/ATRX 
Enriched in functional 
tumours 
T2 
Enriched in specimens 
with mutant MEN1 and 
DAXX/ATRX 
Enriched with ALT+ 
specimens 
Recurrent LOH in 
chromosomes 1, 2, 3, 6, 8, 
10, 11, 15, 16, 21 and 22 
T3 
Enriched in specimens 
with mutant MEN1 
Recurrent loss of 
chromosome 11 






status at PDX1 
gene region 
Subtype A 
Clustered with α-cells 
Enriched in specimens 
with mutant MEN1 or 
DAXX/ATRX 
Reduced overall survival 
probability 
Recurrent loss of 
chromosomes 1, 2, 6, 10, 
16 and 22 
Subtype B 
Clustered with β-cells 
Enriched in specimens 
with wildtype MEN1, DAXX 
and ATRX 
Recurrent loss of 
chromosome 11 
aSubtype characteristics were extracted from the corresponding publications and may simply be based on comparisons 
between subtypes from the same study. ALT: alternative lengthening of telomeres. LVI: lymphovascular invasion, DFS: 
disease-free survival, TSG: tumour suppressor gene, LOH: loss of heterozygosity, TMB: tumour mutation burden. 
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 Transcriptome and subtyping studies of PNENs 
With the advent of affordable molecular profiling technologies, numerous studies 
have been conducted to characterize different cancer types on molecular levels. As a 
result, molecular subtyping has been used to identify groups of tumours based on 
common molecular characteristics and that correlate with clinical outcomes for potential 
prognostic and predictive utility in clinical settings. This approach has precipitated 
clinically relevant subtypes in various cancer types such as colorectal cancer (Guinney 
et al., 2015), exocrine pancreatic cancer (Bailey et al., 2016; Collisson et al., 2011) and 
breast cancer (Sørlie et al., 2001). Similar attempts have recently been made to identify 
PNEN subtypes, albeit with inter-study variations. 
The earliest clustering analysis performed on PNENs was done with miRNA 
profiles. A custom miRNA microarray that included probes for 235 human mature 
miRNAs was used to determine the miRNA expression patterns in rare pancreatic 
cancer types. The profiled specimens included 28 nonfunctional PNETs (11 WDETs and 
17 WDECs based on 2000/2004 WHO classification), 12 insulinomas (11 WDETs and 1 
WDEC), 4 acinar carcinomas and 12 normal pancreas. Unsupervised clustering of the 
miRNA profiles predictably distinguished normal pancreas from all included tumour 
samples but did not identify any distinction between nonfunctional PNETs vs 
insulinomas or WDETs vs WDECs (Roldo et al., 2006). Considering the endocrine 
pancreas is the likely precursor of PNETs, and the endocrine component only makes up 
to 5% of the pancreas volume (Ionescu-Tirgoviste et al., 2015), the finding that the 
normal pancreas samples clustered away from the tumours was unsurprising due to 
distinctions between endocrine and exocrine pancreas. Analysis between nonfunctional 
PNETs and insulinomas only identified differential expression of miR-203, miR-204 and 
miR-211, all of which were more highly expressed in insulinomas. In particular, the 
expression of miR-204 was found to positively correlate with insulin IHC score. Among 
all miRNAs profiled, only miR-21 level was found to associate with presence of 
metastases and Ki67 > 2% (Roldo et al., 2006). 
A microarray-based mRNA profiling study was subsequently performed and used 
to analyze the gene expression patterns of 72 primary PNENs (including both PNETs 
and PNECs, 15 of which were insulinomas), 7 matched metastases and 10 normal 
pancreatic samples (5 bulk pancreas and 5 islet preparations). Similar to miRNA-based 
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analysis, unsupervised clustering of the mRNA expression profiles distinguished normal 
pancreatic samples from the PNENs, while the nonfunctional WDETs, WDECs and 
PDECs (2000/2004 WHO classification) fell into overlapping clusters that also included 
the matched metastases (Missiaglia et al., 2010). Interestingly, the insulinomas clustered 
away from the other PNENs suggesting profound mRNA but subtle miRNA level 
differences between insulinomas and nonfunctional PNENs (Missiaglia et al., 2010; 
Roldo et al., 2006). Differential analyses identified downregulation of TSC2 in both 
insulinomas and nonfunctional PNENs compared to normal samples. As mentioned in 
the previous subsection, IHC analysis of TSC2 and PTEN further established a 
correlation between low level staining of these markers and reduced overall survival and 
progression-free survival and suggested a dysregulated PI3K/AKT/mTOR pathway in 
PNENs (Missiaglia et al., 2010). 
The first formal class discovery study of PNENs was conducted by incorporating 
miRNA and mRNA expression data from patient PNENs and correlating with the PNENs 
from the RIP-Tag mouse model. A qPCR array had previously been used to 
quantitatively measure the levels of 430 miRNAs from RIP-Tag specimens and 
confirmed distinct miRNA profiles between specimens at various disease stages. 
Clustering of miRNAs from RIP-Tag mouse tumour specimens revealed a small subset 
of primary tumours, termed metastasis-like primary (MLP) tumours, more similar to liver 
metastases than other primary tumours based on miRNA profiles (Olson et al., 2009). 
Using the microarray data previously generated from patient PNENs, Sadanandam et al. 
(2015) identified three subtypes from miRNA profiles, one of which had high expression 
of miRNAs also elevated in the MLP tumours from the RIP-Tag mouse. A similar 
analysis approach applied to the mRNA microarray data from the study by Missiaglia et 
al. (2010) identified five clusters: normal islet-like, insulinoma-like, intermediate, MLP-1 
and MLP-2 (Table 1.5). The normal islet-like cluster consisted primarily of normal islet 
samples while insulinomas were predominant in the insulinoma-like cluster. The two 
MLP clusters contained largely metastasis specimens or primary tumours from patients 
with metastatic PNENs and therefore inherited the MLP terminology from the RIP-Tag 
specimen clustering study (Olson et al., 2009; Sadanandam et al., 2015). 
A PanNETassigner-miR signature (n = 30) and a PanNETassigner-mRNA 
signature (n = 221) were derived from the miRNA and mRNA profiles, respectively, and 
used to validate the subtypes in additional cohorts. Analysis of specimens with paired 
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miRNA and mRNA expression data suggested significant enrichment between the three 
miRNA-based subtypes and the four mRNA-based subtypes (excluding the normal islet-
like subtype). Combined analysis of mRNA expression profiles from human and RIP-Tag 
PNENs revealed transcriptomic similarities of insulinoma-like and MLP subtypes to RIP-
Tag insulinomas and MLP tumours, respectively (Sadanandam et al., 2015). Targeted 
sequencing of genes recurrently mutated in PNENs (Jiao et al., 2011) found roughly half 
of the intermediate subtype PNENs with mutations in MEN1 and DAXX/ATRX while only 
12.5% of insulinoma-like PNENs had mutations in MEN1 and none in DAXX/ATRX 
(Sadanandam et al., 2015). Given the abundance of specimens with MEN1 and 
DAXX/ATRX mutations in the intermediate subtype PNENs and their clustering away 
from insulinoma-like and MLP subtype PNENs, the intermediate subtype of specimens 
was proposed to be absent from the RIP-Tag mouse model, which does not harbour 
mutations in MEN1 and DAXX/ATRX (Sadanandam et al., 2015). The MLP subtypes 
were associated with PNENs of higher WHO grade (2010 edition) and characterized with 
relatively higher expression of pancreatic progenitor genes HNF1 homeobox B (HNF1B) 
and GATA binding protein 6 (GATA6). The insulinoma-like PNENs, on the contrary, had 
higher expression of β-cell marker genes pancreatic and duodenal homeobox 1 (PDX1), 
insulin (INS), glucokinase (GCK) and solute carrier familiar 2 member 2 (SLC2A2) as 
well as insulinoma-specific gene INSM1 (Sadanandam et al., 2015).  
In their WGS study, Scarpa et al. (2017) applied RNA-sequencing (RNA-seq) to 
30 of the PNENs and identified three clusters from unsupervised analysis. Two of the 
clusters were moderately similar to the intermediate and MLP subtypes based on 
enrichment analysis using the PanNETassigner-mRNA signature genes. However, the 
cluster most similar to the intermediate subtype was not enriched in PNENs with MEN1 
and DAXX/ATRX mutations, and the third cluster was not particularly similar to any of 
the subtypes identified by Sadanandam et al. (2015) (Scarpa et al., 2017). 
Five studies subsequently identified two to three PNEN subtypes using RNA-seq, 
methylation profiles, enhancer profiles, or a combination of these methods (Boons et al., 
2020; Cejas et al., 2019; Chan et al., 2018; Di Domenico et al., 2020; Lakis et al., 2021; 
Table 1.5). In all except one of these studies, the subtypes were partly dictated by the 
potential cell-of-origin. 
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Unsupervised hierarchical clustering of RNA-seq or DNA methylation microarray 
data from 33 PNETs-G1/2 (of functional or nonfunctional status) identified two clusters 
characterized by presence or absence of mutations in any of MEN1, DAXX or ATRX. 
The correlation between the mutational status of the genes and the two clusters were 
confirmed in external gene expression datasets. The PNET subtype characterized with 
mutations, the A-D-M mutant subtype, was associated with reduced recurrence-free 
survival and exhibited gene expression signatures of pancreatic ɑ-cells. Pancreatic ɑ-
cell-specific genes aristaless related homeobox (ARX) and iroquois homeobox 2 (IRX2) 
were highly expressed while β-cell-specific genes PDX1, MAF bZIP transcription factor A 
(MAFA) and INS were lowly expressed in this A-D-M mutant subtype compared to the A-
D-M WT subtype. The A-D-M WT PNETs were found to be heterogeneous in both gene 
expression profiles and expression of pancreatic cell-type-specific genes (Chan et al., 
2018). 
Cejas et al. (2019) examined the super-enhancer profiles marked by H3 lysine 27 
acetylation (H3K27ac) using chromatin immunoprecipitation sequencing (ChIP-seq) 
among 8 nonfunctional PNETs and identified three subtypes: Type A, B and C. 
Comparison between Type A and B revealed significantly higher H3K27ac in the ARX 
and IRX2 loci of Type A PNETs and in the PDX1 locus of Type B PNETs; Type C 
PNETs had variable H3K27ac signals at these loci. RNA-seq confirmed relatively higher 
ARX and PDX1 mRNA expression in Type A and B PNETs, respectively, and further 
suggested transcriptomic similarity of Type A PNETs to ɑ-cells and Type B PNETs to β-
cells. Subtyping 61 MEN1-mutant PNETs based on ARX and PDX1 IHC analysis 
revealed reduced relapse-free survival in PNETs either with only ARX positivity or 
neither ARX and PDX1 (double-negative). Mutation status of DAXX and ATRX was not 
assessed among the MEN1-mutant cohort, but 48.1% of ARX-positive or double-
negative PNETs were positive for ALT while only 14.3% of PDX1-positive or PDX1-
positive-ARX-positive were positive for ALT (Cejas et al., 2019). However, no prognostic 
differences were found between PDX1-positive and ARX-positive PNETs in an 
international cohort of 668 nonfunctional PNET specimens (Hackeng et al., 2021). 
A subsequent study analyzed the methylation status of the PDX1 gene region 
among 83 PNETs and identified two hierarchical clusters: subtype A and subtype B. 
Subtype A was enriched with PNETs harbouring mutant MEN1, DAXX or ATRX and 
associated with a higher rate of disease recurrence similar to the A-D-M mutant subtype 
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reported by Chan et al. (Boons et al., 2020; Chan et al., 2018). Inference of CNV from 
methylation array identified shared and different CNV patterns between the two 
subtypes. Recurrent loss of chromosome 11 was observed in all PNETs. Recurrent loss 
of chromosomes 1, 2, 6, 10, 16 and 22 and gain of chromosomes 4, 12, 14, 17, 18, 19, 
20 and 21 were observed in subtype A PNETs. Subtype B PNETs, on the other hand, 
had low frequencies of chromosome loss and recurrent gain of chromosome 21. Further, 
subtype B PNETs were associated with a reduced overall survival probability compared 
to subtype A PNETs (Boons et al., 2020). 
Phyloepigenetic analysis of 125 PNETs-G1/2 (including functional and 
nonfunctional) and normal ɑ-cells and β-cells distinguished ɑ-cell-like and β-cell-like 
groups from an intermediate group of PNETs. The methylomes of PNETs and isolated ɑ-
cells and β-cells were profiled using microarray, and the differentially methylated sites 
between ɑ-cells and β-cells were used to perform phyloepigenetic analysis. Hierarchical 
relationships were observed between the PNETs and normal cells, where ɑ-cells and β-
cells sat at two extremities. Subsets of PNETs grouped with normal ɑ-cells or β-cells 
were named as ɑ-like or β-like PNETs, respectively. The majority of the profiled PNETs 
(n = 92), however, were intermediate to the two subtypes and were weakly similar to ɑ-
cells or β-cells. The ɑ-like, β-like and intermediate subtypes exhibited mutational 
differences in MEN1 and DAXX/ATRX, where 67.4% of the intermediate PNETs 
harboured mutations in MEN1 and/or DAXX/ATRX and 57.9% of ɑ-like PNETs 
harboured mutations in MEN1. Mutations in DAXX/ATRX were absent among ɑ-like 
PNETs, and nearly all β-cell PNETs had wildtype MEN1, DAXX and ATRX. In addition, 
the intermediate PNETs were characterized with numerous CNV events, while ɑ-like and 
β-like PNETs had limited CNV events. IHC of ARX and PDX1 confirmed positivity in ɑ-
like and β-like PNETs, respectively, but also found 86% of the intermediate PNETs 
positive for ARX. Survival analysis of the PNETs stratified by phyloepigenetic groups 
showed the intermediate PNETs associated with reduced disease-free survival 
compared to ɑ-like and β-like PNETs (Di Domenico et al., 2020). 
The Scarpa group followed up their WGS study (Scarpa et al., 2017) with a 
microarray-based methylome profiling study. Tumour-specific methylation sites in 
promoter regions were identified from 84 sporadic PNETs after comparative analysis to 
adjacent normal pancreatic tissues and used to perform unsupervised cluster analysis 
that identified three methylation subtypes: T1, T2 and T3. The T1 PNETs were 
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characterized by few mutations in MEN1 and DAXX/ATRX and included 7 of the 11 
functional PNETs included in the cohort. The T2 subtype of PNETs had recurrent 
mutations in MEN1 and DAXX/ATRX, high frequency of tumours with ALT and tumours 
of larger size and higher TMB. Mutations in MEN1 were also common in the T3 subtype, 
but the T3 subtype contained a higher proportion of NETs-G1 and cases without extra-
pancreatic spread of perineural/vascular invasion. Analysis of CNV events found 
recurrent loss of chromosome 11 among T3 PNETs and recurrent LOH in chromosomes 
1, 2, 3, 6, 8, 10, 11, 15, 16, 21 and 22 among T2 PNETs (Lakis et al., 2021), potentially 
matching the T2 and T3 subtypes to Group 1 and 2 described by Lawrence et al. (2018). 
 Proteomic analysis of PNENs 
There is currently no large-scale global proteomic study on PNENs. A literature 
search discovered only three studies that employed a proteomic approach to identify 
proteins either of potential prognostic utility or with metastasis associations. A two-
dimensional gel electrophoresis approach following tissue microdissection was used for 
comparative proteomic analysis between 6 benign and 6 metastatic insulinomas. Eight 
candidate proteins were found more abundant and another eight less abundant in the 
metastatic insulinomas relative to the benign specimens. IHC validation of the 
candidates on a tissue microarray (TMA) of 62 insulinomas confirmed higher levels of 
aldehyde dehydrogenase 1 (ALDH1) and tumor protein D52 (TPD52) in malignant 
insulinomas and benign insulinomas, respectively. TPD52 IHC scores were positively 
correlated with better recurrence-free survival and overall survival in multivariate 
analysis (Alkatout et al., 2015). A comparative analysis of global proteomes of four 
insulinomas and paired pancreatic tissues identified 219 more abundant and 62 less 
abundant proteins in insulinomas among 3,476 identified proteins. Among the more 
abundant proteins in insulinomas, IHC analysis of ubiquitin C-terminal hydrolase L1 
(UCHL1), microtubule associated protein 1B (MAP1B), microtubule associated protein 2 
(MAP2), versican (VCAN) and CDK4 confirmed higher abundance or specific expression 
in 40 PNETs (including functional and nonfunctional) relative to surrounding normal 
tissues. PDX1 and calcium sensing receptor (CASR) were also identified to be more 
abundant from proteomic analysis of PNETs vs normal tissues but were only detected in 
insulinomas and not in other PNETs. In addition, concurrent expression of UCHL1 and 
internexin neuronal intermediate filament protein alpha (INA) was associated with a 
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better overall and disease-free survival outcome (Song et al., 2017). Another 
comparative study of global proteomes of 7 pairs of primary tumours and metastases 
from patients with PNENs found 33 and 76 proteins (among 3,722 identified proteins) 
more abundant in primary tumours or metastases, respectively. IHC of candidate 
proteins associated with metastases confirmed up-regulation of annexin A6 (ANXA6), 
canopy FGF signaling regulator 2 (CNPY2), RAB11B (RAB11B, member RAS oncogene 
family) and tubulin beta 3 class III (TUBB3) in the liver metastases, with CNPY2 absent 
in normal islet cells. Positivity in either CNPY2 and RAB11B was associated with PNENs 
of higher grade. In addition, CNPY2 IHC positivity was an independent prognostic 
marker of reduced liver recurrence-free survival (Shimura et al., 2018). 
1.5. Aims, objectives and chapters overview 
The clinical and molecular heterogeneity of PNENs are now well-appreciated and 
are the major hurdles in the effective clinical management of PNENs. A few therapeutic 
options are available for patients with PNENs, but the response rate is often limited with 
nonexistent molecular predictive biomarkers. Despite mounting efforts over recent years 
to characterize PNENs at the molecular level, the results from existing studies examining 
the genome, epigenome, transcriptome or proteome of PNENs have largely been limited 
to the identification of potential prognostic indicators for patients with PNENs. Little 
advance has been made towards the identification of new therapeutic vulnerabilities and, 
by extension, potential targeted therapeutic agents that may modify the projected 
prognosis in this disease. 
Molecular profiling studies of PNENs using either DNA and/or RNA level 
information have identified up to 5 potential subtypes with mutational and/or prognostic 
differences. However, inconsistencies between various subtyping schemes and 
limitations in their therapeutic implications from various studies hamper their potential 
translational utility. In spite of three studies that examined the proteomic alterations in a 
small number of PNENs, the proteomic landscape of PNENs remains practically 
unknown. Investigation into the multi-omic space of PNENs using DNA-, RNA- and 
protein- level data may lead to a more robust and versatile PNEN stratification and 
further dissect the pathogenesis of this disease to identify novel therapeutic 
vulnerabilities. 
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The majority of patients with PNENs present with distant metastases at the time 
of diagnosis, and the presence of metastases is significantly associated with disease-
specific mortality in these patients. Ironically, molecular studies on the distant 
metastases from these patients are scarce due to specimen availability, where limited 
tissues from biopsies were typically devoted to diagnostic and pathological 
examinations. Elucidating the molecular alterations in metastases from patients with 
PNENs can bolster our knowledge in the biology of these deadly neoplasms to foster 
effective management of PNENs in the metastatic setting. 
The overarching objective of this thesis project was to unravel the molecular 
heterogeneity of PNENs to enable molecular associations with clinicopathological 
characteristics and to identify potential novel therapeutic vulnerabilities in this disease. I 
hypothesized that 1) PNENs can be stratified into clinically relevant molecular subgroups 
based on their proteotranscriptomic profiles and 2) WGS and whole-transcriptome 
sequencing (WTS) of PNEN metastases can identify molecular alterations that offer 
additional insights into the pathogenesis of PNENs. The investigations to support these 
hypotheses resulted in a submitted manuscript (Yang et al., in revision) and a published 
report (Wong et al., 2018) that are described in Chapter 2 and 3, respectively. Chapter 2 
details the molecular identification and characterization of four proteotranscriptomic 
subgroups from one of the largest PNEN cohorts to date. The discovery of these four 
PNEN subgroups accompanies potential novel oncogenic drivers and pathway 
alterations with therapeutic implications. Chapter 3 catalogues the genomic and 
transcriptomic aberrations identified from a small but unique cohort of PNEN metastases 
where two cases were presumably driven by novel oncogenic drivers. This is followed by 
unpublished results correlating the metastatic cases to the subgroups detailed in 
Chapter 2. Finally in Chapter 4, I discuss the roles and potential contributions of these 
findings to the current state of knowledge in PNEN research and suggest potential 
avenues for future research in this disease and other NENs. 
Throughout this thesis, the conventional nomenclatures for genes and proteins 
are used, and the approved gene names from HUGO Gene Nomenclature Committee 
(HGNC) are used. Where applicable, the term “disorder” or “syndrome” is added to 
mentions of hereditary cancer syndromes to differentiate them from the protein products 
of the underlying causative genes. 
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Chapter 2.  
 
Proteotranscriptomic classification and 
characterization of PNENs 
This chapter is modified from a manuscript submitted to Cell Reports and is in 
revision at the time of writing this thesis. The study culminating in the submitted 
manuscript was a combined effort from multiple individuals as detailed in the 
Acknowledgements. My specific roles in this particular study included its 
conceptualization and design (jointly with my supervisor Dr. Sharon Gorski), sample 
coordination, data curation and analysis, results interpretation, figure generation and 
preparation of the submitted manuscript. 
2.1. Introduction 
PNENs are pancreatic neoplasms with neuroendocrine differentiation, in which 
substantial molecular and clinical heterogeneity has caused challenges for disease 
management. The WHO classification system has proven prognostic utility; the 
histological differentiation status in particular has been used to guide treatment regimens 
(Kunz, 2015). While both the functional status and the WHO classification system were 
shown to correlate with particular molecular alterations (Cao et al., 2013; Hong et al., 
2020; Yachida et al., 2012), the roles of molecular features in the management of this 
disease have been limited, and responses to therapies often vary between tumours of 
the same histopathological class (Raymond et al., 2011; Yao et al., 2011). Moreover, the 
categorization of borderline or ambiguous cases based on the presence/absence of 
clinical syndromes and histopathology can be difficult and subjective, thus hindering their 
effective management. 
Data from omics profiling studies have facilitated characterization of the 
molecular landscape of PNENs. WES and WGS of PNEN specimens have identified 
recurrent somatic mutations in MEN1, DAXX, ATRX and negative regulators of the 
PI3K/AKT/mTOR pathway, as well as recurrent germline mutations in MEN1, VHL and 
DNA repair genes MUTYH, BRCA2 and CHEK2 (Jiao et al., 2011; Scarpa et al., 2017). 
Differential gene expression analysis has identified metastasis-associated gene 
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signatures of PNENs (Scott et al., 2020). Several studies have identified altered 
signaling pathways, distinct chromosomal abnormalities and epigenomic profiles among 
PNENs, and up to 5 molecular subtypes with mutational and/or prognostic differences 
(Cejas et al., 2019; Chan et al., 2018; Di Domenico et al., 2020; Missiaglia et al., 2010; 
Sadanandam et al., 2015). However, most of these studies were restricted to pre-
defined subsets of PNENs based on either histological differentiation (Cejas et al., 2019; 
Chan et al., 2018; Di Domenico et al., 2020) or both histological differentiation and 
functional status (Hong et al., 2020). The restriction to pre-defined subsets of PNENs 
may limit the relevance of results to other PNEN cohorts and likely contributed to the 
observed discrepancies among the PNEN subtypes reported by different groups (Cejas 
et al., 2019; Chan et al., 2018; Di Domenico et al., 2020; Sadanandam et al., 2015). With 
the proteome of PNENs as yet virtually unexplored, along with the previous inconsistent 
PNEN subtyping based on transcriptome and/or epigenome profiling of pre-defined 
PNEN subsets, we set out to identify and characterize a non-selected group of PNENs 
by incorporating RNA-seq and global proteome data from patient specimens. Combined 
with WES and inference analysis, four molecularly distinct proteotranscriptomic 
subgroups of PNENs emerged. In this chapter, I present the identification and 
characterization of the four proteotranscriptomic subgroups of PNENs with mutational, 
transcriptomic, proteomic, molecular pathway and potential oncogenic driver differences. 
2.2. Results 
 Whole-transcriptome and global proteome analyses identify 
four distinct proteotranscriptomic subgroups among PNENs 
Consensus non-negative matrix factorization (cNMF)-based clustering was used 
to survey the optimal number of clusters and identify molecularly distinct subgroups. 
cNMF was initially performed on a Discovery cohort of PNEN specimens (n = 36; Table 
2.1 and Supplemental Table 1), 6 islet samples (five cadaveric and one matched to a 
Discovery cohort PNEN) and 2 cell line samples (BON-1 and QGP-1) using the top 25% 
variably expressed mRNAs from RNA-seq. Five clusters were identified, where one 
consisted exclusively of the normal islet samples, and another included the two cell lines 
with a few of the Discovery cohort PNENs (Figure 2.1A). Repeating cNMF on the 
Discovery cohort specimens alone essentially reproduced the same four PNEN clusters 
indicating robust separations between the four subgroups of PNENs (Figure 2.1B). 
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Table 2.1. Clinicopathological characteristics of the PNEN cohorts 
Characteristics Discovery 
N = 36 
Validation 
N = 48 
Total 
N = 84 
Median Follow-up Time – mo. (Range) 83.5 (2-211) 58 (0-87) 64 (0-211) 
Sex – no. (%)    
Male 18 (50) 18 (37.5) 36 (43) 
Female 18 (50) 30 (62.5) 48 (57) 
Functional Status – no. (%)    
Functional 3 (8) 7 (15) 10 (12) 
Nonfunctioning 33 (92) 41 (85) 74 (88) 
All-cause Mortality – no. (%)    
Censored 21 (58) 41 (85) 62 (74) 
Deceased 15 (42) 7 (15) 22 (26) 
Histological Differentiation – no. (%)    
Well Differentiated 33 (91.7) 45 (94) 78 (93) 
Poorly Differentiated 3 (8.3) 3 (6) 6 (7) 
Ki67 Index – no. (%)    
<3% 19 (53) 22 (46) 41 (49) 
3-20% 14 (39) 23 (48) 37 (44) 
>20% 3 (8) 3 (6) 6 (7) 
pTa: Primary Tumour – no. (%)    
pT1 4 (11) 19 (40) 23 (27) 
pT2 12 (33) 15 (31) 27 (32) 
pT3 15 (42) 10 (21) 25 (30) 
pT4 5 (14) 3 (11) 8 (10) 
pTX - 1 (2) 1 (1) 
pNa: Regional Lymph Nodes – no. (%)    
pN0 14 (39) 25 (69) 39 (46) 
pN1 22 (61) 9 (19) 31 (37) 
pNX - 14 (29) 14 (17) 
Metastases at Diagnosis – no. (%)    
Absent 25 (69) 36 (75) 61 (73) 
Present 5 (14) 12 (25) 17 (20) 
Unknown 6 (17) - 6 (7) 
All-time Metastases – no. (%)    
Absent 16 (44) 26 (54) 42 (50) 
Present 19 (53) 22 (46) 41 (49) 
Unknown 1 (3) - 1 (1) 
a. pT and pN were defined according to the 8th edition of American Joint Committee on Cancer Pancreas Cancer 
Staging system. pTX or pNX denotes specimens with insufficient information, due to specimens being biopsy material 
or absence of lymph nodes in the specimens. mo.: months; no.: number. The case-by-case clinicopathological 
characteristics are included in Supplemental Table 1. 
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Figure 2.1. cNMF rank survey of the Discovery cohort specimens based on 
transcriptomic profiles. 
cNMF was used to perform unsupervised clustering of the transcriptome data from the Discovery 
cohort PNEN specimens (n = 36). Cophenetic coefficients were used to evaluate how well the 
clustering results represented the original data, and silhouette coefficients were used to assess 
how similar a given sample was to its cluster compared to other clusters, respectively. A rank 
survey was performed to estimate the optimal rank based on cophenetic and silhouette 
coefficients (left). The consensus heatmap from the selected rank (right) was visually inspected 
for robust inter-cluster separation. The rank survey results are shown for the analysis of (A) the 
Discovery cohort specimens plus control samples or (B) the Discovery cohort specimens alone. 
Control samples included 6 normal islet and 2 cell line, BON-1 and QGP-1, samples. 
Global proteome profiling was used to augment the transcriptome data from the 
Discovery cohort specimens. A total of 86,439 unique peptides mapped to 10,656 
unique proteins were identified, 6,036 of which were quantified across all specimens. 
cNMF analysis using the top 25% variably abundant proteins similarly identified four 
clusters (Figure 2.2). Comparison between transcriptome- and proteome- based 
clustering results obtained from 35 Discovery cohort specimens with paired 
transcriptome and proteome data (Figure 2.3A-B) confirmed significant overlaps in the 
transcriptome- and proteome- based cluster assignments (Figure 2.3C), supporting the 
existence of four molecularly distinct proteotranscriptomic subgroups. Principal 
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component analysis (PCA) using either mRNA expression or protein abundance 
confirmed the molecular distinctions between the four subgroups and revealed one 
subgroup with greater intra-subgroup heterogeneity and inter-subgroup differences 
(Figure 2.4; purple). 
 
Figure 2.2. cNMF rank survey of the Discovery cohort specimens based on 
proteomic profiles. 
cNMF-based rank survey was performed to estimate the optimal rank based on cophenetic and 
silhouette coefficients (left) from the proteome data of 40 PNENs, including 35 of the Discovery 
cohort PNEN specimens. The consensus heatmap from the selected rank (right) was visually 
inspected for robust inter-cluster separation. 
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Figure 2.3. Whole-transcriptome and global proteome analyses identify four 
distinct proteotranscriptomic subgroups among PNENs. 
cNMF analysis was independently performed using (A) transcriptome or (B) proteome data from 
35 Discovery cohort PNEN specimens with paired information at the estimated optimal rank (k = 
4). Shown are the consensus heatmap with the subgroup assignments derived from each 
analysis colour-coded at the top. (C) A 4x4 table summarizes the mRNA- and protein- based 
subgroup assignments of each Discovery cohort specimen, where the intersections indicate the 
number of specimens assigned to a particular mRNA- and protein- based subgroup. The 
significance of each mRNA- and protein- based subgroup intersection (ie. overlap) is colour-
coded to reflect p-value computed from hypergeometric test with FDR correction. Comparisons 




Figure 2.4. PCA of the Discovery cohort specimens. 
PCA was performed for the Discovery cohort specimens with paired transcriptome and proteome 
data using either all expressed (A) mRNAs (n = 19,053) or (B) all quantified proteins (n = 6,036). 
Each dot represents a specimen and is colour-coded according to the subgroup assignments in 
Figure 2.3A-B. 
To identify mRNAs and proteins that differed significantly between the four 
subgroups, I used differential expression/abundance analysis. A total of 1,637 
differentially expressed genes (DEGs) and 354 differentially abundant proteins (DAPs) 
were identified between the subgroups among the Discovery cohort specimens. The list 
of DEGs and DAPs as well as their differential analysis statistics are available in 
Supplemental Table 2. 
 Analysis of a separate cohort of PNENs confirms the four 
proteotranscriptomic subgroups 
To confirm the four proteotranscriptomic subgroups, a Validation cohort of 48 
PNEN cases was identified (Table 2.1). Specimens from this cohort were collected, 
processed, sequenced and analyzed independently from the Discovery cohort to enable 
cross comparisons. cNMF analysis of the Validation cohort specimens, 4 islet samples 
and two NT-3 cell line (Benten et al., 2018) samples using the top 25% variably 
expressed mRNAs revealed six clusters where four consisted only of PNENs and two of 
either normal islet or cell line samples (Figure 2.5). Different from BON-1 and QGP-1, 
the NT-3 cell line samples formed a distinct cluster, which did not include any of the 
patient specimens. Repeating cNMF solely on the PNENs confirmed the existence of 
four clusters among the Validation cohort specimens (Figure 2.6A). To compare the 
subgroups identified from independent cluster analyses of the Discovery and Validation 
cohort specimens, the Discovery cohort-derived DEGs (Supplemental Table 2) were 
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used to perform cNMF on the Validation cohort specimens. This resulted in four 
subgroups (Figure 2.6B) that recapitulated the subgroups identified using Validation 
cohort variably expressed mRNAs (Figure 2.6C). Hence, I identified the same four 
subgroups of PNENs in two separate cohorts confirming the existence of four 
proteotranscriptomic subgroups among PNENs. Finally, I used the DEGs to perform 
cNMF to determine the final subgroup assignment of each of the 84 PNEN specimens 
included in this study. Four subgroups were identified (Figure 2.7A) and consisted of 
roughly equal numbers of specimens from the Discovery and Validation cohorts (Figure 
2.7B). I proceeded with these DEGs-defined subgroups for downstream analysis while 
keeping the molecular analysis independent between the two cohorts. 
 
Figure 2.5. cNMF rank survey of the Validation cohort specimens plus control 
samples based on transcriptomic profiles. 
cNMF-based rank survey was performed to estimate the optimal rank based on cophenetic and 
silhouette coefficients (left) from the transcriptome data of the Validation cohort PNEN specimens 
(n = 48) plus control samples. The consensus heatmap from the selected rank (right) was visually 
inspected for robust inter-cluster separation. Control samples included 4 normal islet and 2 NT-3 
cell line samples. 
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Figure 2.6. cNMF rank survey and comparison of subgroup assignments of the 
Validation cohort specimens. 
cNMF-based rank survey was performed using either (A) variably expressed mRNAs or (B) the 
Discovery cohort-derived DEGs to estimate the optimal rank based on cophenetic and silhouette 
coefficients (left) from the transcriptome data of the Validation cohort PNEN specimens. The 
consensus heatmap from the selected rank (right) was visually inspected for robust inter-cluster 
separation. (C) A 4x4 table summarizes the number of Validation cohort specimens that were 
assigned to each of the subgroups identified using variably expressed mRNAs or the Discovery 
cohort-derived DEGs, where the intersections indicate the number of specimens assigned to a 
particular subgroup. The significance of each intersection (ie. overlap) is colour-coded to reflect p-
value computed from hypergeometric test with FDR correction. 
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Figure 2.7. cNMF rank survey and subgroup distribution of the Discovery and 
Validation cohort specimens. 
(A) cNMF-based rank survey was performed using the Discovery cohort-derived DEGs to 
estimate the optimal rank based on cophenetic and silhouette coefficients (left) from the 
transcriptome data of the Discovery and Validation cohort PNEN specimens (n = 84). The 
consensus heatmap from the selected rank (right) was visually inspected for robust inter-cluster 
separation. (B) The consensus heatmap from the cNMF analysis of the Discovery and Validation 
cohort specimens overlaid with subgroup assignments and cohort designations colour-coded at 
the top. 
Sadanandam et al. previously analyzed microarray-based gene expression 
profiles (GEPs) from a non-selected cohort of PNENs (Missiaglia et al., 2010) but 
identified five subtypes: normal islet-like, insulinoma-like, MLP-1, MLP-2, and 
intermediate (Sadanandam et al., 2015). I reanalyzed their PNEN GEPs using my 
bioinformatic workflow and the Discovery cohort-derived DEGs and identified five 
subgroups that partially recapitulated the five Sadanandam subtypes (Figures 2.8A). 
While two of the DEGs-defined subgroups largely resembled the intermediate and MLP-
2 subtypes, one DEGs-defined subgroup combined normal islet-like and insulinoma-like 
samples together, and two DEGs-defined subgroups constituted the MLP-1 (Figure 
2.8B). The latter refinement of one subtype into two subgroups was likely due to my 
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approach using a greater number of genes in subgroup identification (1,637 vs 221 with 
155 overlap) and RNA-seq which has enhanced dynamic range over microarrays thus 
capturing other molecular differences between the subgroups. 
 
Figure 2.8. cNMF rank survey and subgroup comparisons of the Sadanandam 
et al. dataset. 
cNMF-based rank survey was performed using the Discovery cohort-DEGs to estimate the 
optimal rank within the microarray dataset from Sadanandam et al.. (A) The cophenetic and 
silhouette coefficients at the tested ranks, and (B) the consensus heatmap at the selected rank. 
(C) Enrichment of the subgroups identified using the Discovery cohort-derived DEGs (rows) in the 
five subtypes previously identified by Sadanandam et al. (columns). The colour of each block 
reflects the significance of the enrichment computed by hypergeometric test followed by FDR 
correction. MLP: metastasis-like primary 
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 Comparison of paired transcriptome and proteome profiles 
reveals modest single gene correlations but shared patterns of 
gene set enrichment 
Analogous results obtained from the transcriptome- and proteome- based 
clustering analyses suggested distinct mRNA and protein features between the four 
proteotranscriptomic subgroups. Comparison between global transcriptomes and 
proteomes of the Discovery cohort samples showed modest but positive correlations 
(median Spearman’s rho = 0.2776; Figure 2.9A). Comparison of paired mRNA 
expression and protein abundance from 5,931 available genes showed a wide spectrum 
of correlations between mRNA and protein variation (-0.4406~0.8840; Figure 2.9B) 
similar to previous studies in colorectal cancer (Mertins et al., 2016) and breast cancer 
(Zhang et al., 2014). Consistent with a low but variable number of genes showing 
concordant mRNA- and protein- level enrichment across normal tissues (Jiang et al., 
2020), the majority of DEGs and DAPs were mutually exclusive with only 121 genes in 
common (Figure 2.9C). However, the correlations between mRNA and protein variation 
of these 121 intersecting genes were significantly higher compared to the correlations 
between global mRNA and protein variation (median Spearman’s rho of 0.6807 vs. 
0.3804, p < 2.2 x 1016, Kolmogorov-Smirnov test; Figure 2.9B) suggesting that a subset 
of subgroup-specific genes was under concerted directional regulation. Indeed, gene set 
analysis (GSA) independently performed with transcriptome or proteome data using the 
Hallmark gene sets from MSigDB (Liberzon et al., 2015) produced results with similar 
patterns and revealed distinct molecular features of each subgroup (Figure 2.10; 
Supplemental Table 3). Analysis of the Validation cohort specimens identified similarly 
enriched or depleted gene sets between the subgroups (Supplemental Table 3). Based 
on these prominent molecular features, as well as similarities to two previously reported 
PNEN subtypes (Cejas et al., 2019; Chan et al., 2018), the four subgroups were named 
as follow: Proliferative (purple), Alpha-cell-like (green), PDX1-high (red) and 




Figure 2.9. Comparison of paired transcriptome and proteome profiles reveals 
modest single gene correlations. 
Comparisons between mRNA expression and protein abundance were made for 5,931 genes 
from the 35 Discovery cohort specimens with paired transcriptome and proteome data to evaluate 
(A) the correlation between steady state mRNA expression and protein abundance for each of the 
specimens, and (B) the correlations between mRNA and protein variation. For (B), shown in light 
grey are Spearman’s rho for all genes, and shown in dark grey are Spearman’s rho for the 121 
genes that overlap between DEGs and DAPs. (C) is an UpSet plot that details the number of 
genes overlapping between whole-transcriptome (mRNA), proteome (protein), the list of DEGs 
and the list of DAPs. The complete list of DEGs and DAPs are included in Supplemental Table 2. 
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Figure 2.10. Paired transcriptome and proteome profiles exhibit shared patterns 
of gene set enrichment. 
Gene set analysis using the Hallmark gene sets from MSigDB identified subgroup-specific 
features and revealed consistency between mRNA- (top) and protein- (bottom) level gene set 
enrichments among the Discovery cohort specimens. Each dot describes the enrichment (pink) or 
depletion (green) of each Hallmark gene set (rows) in each of the four proteotranscriptomic 
subgroups (columns), where its size and the length of its trailing grey bar are proportional to the 
significance of the enrichment/depletion. The same gene sets and order are shown in both the 
mRNA and protein plots. Only gene sets significantly enriched or depleted (FDR-adjusted p-value 
< 0.01; vertical dotted line) in at least one subgroup are shown. The complete results, including 
those from the Validation cohort comparison, are included in Supplemental Table 3. 
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 A Proliferative PNEN subgroup is associated with unfavourable 
clinicopathological characteristics and molecular features of 
cell cycle progression 
To increase statistical power and clinicopathological diversity, the associations 
between subgroups and available characteristics were evaluated using all 84 PNENs 
included in this study (Table 2.1). The Proliferative subgroup was associated with a 
reduced overall survival probability (p = 0.0024; logrank test; Figure 2.11), and 
significantly enriched with specimens of poorly-differentiated histology (i.e. PNECs) and 
Ki67 index > 20% (Table 2.2). Although PNECs are known to be genetically distinct from 
PNETs (Yachida et al., 2012), more than half of the Proliferative subgroup specimens 
had a well-differentiated histology and included one PNET-G1, four PNETs-G2, and one 
PNET-G3 (Supplemental Table 1). This observation suggests that a subset of PNETs 
may be more similar to PNECs than other PNETs at least at the transcriptome level. All 
four PNENs that had initially clustered with the BON-1 and QGP-1 cell line samples also 
fell within the Proliferative subgroup. 
 
Figure 2.11. Overall survival probability of all 84 PNEN patients included in this 
study. 
Patients were stratified by the proteotranscriptomic subgroup assignment of their specimens. 
Logrank test was used to evaluate whether the survival probabilities between the four subgroups 
were significantly different, and the resultant p-value is shown. 
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Table 2.2. Clinicopathological associations of the proteotranscriptomic 




Alpha cell-like Proliferative p-value 
Sex     
0.69 Female 13 12 17 6 
Male 7 13 11 5 
Functional Status     
0.47 Functional 5 1 3 1 
Nonfunctional 10 11 11 7 
All-cause mortality     
3.3 x 10-2 Censored 17 19 22 4 
Deceased 3 6 6 7 
Histological 
Differentiation 
    
5.2 x 10-5 
Well 20 24 28 6 
Poor 0 1 0 5 
Ki67     
4.7 x 10-4 
< 3% 14 12 14 1 
3 – 20% 6 12 14 5 
> 20% 0 1 0 5 
pTa     
0.28 
pT1 4 7 10 2 
pT2 4 10 10 3 
pT3 11 4 6 4 
pT4 1 4 2 1 
pNa     
0.26 pN0 7 14 14 4 
pN1 11 8 7 5 
Metastases at 
Diagnosis 
    
0.88 
No 13 20 20 8 
Yes 4 4 6 3 
All-time Metastases     
0.59 No 10 15 13 4 
Yes 9 10 15 7 
a. pT and pN were defined according to the 8th edition of American Joint Committee on Cancer Pancreatic Cancer 
Staging System. Cases with insufficient information were excluded. p-values were obtained from Fisher’s exact test 
with Monte Carlo simulation. 
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The molecular features of the Proliferative subgroup included enrichment of cell 
cycle-related gene sets such as E2F targets and G2M checkpoints, which were evident 
at both the mRNA and protein levels (Figure 2.10). The mRNA expression and protein 
abundance of marker of proliferation Ki-67 (MKI67) were also significantly higher in the 
specimens of this subgroup consistent with their higher Ki67-based grading 
(Supplemental Table 2). Signaling pathway impact analysis (SPIA) was used to identify 
KEGG pathways enriched among the subgroup-specific DEGs and infer the relative 
activation state of each pathway (Tarca et al., 2008). The results from SPIA further 
supported the activation of cell cycle pathways in the Proliferative subgroup 
(Supplemental Table 4). GSA using cellular component gene ontologies revealed 
enrichment of proteins involved in chromosomes and spliceosomes suggesting 
increased DNA replication and active transcription (Figure 2.12; Supplemental Table 5). 
In particular, the mRNA and protein levels of multiple members of the minichromosome 
maintenance (MCM) family were higher in the Proliferative subgroup (Supplemental 
Table 2). The MCM family of proteins are involved in DNA replication initiation and 
elongation as well as chromosome maintenance (Forsburg, 2004). Altogether, the 
Proliferative subgroup was associated with a reduced overall survival probability and 
exhibited histology-, mRNA- and protein- level evidence of increased cell proliferation 
consistent with poorer outcomes typically observed in patients with PNECs or PNETs of 
higher grade (Dasari et al., 2017). 
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Figure 2.12. The top cellular components enriched or depleted on the protein 
level in each proteotranscriptomic subgroup. 
The five highest ranking cellular component gene ontologies enriched (yellow) or depleted 
(purple) on the protein level in each of the four proteotranscriptomic subgroups depicted using 
circular barplot. The height and colour fill of each bar corresponds to the significance of the 
enrichment/depletion. Axis for the significance levels (FDR-adjusted p-values) are depicted as 
circular dashed lines for reference. All ontologies shown have FDR-adjusted p-value less than 
0.05. The complete results are included in Supplemental Table 5. 
 Transcriptomic and proteomic analysis reveals differential 
enrichment of ARX, PDX1 and organellar proteins between 
subgroups 
Similar to two PNET subtypes previously reported (Cejas et al., 2019; Chan et 
al., 2018), the Alpha cell-like and PDX1-high subgroups showed increased expression of 
the transcription factors ARX and PDX1, respectively, in both the Discovery and 
Validation cohorts. The expression levels of ARX and PDX1 in these two subgroups 
were also significantly higher (p = 0.014 and 0.023, respectively; Figure 2.13A) 
compared to levels observed in normal islets, indicating these transcription factors were 
selectively dysregulated. Considering that PDX1 and ARX are cell fate-determining 
transcription factors, I evaluated the transcriptomic similarity of the samples to major 
pancreatic cell types using gene set variation analysis (GSVA). The results indicated 
significant similarity of the Alpha cell-like subgroup to pancreatic alpha cells, while none 
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of the four PNEN subgroups were similar to pancreatic beta cells or other endocrine cell 
types across both cohorts (Figure 2.13B-C). The Alpha cell-like subgroup was further 
characterized by increased mRNA expression and protein abundance of genes involved 
in oxidative phosphorylation (OxPhos; Figure 2.10) and increased abundance of 
mitochondrial proteins (Figure 2.12). Notably, the protein abundance of arginine 
(arginase 2; ARG2) and glutamine/glutamate metabolic enzymes (glutaminase, GLS; 
glutamate-ammonia ligase; GLUL; and glutamate dehydrogenase 2, GLUD2) was 
significantly higher in the Alpha cell-like subgroup (Supplemental Table 2), suggesting a 
potential reliance on these amino acids. 
Given the differential expression of PDX1 and ARX and their known roles in 
transcriptional regulation, I performed transcription factor enrichment analysis (TFEA) 
using ChEA3 (Keenan et al., 2019) to identify other transcription factors that may 
contribute to the molecular differences between the subgroups. Among the 1,632 
transcription factors used by ChEA3 computation, one cut homeobox 1 (ONECUT1), 
paired related homeobox 2 (PRRX2), AE binding protein 1 (AEBP1) and forkhead box 
M1 (FOXM1) were the highest ranking in the PDX1-high, Stromal/Mesenchymal, Alpha 
cell-like and Proliferative subgroup, respectively. Both ARX and PDX1 were ranked 
among the top 10% transcription factors for both the Alpha cell-like and PDX1-high 
subgroups. The results from ChEA3 also suggested potential roles of ONECUT1/2, 
pancreas associated transcription factor 1a (PTF1A), SRY-box transcription factor 9 
(SOX9) and neurogenin 3 (NEUROG3), all reported to be expressed in pancreatic 
progenitor cells (Bastidas-Ponce et al., 2017; Shih et al., 2013), in shaping the GEPs of 
the PDX1-high subgroup specimens (Supplemental Table 6). The expression of 
NEUROG3 in human pancreas is transiently detected in endocrine progenitor and 
newly-differentiated endocrine cells (Jennings et al., 2013). The relatively higher mRNA 
levels of PDX1 and NEUROG3 observed in the PDX1-high subgroup specimens (Figure 
2.13A; Supplemental Table 2) further support that this subgroup may be relatively similar 
to endocrine progenitor cells. Together, these results support that the Alpha-cell-like 
subgroup specimens resemble pancreatic alpha cells and exhibit increased abundance 
of mitochondrial proteins and expression of OxPhos-related genes, while the PDX1-high 
subgroup is characterized by high mRNA expression of PDX1 and involvement of other 




Figure 2.13. Subgroups are characterized by difference in enrichment of cell 
types. 
(A) The mRNA expression of PDX1 and ARX between the four subgroups in the Discovery (left) 
or Validation (right) cohort. Statistical significance from differential expression analysis is shown 
for the PDX1-high subgroups (in the case of PDX1) or Alpha cell-like subgroups (in the case of 
ARX) vs. other PNENs (black asterisks) or normal islets (orange asterisks). (B) and (C) show the 
transcriptomic similarity of each (B) Discovery cohort or (C) Validation cohort (C) PNEN specimen 
to each of the 9 tested pancreatic cell types. Statistical significance in (B) and (C) was computed 
using Wilcoxon test to compare the scores from each subgroup of specimens to the rest. *: p < 
0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001. Ph: PDX1-high subgroup; S: 
Stromal/Mesenchymal subgroup; A: Alpha cell-like subgroup; P: Proliferative subgroup; I: Normal 
Islet. Each box marks the median, 25th quartile and 75th quartile, and the whiskers extend to 1.5 
times the inter-quartile range. 
 The Stromal/Mesenchymal subgroup specimens are enriched in 
stromal and immune cells 
Most sporadic PNETs present as well-demarcated solitary masses and are 
vascularized with small vessels and little fibrotic stroma (Capelli et al., 2009; Kasajima et 
al., 2015). PNETs often contain few tumour infiltrating lymphocytes (TILs) compared to 
PNECs or PDACs, but a subset of PNETs was previously observed with higher 
abundance of TILs (Takahashi et al., 2018). Among the specimens in this study, I 
identified a Stromal/Mesenchymal subgroup that showed mRNA- and protein- level 
enrichment of genes involved in epithelial-to-mesenchymal transition (EMT) and immune 
responses (Figure 2.10, Supplemental Table 3). In combination with inferred activation 
of focal adhesion and gap junction pathways (Supplemental Table 4), as well as 
increased abundance of proteins associated with the extracellular matrix (Figure 2.12), 
these results suggested a relatively higher involvement of tumour microenvironment 
(TME) and/or mesenchymal cell-related molecular features in this particular subgroup. 
The Stromal/Mesenchymal subgroup specimens also exhibited significantly higher 
transcriptomic similarities to mesenchymal and endothelial cells (Figure 2.13B-C), 
though platelet and endothelial cell adhesion molecule 1 (PECAM1/CD31) and CD34 
molecule (CD34) IHC staining of the primary specimens showed no evidence of 
increased microvessel densities (p = 0.81 and 0.26, respectively) (Figure 2.14A). GEP-
based stromal and immune cell inference analysis using ESTIMATE (Yoshihara et al., 
2013) and CIBERSORT (Newman et al., 2015) also found higher stromal and immune 
fractions in the specimens of this subgroup (Figure 2.14B-C). Together, these data 
indicate that the Stromal/Mesenchymal subgroup exhibited molecular characteristics 




Figure 2.14. Differences in enrichment of non-tumour cells between the four 
subgroups. 
(A) Microvessel density in each available Discovery cohort specimen (n = 36) assessed using 
either immunohistochemical staining of CD31 or CD34. The statistical significance was computed 
using Kruskal-Wallis test to test for differences between the subgroups. (B) The immune and 
stromal scores for each Discovery cohort (left) or Validation cohort (right) specimen from 
ESTIMATE analysis. (C) The absolute score from CIBERSORT for each Discovery cohort (left) or 
Validation cohort (right) specimen. In all panels, the specimens were stratified based on their 
subgroup assignments. In (B) and (C), the results from normal islet samples are included for 
reference, and the statistical significance was computed using Wilcoxon test to compare the 
scores from each subgroup of specimens to the rest. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Ph: 
PDX1-high subgroup; S: Stromal/Mesenchymal subgroup; A: Alpha cell-like subgroup; P: 
Proliferative subgroup; I: Normal Islet. Each box marks the median, 25th quartile and 75th quartile, 
and the whiskers extend to 1.5 times the inter-quartile range. 
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 Mutational differences between the proteotranscriptomic 
subgroups suggest distinct oncogenic drivers 
To identify recurrent and potentially pathogenic sequence variants between the 
four subgroups, WES was performed on the 35 Discovery cohort specimens with paired 
transcriptome and proteome data. A total of 355 mutations in 227 cancer-related genes 
were identified among the 35 Discovery cohort specimens, where 10 (4.4%) cancer-
related genes were mutated in more than 10% of the cohort (Supplemental Table 7). 
Among the most recurrently mutated cancer-related genes were those previously 
implicated in PNENs such as MEN1, DAXX, ATRX and VHL, with mutation frequencies 
of 22.9%, 17.1%, 8.6% and 11.4%, respectively (Figure 2.15). Comparison between the 
four subgroups showed a trend toward enrichment of deleterious MEN1 mutations (p = 
0.066; Fisher’s exact test) and significant enrichment of deleterious DAXX mutations (p = 
0.013; Fisher’s exact test) in the Alpha cell-like subgroup specimens. The Alpha cell-like 
subgroup was also the only subgroup with ATRX mutations or deleterious TSC1/2 
mutations. IHC staining of DAXX and ATRX showed no significant association between 
the detected DNA mutations and DAXX/ATRX scores (Figure 2.15). 
Germline mutations in VHL or NF1 can cause VHL syndrome or NF1 disorder, 
both potentially leading to PNEN development (Alexakis et al., 2004; Hammel et al., 
2000). There were four cases with VHL syndrome among the Discovery cohort patients 
all of which fell within the Stromal/Mesenchymal subgroup (Figure 2.15; Supplemental 
Table 1), consistent with the prominence of small vessels and stroma in VHL-associated 
neoplasms (Lubensky et al., 1998). In three of these VHL patients, at least one 
missense mutation in VHL was found in their sequenced specimens. None of the 
patients in our cohorts were diagnosed with neurofibromatosis, but a truncating mutation 
affecting NF1 was found in one PDX1-high case (Figure 2.15; Supplemental Table 7). 
Missense mutations in proto-oncogenes, experimentally shown to be 
hypermorphic in previous reports, were also found among the sequenced PNENs. These 
include a Proliferative subgroup specimen with a CTNNB1 p.D32N variant (Al-Fageeh et 
al., 2004) concomitant with high mRNA expression (470.7 transcripts per million (TPM) 
vs cohort average = 114.5, SD = 71.1) and protein abundance (normalized, log2-scale 
abundance of 7.1 vs cohort average = 5.7, SD = 0.5) of CTNNB1, two PDX1-high 
specimens with an activating HRAS (HRas proto-oncogene, GTPase) or NRAS (NRAS 
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proto-oncogene, GTPase) p.Q61R variant (Burd et al., 2014; Geyer et al., 2018; Muñoz-
Maldonado et al., 2019), another PDX1-high specimen with a weakly activating RET (ret 
proto-oncogene) p.V292M variant (Castellone et al., 2010), and a Stromal/Mesenchymal 
specimen with weakly activating KRAS p.L19F and p.Q22K variants (Smith et al., 2010a; 
Tsukuda et al., 2000) (Supplemental Table 7). Collectively, hypermorphic mutations 
affecting proto-oncogenes were identified in five of the sequenced specimens, all of 
which were histologically defined as PNETs (Figure 2.15). 
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Figure 2.15. Mutational differences between the proteotranscriptomic subgroups 
suggest distinct genetic drivers 
Oncoprint depicting the mutational status and the types of mutation in select genes among the 35 
Discovery cohort specimens with paired transcriptome and proteome data. The genes were 
selected based on mutational frequency > 10%, known relevance to PNENs or known roles as 
proto-oncogenes in which at least one hypermorphic mutation was found (see also Table S7). 
Samples are ordered and colour-coded according to their subgroup assignments (top row). The 
barplot (second row) shows, in each patient sample, the total number and types of variants 
affecting the genes shown. The barplot on the far right shows the total number and types of 
variants affecting the indicated gene. Additional clinicopathological characteristics of interest are 
shown at the bottom. Shown mutations are categorized into Deleterious mutations: nonsense or 
frameshift mutations, Indel: inframe insertions or deletions, Missense mutations, or Activating 
mutations: point mutations experimentally shown to be hypermorphic. 
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 Inferred activities of key cellular regulators are consistent with 
mutational differences and suggest involvement of the Hippo 
signaling pathway in the Stromal/Mesenchymal subgroup 
To evaluate the functional impacts of the identified mutations and particularly 
their effects on GEPs, I used VIPER (Alvarez et al., 2016) to infer the activity of key 
cellular regulators based on subgroup-specific gene expression signatures. The VIPER 
results are included in Supplemental Table 8. Consistent with the observed mutations 
and mutational differences, MEN1, DAXX and ATRX were relatively inhibited in the 
Alpha cell-like subgroup, while the PDX1-high subgroup showed relative activation of 
HRAS and NRAS along with inhibition of NF1. Similarly, the identified activating KRAS 
mutations and deleterious TSC2 mutations in the Stromal/Mesenchymal subgroup 
specimens were supported by the relative activation of KRAS and inhibition of TSC2 in 
this subgroup (Figures 2.15 and 2.16A). 
I further exploited the VIPER results and found Yes1 associated transcription 
regulator (YAP1) and WW domain containing transcription regulator 1 (WWTR1) to be 
the top 1 and 3 activated regulators, respectively, in the Stromal/Mesenchymal subgroup 
(Figure 2.16A; Supplemental Table 8). WWTR1, also known as TAZ, along with YAP1 
are transcriptional coactivators and downstream effectors of the Hippo signaling pathway 
(Varelas, 2014). Indeed, SPIA identified an over-representation of Hippo signaling 
pathway genes among the subgroup-specific DEGs in the Stromal/Mesenchymal 
subgroup (Supplemental Table 4). Further, differential analysis identified significantly 
higher mRNA expression of YAP1 and WWTR1 in the Stromal/Mesenchymal subgroup 
specimens compared to other PNENs or normal islets (Figure 2.16B). Given that YAP1 
and WWTR1 act as transcriptional coactivators, a direct measurement of YAP1/ 
WWTR1 protein activity can be made by examining the transcriptional levels of their 
target genes. For this, I used a previously curated panel of 22 YAP1/WWTR1 target 
genes (Wang et al., 2018) as a reference gene set. Significantly higher YAP1/WWTR1 
target enrichment scores in the Stromal/Mesenchymal subgroup specimens suggested 
the relative activation of YAP1/WWTR1 in this subgroup compared to other PNENs or 
normal islets (Figures 2.16C). Together, these results support the activation of the 
YAP1/WWTR1 signaling axis in the Stromal/Mesenchymal subgroup and mark the 




Figure 2.16. Inferred activities of cellular regulators are consistent with 
mutational differences and suggest involvement of the Hippo 
signaling pathway in the Stromal/Mesenchymal subgroup 
(A) Inferred activity (outer ring) of select cellular regulators of interest are illustrated along with 
their mRNA expression (centre fill) and protein abundance (outer fill) fold-changes between the 
four proteotranscriptomic subgroups, among the 35 Discovery cohort specimens with paired 
transcriptome and proteome data. The mRNA expression of protein abundance of a gene is 
outlined in black if the fold-change was significant with an adjusted p-value less than 0.05. Only 
genes with an adjusted p-value < 0.05 from the inference analysis are considered as activated or 
inhibited. (B) mRNA expression levels of YAP1 and WWTR1 in each of the Discovery cohort (left) 
or Validation cohort (right) specimens, stratified by subgroup assignments, or in normal islet 
samples. mRNA expression levels shown as log2-TPM values. Statistical significance from 
differential expression analysis is shown for the Stromal/Mesenchymal subgroup vs. other PNENs 
(black asterisks) or normal islets (orange asterisks). Statistical significance from differential 
expression analysis is shown for the Stromal/Mesenchymal subgroup vs. other PNENs (black 
asterisks) or normal islets (orange asterisks). (C) YAP1/WWTR1 target gene enrichment score for 
each Discovery cohort (left) or Validation cohort (right) specimen, stratified by subgroup 
assignments, or for normal islet samples. Statistical significance was computed using Wilcoxon 
test to compare the scores from each subgroup of specimens to the rest. **: p < 0.01; ***: p < 
0.001; ****: p < 0.0001. Ph: PDX1-high subgroup; S: Stromal/Mesenchymal subgroup; A: Alpha 
cell-like subgroup; P: Proliferative subgroup; I: Normal Islet. Each box marks the median, 25th 
quartile and 75th quartile, and the whiskers extend to 1.5 times the inter-quartile range. 
2.3. Discussion 
Using a multi-omics approach that combined exome-, transcriptome- and 
proteome- level data to portray an unselected group of PNENs, I identified four 
proteotranscriptomic subgroups. I also uncovered previously unrecognized metabolism-
related molecular differences in an Alpha cell-like subgroup and involvement of the 
Hippo signaling pathway in a Stromal/Mesenchymal subgroup of PNENs. Combined with 
subgroup-specific cellular regulators and oncogenic features, my findings provide a 
basis for potential patient stratification strategies with therapeutic implications. 
ARX and PDX1 are two transcription factors that may distinguish pancreatic 
alpha versus beta cells, respectively, with PDX1 also being expressed early during 
pancreas organogenesis (Shih et al., 2013). An ARX-high subtype of PNETs was shown 
to resemble pancreatic alpha cells, while a PDX1-high subtype of PNETs exhibited 
enhancer profiles resembling pancreatic beta cells but with more heterogeneity in intra-
subtype GEPs and PDX1 expression levels (Cejas et al., 2019; Chan et al., 2018). I 
similarly identified elevated PDX1 or ARX mRNA expression levels in PDX1-high and 
Alpha-cell like subgroups, respectively. The Alpha cell-like specimens showed 
transcriptomic similarity to pancreatic alpha cells and enrichment of mutations in ATRX, 
DAXX and MEN1, consistent with the A-D-M mutant PNET subtype reported by Chan et 
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al. (2018) and the Type A subtype reported by Cejas et al. (2019). However, the PDX1-
high subgroup did not exhibit any other molecular features suggestive of its similarity to 
pancreatic beta cells or any other endocrine cell types. These variations in the subset of 
PNENs with high PDX1 mRNA expression across studies warrant further investigation 
using larger and broader cohorts of PNENs. Furthermore, the majority of PNENs in this 
and previous studies (Cejas et al., 2019; Chan et al., 2018) were clinically identified as 
nonfunctional PNENs. The discovery of a subset of PNENs with transcriptomic similarity 
to pancreatic alpha cells but without clinically significant glucagon detection suggests a 
disconnection between molecular characteristics and clinical phenotypes and the 
importance of employing an unbiased approach to fully understand PNENs as a disease. 
In the Alpha cell-like subgroup specimens, I found previously unknown molecular 
features that revealed potential therapeutic angles. The Alpha cell-like subgroup showed 
mRNA- and protein- level enrichment of OxPhos-related genes as well as increased 
abundance of mitochondrial proteins, such as GLS, GLUL and ARG2. Some cancer 
types require utilization of GLS to catabolize glutamine and are susceptible to GLS 
inhibition (Cluntun et al., 2017). For example, in a hepatocellular carcinoma murine 
model with increased Gls mRNA expression and protein abundance, loss of a Gls allele 
or pharmacological inhibition of Gls using BPTES delayed tumour growth and prolonged 
survival (Xiang et al., 2015). The markedly higher abundance of glutamine and arginine 
metabolic enzymes in the Alpha cell-like subgroup may reflect the subgroup’s reliance 
on these amino acids and therefore sensitivity to interventions that affect their 
supply/availability. Considering multiple groups have reported a subset of PNENs with 
elevated ARX expression or ARX IHC positivity (Cejas et al., 2019; Chan et al., 2018; Di 
Domenico et al., 2020; Hackeng et al., 2021) similar to the Alpha cell-like subgroup, 
therapeutic agents such as BPTES that inhibit glutamine metabolism may provide 
therapeutic benefit for patients within this subgroup. With the frequent mutation of 
MEN1, DAXX or ATRX and the high expression level of ARX in the Alpha cell-like 
subgroup of PNENs, the relationship between these genetic alterations and its distinct 
metabolism-related expression profile could be exploited for the discovery of potential 
targeted treatments and corresponding predictive biomarkers. 
While I did not investigate the genomic landscapes of the PNEN specimens 
examined in this study, the Alpha cell-like subgroup may also correlate with other 
previously described subtypes without RNA-level characterization. Based on its 
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enrichment of specimens with mutant MEN1 and DAXX, higher ARX expression and/or 
clustering with pancreatic α-cells, the Alpha cell-like subgroup may resemble the Group 
1 subtype described by Lawrence et al. (2018), the Intermediate subtype by Di 
Domenico et al. (2020), the NF-Amp subtype by Hong et al. (2020), the T2 subtype by 
Lakis et al. (2021) and the Subtype A by Boons et al. (2020). Of note, three of these 
subtypes were characterized with recurrent LOH or loss in chromosomes 1, 2, 6, 10, 16 
and 22 (Boons et al., 2020; Lakis et al., 2021; Lawrence et al., 2018), suggesting 
potential links between concurrent alterations in MEN1 and DAXX and loss of these 
chromosomes. 
PNETs are typically known as a “tumour-suppressor” disease, wherein potential 
driver mutations most often affect tumour suppressor genes and rarely proto-oncogenes 
(Jiao et al., 2011; Scarpa et al., 2017; Wong et al., 2018). I found a surprising number of 
PNET cases with hypermorphic variants of proto-oncogenes: CTNNB1 (p.D32N), HRAS 
(p.Q61R), NRAS (p.Q61R), KRAS (p.L19F and p.Q22K), and RET (p.V292M) that result 
in either their constitutive activation or stabilization (Al-Fageeh et al., 2004; Burd et al., 
2014; Castellone et al., 2010; Geyer et al., 2018; Smith et al., 2010a; Tsukuda et al., 
2000). In particular, one third (3/9) of the PDX1-high subgroup specimens harboured 
gene variants that potentially lead to activated RAS signaling. Altogether, 5 out of 32 
(15.6%) PNETs, or 5 out of 35 (14.3%) PNENs, and no PNECs, among the Discovery 
cohort specimens harboured hypermorphic mutations affecting proto-oncogenes. 
Through inference analysis, I also found accompanying transcriptomic changes 
consistent with relative activation of these genes in the corresponding subgroups. It 
remains uncertain what led to the higher-than-expected number of activating mutations 
in these sequenced PNETs, but the inclusive nature of the current study and the 
epidemiology of the included PNENs may contribute to the observed differences. 
Nonetheless, the clustering of the cases harbouring potentially oncogenic mutations with 
other PNENs lacking obvious driver genetic alterations could reflect common intra-
subgroup molecular features. 
The Hippo signaling pathway elicits downstream transcriptional effects through 
YAP1 and WWTR1 (Hansen et al., 2015). I identified an unexpected activation of the 
YAP1 and WWTR1 transcriptional coactivators in the Stromal/Mesenchymal subgroup. 
Phenotypic consequences of YAP1 and WWTR1 activation include a myriad of cancer 
hallmarks, among which are the induction of EMT (Lei et al., 2008), promotion of 
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angiogenesis (Choi et al., 2015; Kim et al., 2017a) and modification of the TME 
(Zanconato et al., 2019) - all of which were observed in the Stromal/Mesenchymal 
subgroup (Figures 2.10 and 2.12). Both increased mRNA expression and relative 
activation of YAP1 and WWTR1 were found in the Stromal/Mesenchymal subgroup and 
were further supported by transcriptomic signatures previously shown to correlate with 
YAP1 and WWTR1 activation in pan-cancer analysis (Wang et al., 2018). YAP1 and 
WWTR1 are favoured therapeutic targets among the Hippo signaling pathway due to 
their direct roles in transcriptional regulation. Investigative drugs targeting YAP1 and 
WWTR1 are being explored (Crawford et al., 2018). Verteporfin, a photosensitizer used 
in photodynamic therapies, has demonstrated YAP1 inhibitory effects and anti-tumour 
effects in hepatocellular carcinoma, retinoblastoma and glioblastoma (Brodowska et al., 
2014; Liu-Chittenden et al., 2012; Vigneswaran et al., 2021), and may provide 
therapeutic benefit to patients with PNENs of the Stromal/Mesenchymal subgroup or 
exhibiting elevated YAP1/WWTR1 expression. The observation of high expression and 
activity of YAP1 and WWTR1 in the Stromal/Mesenchymal subgroup specimens could 
indicate their reliance on the activation of these Hippo signaling pathway effectors and 
susceptibility to inhibition of YAP1/WWTR1 activity. 
Epidemiological factors, the nonselective nature of case accrual, and an 
unprecedent multi-omic approach all likely contributed to the discovery of the new PNEN 
molecular features revealed in this study. Also, the PNEN specimens profiled in this 
study were mostly resected during the early stage of disease, as reflected by the few 
cases with metastases at the time of diagnosis. While the molecular landscapes of these 
early-stage PNEN specimens may partially differ from those of late-stage, metastatic 
disease, our study revealed biological subgroups that may aid treatment planning in the 
early stages of this highly heterogeneous disease. Given the rarity of PNENs and 
limitations of the specimens in the current studies, there may be additional PNEN 
subgroups not represented among our cohort specimens that could explain the distinct 
clustering of the NT-3 cell line samples. A meta-analysis combining the present study 
and previous PNEN profiling studies would be invaluable to more comprehensively 
understand the disease from both biological and therapeutic perspectives. 
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2.4. Methods 
 Case and clinical information accrual 
Tumour specimens 
The Discovery cohort consisted of PNEN cases included in a previously 
constructed pancreatic TMA (Riazy et al., 2015; Tessier-Cloutier et al., 2017). To identify 
PNEN cases for the Validation cohort, the pathology archives at Vancouver General 
were searched for PNEN cases, where the only criterion for inclusion in the study was a 
confirmed PNEN diagnosis. No exclusion criteria were implemented. For all identified 
cases with specimen availability, archival formalin-fixed paraffin-embedded (FFPE) 
tissue and corresponding data were retrieved and used in accordance with the ethical 
approval granted by the University of British Columbia (UBC) Clinical Research Ethics 
Board (H12-03484) and the UBC BC Cancer Research Ethics Board (H16-01577). The 
original slides were reviewed by a board certified pathologist (Dr. John Aird) to confirm 
the diagnosis, the pathological classification and the grade. 
A total of 41 PNENs from the Discovery cohort and 51 PNENs from the 
Validation cohort were subjected to RNA-seq. Forty of the Discovery cohort PNENs were 
characterized with proteomic profiling. Samples that failed RNA-seq or yielded inferior 
sequencing quality were excluded (see the RNA quantification and sample exclusion 
subsection under Section 2.4.2), resulting in the final Discovery cohort of 36 PNENs and 
the final Validation cohort of 48 PNENs. Thirty-five of the Discovery cohort PNENs with 
both RNA-seq and proteomic data were additionally characterized with WES. The two 
cohorts included patients at various disease and pathological stages diagnosed between 
1999 and 2016. 
For molecular assays, tumour-rich regions from FFPE tumour blocks were 
marked and cored. Areas with the highest Ki67 proliferative index were targeted. Due to 
limited material, tissue scrolls were instead obtained for two cases where only biopsied 
materials were available. For sequencing and proteomic sample extractions, two cores 




BON-1 was a gift from Drs. Courtney Townsend and Mark Hellmich at the 
University of Texas Medical Branch, Texas, USA. QGP-1 was purchased from the 
Japanese Cancer Resource Bank. NT-3 was previously developed and provided by Dr. 
Jörg Schrader at University Medical Center Hamburg-Eppendorf, Hamburg, Germany 
(Benten et al., 2018). BON-1 cells were cultured in DMEM:F12 (Gibco) supplemented 
with 10% fetal bovine serum (FBS; Gibco) and 10 mM HEPES (Gibco). QGP-1 cells 
were cultured in RPMI 1640 (Gibco) supplemented with 10% FBS. NT-3 cells were 
cultured in RPMI 1640 supplemented with 10% FBS, 100 U/mL penicillin-streptomycin 
(Gibco), 20 ng/mL EGF (Sigma-Aldrich) and 10 ng/mL FGF2 (Sigma-Aldrich). For 
culturing NT-3 specifically, cell culture vessels were coated with collagen IV (Sigma-
Aldrich) to ensure adherent growth. All three cell lines were developed from tumours 
from male patients. All cell cultures were maintained at 37°C with 5% CO2 and were 
checked regularly to be free of mycoplasma. Cells were harvested at 70~90% 
confluence and immediately snap-frozen. 
Normal islet samples 
Islet extractions were obtained from the IsletCore at the Alberta Diabetes 
Institute, Alberta, Canada, between 2016 and 2018. All extractions were derived from 
cadaveric pancreas from individuals (age: 22~74; BMI: 21.5~32.5; 6 males and 3 
females) without documented pancreas-related health conditions and of causes of death 
unrelated to cancer. All islet extractions were hand-picked after receipt to ensure 
maximum purity and snap-frozen immediately. An additional normal islet sample, 
matched to one of the FFPE tumour blocks was acquired by laser capture 
microdissection (LCM) of islets from fifteen 8 µm sections. 
Clinicopathological characteristics 
Where applicable, the grading (including the histological differentiation status and 
proliferative index) of the PNEN cases was updated to conform with the 2019 WHO 
classification system (Nagtegaal et al., 2020). The clinicopathological characteristics 
such as sex, tumour stage and WHO class of the study cohort are provided in 
Supplemental Table 1. The overall survival time was calculated by subtracting the date 
of diagnosis from the last follow-up date. pT and pN staging were defined according to 
the AJCC Staging Manual (8th edition). 
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 Sample processing 
FFPE tissue nucleic acid extraction 
Total nucleic acid extraction from FFPE specimens was performed using a 
modified version of Agencourt’s FormaPure protocol developed in-house and described 
previously (Haile et al., 2017, 2018). Briefly, Agencourt® FFPE FormaPure Kit (Beckman 
Coulter) was used per manufacturer’s instructions for total RNA extraction except 1) the 
DNase treatment step was excluded, 2) the deparaffinization/lysis step was extended to 
two hours, and 3) a reverse cross-linking step was included between proteinase K 
treatment and bead binding steps. 
Snap-frozen tissue nucleic acid extraction 
Frozen tissue or cell line pellets were homogenized in lysis buffer (RLT Plus + 
TCEP) for total nucleic acid (DNA and RNA) extraction using the EvoPure RNA Tissue 
Isolation kit (Aline Biosciences) automated on a Microlab NIMBUS liquid handler 
(Hamilton Robotics). Frozen tissue pieces were immersed in 420 µL of RLT Plus buffer 
(Qiagen) containing the reducing agent TCEP and a unique sample tracking DNA 
plasmid and gently agitated overnight at room temperature. Lysates were transferred 
from 2 mL tubes to wells of a 1.2 mL plate (Thermo Scientific, AB1127) into which was 
added 400 µL of 5x bind buffer (80 µL beads in 320 µL IPA). Following a 5 minute 
incubation at room temperature lysates were cleared on a magnet (Alpaqua, 96M-EX) 
for 6 minutes and the protein-containing supernatant removed. The beads, with bound 
nucleic acids, were washed by pipetting 10 times in wash buffer and returned to the 
magnet. Beads were washed three times in 70% ethanol then dried for 10 minutes. 40 
µL nuclease-free water was added to the dried beads and returned to the magnet. The 
eluted total nucleic acids were transferred to a 96-well storage plate and aliquots taken 
for fluorometric quantification using Qubit 4 Fluorometer (Thermo Scientific). 
RNA-seq 
To remove cytoplasmic and mitochondrial ribosomal RNA (rRNA) species from 
total RNA, NEBNext® rRNA Depletion Kit was used (New England Biolabs, NEB). 
Enzymatic reactions were assembled in a 96-well plate on a Microlab NIMBUS liquid 
handler. 100 ng of DNase I-treated total RNA in 6 µL was hybridized to rRNA probes in a 
7.5 µL reaction. Heat-sealed plates were incubated at 95oC for 2 minutes followed by 
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incremental reduction in temperature by 0.1oC per second to 22oC (730 cycles). The 
rRNA in DNA hybrids was digested using RNase H in a 10 µL reaction incubated in a 
thermocycler at 37oC for 30 minutes. To remove excess rRNA probes (DNA) and 
residual genomic DNA contamination, DNase I was added in a total reaction volume of 
25 µL and incubated at 37oC for 30 minutes. RNA was purified using RNA MagClean DX 
beads (Aline Biosciences) with 15 minutes of binding time, 7 minutes clearing on a 
magnet followed by two 70% ethanol washes, 5 minutes to air dry the RNA pellet and 
elution in 36 µL DEPC water. The plate containing RNA was stored at -80oC prior to 
cDNA synthesis. 
First-strand cDNA was synthesized from the purified RNA (minus rRNA) using 
the Maxima H Minus First Strand cDNA Synthesis kit (Thermo Scientific) and random 
hexamer primers at a concentration of 8 ng/µL along with a final concentration of 0.04 
µg/µL Actinomycin D, followed by PCRClean DX bead (Aline Biosciences) purification on 
a Microlab NIMBUS liquid handler. The second strand cDNA was synthesized following 
the NEBNext® Ultra™ Directional Second Strand cDNA Synthesis Module (NEB) that 
incorporates dUTP in the dNTP mix, allowing the second strand to be digested using 
USERTM enzyme (NEB) in the post-adapter ligation reaction and thus achieving strand 
specificity. 
cDNA was fragmented by sonication (Covaris, LE220) for 130 seconds (2x65 
seconds) at a “Duty cycle” of 30%, 450 Peak Incident Power (W) and 200 Cycles per 
Burst in a 96-well microTUBE Plate (Covaris, 520078) to achieve 200-250 bp average 
fragment lengths. The paired-end sequencing library was prepared following the 
Genome Sciences Centre (BC Cancer, Canada) strand-specific, plate-based library 
construction protocol on a Microlab NIMBUS liquid handler. Briefly, the sheared cDNA 
was subject to end-repair and phosphorylation in a single reaction using an enzyme 
premix (NEB) containing T4 DNA polymerase, Klenow DNA Polymerase and T4 
polynucleotide kinase, incubated at 20oC for 30 minutes. Repaired cDNA was purified in 
96-well format using PCRClean DX beads and 3’ A-tailed (adenylation) using Klenow 
fragment (3’ to 5’ exo minus) and incubation at 37oC for 30 minutes prior to enzyme heat 
inactivation. Illumina PE adapters were ligated at 20oC for 15 minutes. The adapter-
ligated products were purified using PCRClean DX beads, then digested with USERTM 
enzyme (1 U/µL) at 37oC for 15 minutes followed immediately by 13 cycles of indexed 
PCR using PhusionTM High-Fidelity DNA Polymerase (Thermo Scientific) and Illumina’s 
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PE primer set. PCR parameters: 98˚C for 1 minute followed by 13 cycles of 98˚C for 15 
seconds, 65˚C for 30 seconds and 72˚C for 30 seconds, and then 72˚C for 5 minutes. 
The PCR products were purified and size-selected using a 1:1 PCRClean DX beads-to-
sample ratio twice, and the eluted DNA quality was assessed with LabChip® GX 
(Caliper) for DNA samples using the DNA High Sensitivity Reagent Kit (PerkinElmer). 
Samples were then quantified using a Quant-iTTM dsDNA Assay Kit, high sensitivity 
(Thermo Scientific) on Qubit 4 Fluorometer prior to library pooling and size-corrected 
final molar concentration calculation for Illumina HiSeq2500 sequencing with paired-end 
75 base reads. Library pooling was done in sets of three, with the exception of the library 
from the one LCM islet sample, which was not pooled with other libraries. 
Protein extraction and digestion 
FFPE tissues were first deparaffinized using xylene. Lysis buffer (500 mM Tris-Cl 
pH 8, 2% SDS, 1% NP40, 1% Triton X-100, 5mM EDTA, 50mM NaCl, 10mM TCEP and 
40mM CAA) was then added to each sample. Proteins were denatured using heat (for 
130 minutes at 95°C with shaking at 1,100 RPM), followed by a 30 minute incubation at 
room temperature in the dark to allow reduction and alkylation of disulfide bonds. 
Protein clean-up and digestion was done using the SP3 protocol developed in-
house (Hughes et al., 2014, 2019). Briefly, paramagnetic beads were prepared by 
mixing two types of Sera-Mag Speed beads (GE Life Sciences) at 1:1 ratio, and 20 µg of 
bead mix was added to each protein mixture. Ethanol was added to a final concentration 
of 50% (v/v), and the sample was mixed and incubated for 10 minutes at room 
temperature to ensure protein-bead binding. The samples were then placed on a 
magnetic rack to stabilize the beads, and the supernatants were discarded, and two 
rinses with 70% absolute ethanol and one rinse with 100% absolute ethanol were 
applied. The beads were reconstituted in aqueous buffer (50 mM HEPES pH 8) 
containing trypsin/LysC mix (Promega) at 1:50 (ug/ug) enzyme to protein amount and 
sonicated for 30 seconds in a water bath to disaggregate the beads. The mixtures were 
then incubated for 14 hours at 37°C, sonicated for 10 seconds to resuspend the beads, 
and the supernatants recovered. 
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Peptide labeling and fractionation 
The digested peptide samples were prepared for mass spectrometry (MS) 
analysis in batches of 10, where each batch contained 8 randomly assigned patient 
samples and two common inter-batch controls. One control was a pooled all-sample 
mixture consisting of an aliquot of each patient sample. The second control was a 
universal standard consisting of digested peptides from thirteen cell lines. The peptide 
mixtures were labeled with tandem mass tag (TMT) using the TMT10plex labeling kit 
(Pierce) according to manufacturer's instructions. High-pH reversed phase analysis was 
performed on an Agilent 1100 HPLC system equipped with a diode array detector (254, 
260, and 280 nm). Fractionation was performed on a Kinetix EVO C18 column (2.1 mm 
x 150 mm, 1.7 μm core shell, 100 Å, Phenomenex). Elution was performed at a flow rate 
of 0.2 mL per minute using a gradient of mobile phase A (10 mM ammonium 
bicarbonate, pH 8) and B (acetonitrile), from 3% to 35% over 60 minutes. Fractions were 
collected every minute across the elution window for a total of 48 fractions, which were 
concatenated to a final set of 12 (e.g. 1 + 13 + 25 + 37 = fraction 1). Fractions were dried 
in a SpeedVac centrifuge and reconstituted in 1% formic acid with 1% DMSO in water 
prior to MS analysis. 
MS analysis 
Analysis of TMT-labeled peptide fractions was carried out on an Orbitrap 
FusionTM TribridTM MS platform (Thermo Scientific). Samples were introduced using an 
Easy-nLC 1000 system (Thermo Scientific). Columns used for trapping and separations 
were packed in-house. Trapping columns were packed in 100 μm internal diameter 
capillaries to a length of 25 mm with ReproSil-Pur C18 beads (3 µm particle size, Dr. 
Maisch). Trapping was carried out for a total volume of 10 μL at a pressure of 400 bar. 
After trapping, gradient elution of peptides was performed on a ReproSil-Pur C18 (1.9 
µm particle size, Dr. Maisch) column packed in-house to a length of 15 cm in 100 μm 
internal diameter capillaries with a laser-pulled electrospray tip and heated to 45°C using 
AgileSLeeve column ovens (Analytical Sales & Service). Elution was performed with a 
gradient of mobile phase A (water and 0.1% formic acid) to 8% B (acetonitrile and 0.1% 
formic acid) over 5 minutes, to 25% B over 88 minutes, to 40% B over 20 minutes, with 
final elution (80% B) and equilibration (5% B) using a further 7 minutes at a flow rate of 
375 nL per minute. 
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Data acquisition on the Orbitrap Fusion (control software v2.1.1565.20) was 
carried out using a data-dependent method with multi-notch synchronous precursor 
selection MS3 scanning for TMT tags. Survey scans covering the mass range of 350 – 
1500 were acquired at a resolution of 120,000 (at m/z 200), with quadrupole isolation 
enabled, an S-Lens RF Level of 60%, a maximum fill time of 50 ms, and an automatic 
gain control (AGC) target value of 4e5. For MS2 scan triggering, monoisotopic precursor 
selection was enabled, charge state filtering was limited to 2 – 4, an intensity threshold 
of 5e3 was employed, and dynamic exclusion of previously selected masses was enabled 
for 60 seconds with a tolerance of 20 ppm. MS2 scans were acquired in the ion trap in 
Rapid mode after CID fragmentation with a maximum fill time of 20 ms, quadrupole 
isolation, an isolation window of 1 m/z, collision energy of 30%, activation Q of 0.25, 
injection for all available parallelizable time turned OFF, and an AGC target value of 1e4. 
Fragment ions were selected for MS3 scans based on a precursor selection range of 
400-1600 m/z, ion exclusion of 20 m/z low and 5 m/z high, and isobaric tag loss 
exclusion for TMT. The top 10 precursors were selected for MS3 scans that were 
acquired in the Orbitrap after HCD fragmentation (NCE 60%) with a maximum fill time of 
90 ms, 50,000 resolution, 120-750 m/z scan range, ion injection for all parallelizable time 
turned OFF, and an AGC target value of 1e5. The total allowable cycle time was set to 4 
seconds. MS1 and MS3 scans were acquired in profile mode, and MS2 in centroid 
format. 
Genomic library construction 
A 96-well library construction protocol was performed for library construction from 
genomic DNA as previously described (Haile et al., 2017, 2018). Since DNA extracted 
from FFPE tissues is damaged by the fixation process and prolonged storage in non-
ideal conditions, variable DNA quality across the collection was expected with some 
highly degraded samples. An S1 nuclease treatment step was added to further remove 
single-stranded DNA as previously described (Haile et al., 2018). DNA was normalized 
to 300 ng in a volume of 62 μL elution buffer (Qiagen) and transferred into a 96-well 
microTUBE Plate (Covaris, 520078) for shearing on an LE220 (Covaris) acoustic 
sonicator using the conditions: Duty Factor - 20%, Peak Incident Power – 450W, Cycle 
per burst – 200, Duration – 2X 60 seconds with an intervening spin. The protocol for 
FFPE-derived DNA generates a dominant DNA peak in the 300-400 bp size range. 
Highly degraded DNAs can dominate the final amplified library. To improve library quality 
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of FFPE-derived DNA library, solid phase reversible immobilization (SPRI) bead-based 
size selection was performed before library construction to remove smaller fragments 
potentially from degraded DNAs. The NEBNext® FFPE End Repair Kit (NEB) was then 
used, followed by bead purification using a 0.8:1 (bead:sample) ratio to remove small 
FFPE-derived DNA fragments. Repaired DNA fragments were A-tailed and adaptor-
ligated to paired-end, partial Illumina sequencing adapters using the NEB Paired-End 
Sample Prep Premix Kit – A Tail (NEB) and the NEB Paired-End Sample Prep Premix 
Kit – Ligation (NEB), respectively, then purified twice with PCRClean DX beads (0.9:1 
ratio). Full-length, adaptor-ligated products were achieved by performing 8 cycles of 
PCR with primers, in which we introduced fault-tolerant hexamer “barcodes” to allow 
library multiplexing. Indexed PCR products were double purified with 0.9:1 ratio of 
library:beads. The concentrations of final library products were determined using size 
profiles obtained from a LabChip® GX using the DNA High Sensitivity Reagent Kit and 
quantified using the Quant-iTTM dsDNA Assay Kit with high sensitivity on the Qubit 4 
Fluorometer. 
WES 
Eight different genomic libraries (total of >500 ng) were pooled prior to whole-
exome capture using the xGen® Exome Research Panel v1.0 (Integrated DNA 
Technologies). The pooled libraries were hybridized to the capture probes at 65oC for a 
minimum of 4 hours. Following hybridization, Dynabeads™ M-270 Streptavidin (Thermo 
Scientific) was used for exome capture. Post-capture enrichment using 6 PCR cycles 
and primers that maintained the library-specific indices was performed. The pooled 
libraries were sequenced with paired-end 125 base reads in a single lane of an Illumina 
HiSeq2500 flowcell. 
 Data analysis 
RNA quantification and sample exclusion 
Raw RNA-seq data was aligned to the human reference genome hg19 using 
STAR in two-pass mode (Dobin et al., 2012), and duplicate reads were identified using 
Picard’s MarkDuplicates. Gene counts were obtained using featureCounts (part of 
Subread) (Liao et al., 2013) using transcript annotations obtained from Ensembl (v87). 
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Transcripts per million (TPM) values were calculated from the gene counts using the 
formula: 
(Count Effective length⁄ ) × 1,000,000
Sum(Count Effective length⁄ )
. 
As most of the samples were FFPE specimens, which typically yield degraded 
RNA, we excluded samples of inferior RNA-seq data quality based on strong deviation in 
quality measures from other FFPE samples within the same cohort. The decision to 
remove a sample was made based on a combination of factors including a low 
percentage of properly mapped reads, a much higher percentage of reads that were too 
short or mitochondrial, and a much higher percentage of duplicate reads. In addition, 
unsupervised clustering of the least variably expressed mRNAs (the 25% lowest ranking 
mRNAs based on coefficient of variation; n = 4,820) was used to identify outlier samples 
with strongly deviating mRNA expression profiles. 
Protein quantification and preprocessing 
Data from the Orbitrap Fusion were processed using Proteome Discoverer 
(Thermo Fisher) as previously described (Hughes et al., 2016). Briefly, Sequest HT was 
used to search for MS2 spectral matches against a combination of UniProt Human and 
Escherichia coli proteomes and a list of common contaminants. Percolator was used to 
determine peptide spectral match (PSM) error rates. A q-value cut-off of 0.05 was used 
to control for false discoveries. Reporter ions were quantified from MS3 scans where the 
output quantification values represented the signal-to-noise of the TMT value relative to 
the Orbitrap preamplifier. 
Quantification outputs from Proteome Discoverer were exported and analyzed in 
R. PSM data were filtered to remove contaminant and decoy proteins and those that 
were mapped to more than one protein. The abundance of uniquely identified peptides 
were computed from the quantification values of the PSMs mapped to the peptides by 
taking the median of all mapped PSMs. Peptide abundances were then treated with 
variance-stabilization normalization using the vsn R package (Huber et al., 2002, 2019) 
and collapsed into normalized protein abundance by taking their median values. The 
normalized protein abundance (log2-scale) was used in differential protein abundance 
analysis. 
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For clustering and visualization, ComBat from the sva R package (Leek et al., 
2019) was used on the normalized protein abundance values to adjust for batch 
covariates associated with different TMT batches. 
cNMF 
For initial cNMF analyses of the Discovery and Validation cohorts, I included 
normal human pancreatic islet samples and human PNEN cell lines as normal 
counterparts and to represent PNENs with known phenotypes and proliferative potential 
(Hofving et al., 2018), respectively. Six different normal (including one LCM) islet 
samples and BON-1 and QGP-1 cell line samples were included with the analysis of the 
Discovery cohort PNENs. For the analysis of the Validation cohort PNENs, four different 
normal islet samples and two biological replicate samples of NT-3 cell line were 
included. The final PNEN subgroups were identified among tumour specimens only. 
cNMF was performed using the NMF R package (Gaujoux and Seoighe, 2010, 
2020) using either the top 25% ranking genes (mRNAs or proteins) based on coefficient 
of variation or DEGs derived from the differential analysis between the four subgroups 
among the Discovery cohort (see the Differential analysis subsection below for details). 
cNMF analysis was done using either log2-transformed TPM values or normalized, 
batch-adjusted protein abundance values for mRNAs or proteins, respectively. mRNAs 
with expression level below 1 TPM in at least half of the sample cohort were excluded 
from the analysis. To survey the optimal rank and therefore the number of subgroups, 50 
iterations of NMF were performed assuming a possible rank at 2~7, and an optimal rank 
was selected based on high cophenetic and silhouette coefficients. The rank survey was 
performed on all PNEN specimens where information was available to maximize sample 
variation: n = 36 for RNA-seq data from the Discovery cohort specimens, n = 40 for 
proteomic profiles (including 35 of the Discovery cohort specimens), and n = 48 for RNA-
seq data from the Validation cohort specimens. To obtain the final subgroup assignment 
for each sample at the optimal rank, 200 iterations of NMF were performed followed by 
hierarchical cluster analysis of the resultant consensus matrix. Hierarchical cluster 
analysis was done using the hclust function from the stats R package (R Core Team, 
2020) with distance computed from 1 – consensus matrix. Where applicable, an initial 
seed of 123456 was set for reproducibility in computation. 
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Differential analysis 
Differential gene expression and protein abundance analyses were done using 
the limma R package (Ritchie et al., 2015; Smyth et al., 2020). For transcriptome data, 
RNAs expressed below 1 counts per million (CPM) in 10% of the samples were 
considered noise and removed. The read counts of the resultant 25,373 RNAs were 
transformed to log2-CPM using voom from the edgeR R package (Chen et al., 2020; 
Robinson et al., 2010). For proteome data, the normalized protein abundance was used, 
with the batch covariates associated with TMT-10 batches included in the design matrix 
to account for variations between different TMT-10 batches. DEGs or DAPs were 
identified between the PDX1-high, Stromal/Mesenchymal and Alpha cell-like subgroups. 
The Proliferative subgroup was analyzed independently and compared to the rest of the 
tumour samples to account for its higher intra-subgroup heterogeneity. Using a 
significance threshold of absolute log2-fold change (log2FC) > 2 and false discovery 
rate-adjusted p-value (p.FDR) < 0.05 for mRNAs, and absolute log2FC > 1 and p.FDR < 
0.05 for proteins, 1,637 DEGs and 354 DAPs were identified. 
Gene and protein ID conversions 
Different software and algorithms may require different gene/protein identifiers. I 
used biomaRt (Durinck and Huber, 2020; Durinck et al., 2005, 2009) and org.Hs.eg.db 
(Carlson, 2019) for conversions of identifiers. In instances where an analysis referenced 
both mRNAs and proteins, the official gene symbols approved by HGNC were used, and 
the mRNAs and proteins without official gene symbols were excluded. 
Enrichment analysis 
GSA was performed using Camera (Wu and Smyth, 2012) from the limma R 
package. The Hallmark and cellular components gene ontology gene sets were obtained 
from the Molecular Signatures Database (Liberzon et al., 2015) (downloaded June 25th, 
2019) and used as the reference gene sets. 
Signaling pathway impact analysis (Tarca et al., 2008) was used to identify the 
list of KEGG pathways over-represented by the subgroup-specific DEGs using the 
iLINCS web-based platform (http://ilincs.org). Only pathways with adjusted p-value 
(SPIA pajd) less than 0.05 were considered, and the status of each enriched pathway 
was only considered if the topology p-value (Top pval) was less than 0.05.  
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ESTIMATE analysis was performed using the estimate R package (Yoshihara et 
al., 2013). Log2-TPM values were used as the input, and the analysis was run using 
default parameters.  
TFEA was performed using the ChEA3 (Keenan et al., 2019) web portal 
(https://amp.pharm.mssm.edu/chea3/) using default parameters and the subgroup-
specific DEGs. 
PCA 
PCA was performed using log2-transformed TPM values from protein-coding 
genes using the stats R package (R Core Team, 2020). 
GSVA 
GSVA was performed using the GSVA R package (Guinney and Castelo, 2019; 
Hänzelmann et al., 2013) using log2-TPM values from protein-coding genes. To 
measure the transcriptomic similarity of each sample to a panel of pancreatic cell types, 
cell type-specific gene sets were constructed from a previous report comparing single-
cell RNA-seq data from different pancreatic cell types (Muraro et al., 2016). The genes 
found to be over-expressed (defined by a log2-fold change > 2 and an adjusted p-value 
< 0.05) in a cell type relative to others constituted the cell type-specific genes for that cell 
type. To estimate the transcriptional activity of YAP1/WWTR1, a panel of 22 
YAP1/WWTR1 target genes from a previous report (Wang et al., 2018) was used as the 
reference, and GSVA was used to transform the gene expression profile of each sample 
into a YAP1/WWTR1 target enrichment score. 
CIBERSORT 
The CIBERSORT source code in R was requested from 
https://cibersort.stanford.edu/download.php (downloaded February 18th, 2019). To run 
CIBERSORT, TPM values from RNA-seq and the LM6 signature genes were used 
(Newman et al., 2015). CIBERSORT was run at the absolute mode without quantile 
normalization, using sig.score as the absolute method. 
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Cellular regulator activity inference analysis 
Activities of cellular regulators were inferred using the viper R package (Alvarez, 
2019; Alvarez et al., 2016) and a previously constructed neuroendocrine neoplasm-
specific regulatory network (Alvarez et al., 2018). Subgroup-specific gene expression 
signatures were constructed from the moderated t-statistics from limma (described under 
the Differential analysis section), and the msVIPER function was used to infer the 
relative activities of cellular regulators between subgroups. The ledge function was used 
to perform leading edge analysis. A significance cut-off was set at an adjusted p-value of 
0.005, at which the number of false positive roughly equals to one. 
Variant calling and prioritization 
To increase the detection while reducing the number of false positive variants, 
SNVs and Indels were identified from both WES and RNA-seq reads from the 35 
Discovery cohort specimens with paired transcriptome and proteome data. WES and 
RNA-seq reads were aligned to hg19 with BWA-MEM (Li and Durbin, 2009) (parameters 
-M). Read duplicates were marked using sambamba (Tarasov et al., 2015). After 
alignment, RNA-seq reads that were aligned to exon junctions were repositioned in the 
genome as large-gapped alignments using JAGuaR (Butterfield et al., 2014). Four 
variant callers were used on the WES reads: Platypus (Rimmer et al., 2014), LoFreq 
(Wilm et al., 2012), Pisces (Dunn et al., 2019) and Mutect2 (Benjamin et al., 2019); all 
callers were run using default parameters including the respective quality filters. SNVs 
and Indels were identified in the RNA using SAMtools mpileup (Li et al., 2009) 
(parameters -C50 -ABuf) and filtered to remove variants with mapping quality score less 
than 20. 
SnpEff (Cingolani et al., 2012) was used to annotate and predict the functional 
impacts of the identified variants using GRCh37 annotation (ensemble v69). Consensus 
variants called by two or more variant callers were then identified from the WES and 
RNA-seq variants. The identified variants were additionally annotated with minor allele 
frequencies from gnomAD v2 (Karczewski et al., 2020), COSMIC mutation identifiers 
and functional prediction scores from COSMIC Coding Mutation Data (Tate et al., 2018) 
(downloaded March 12th, 2020)  and COSMIC Cancer Gene Census (Sondka et al., 
2018) (downloaded October 18th, 2019). 
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Formalin fixation is known to cause sequencing artifacts (Do and Dobrovic, 2015; 
Haile et al., 2018) and can potentially lead to false discovery of sequence variants. 
Considering that we used FFPE tumour specimens, and to compensate for the absence 
of matched normal control samples to help subtract germline variants from somatic 
variants called from individual tumour samples, we introduced several exclusion criteria 
to filter out variants that were unlikely to be pathogenic. For this study, we assumed that 
a disease-causing variant would 1) affect known cancer-related genes, 2) be rare among 
populations, 3) be present in substantial fraction of the bulk tumour, and 4) be predicted 
to impact the function of the protein product. Specifically, we filtered out variants 
considered as small nucleotide polymorphisms or with minor allele frequencies greater 
than 0.1% in gnomAD (Karczewski et al., 2020) or variant allele frequencies less than 
0.33 and focused on the variants affecting the 723 genes in the COSMIC Cancer Gene 
Census. Considering that PNENs generally have low mutation rates (Scarpa et al., 
2017) and recurrent hotspot mutations are rare, we filtered out identical mutations (that 
cause identical nucleotide changes at exact same genomic locations) found in more than 
10% of specimens in our cohort, which were likely due to technical artifacts. Variants in 
which the predicted functional impacts were benign according to COSMIC Coding 
Mutation Data (a FATHMM prediction of “Neutral”) were also filtered out. In addition, we 
filtered out variants with non-deleterious impacts (according to SnpEff) that affect the 
500 most frequently mutated genes in public exomes (Shyr et al., 2014). Lastly, eight in-
frame insertions or deletions affecting the two polymorphic trinucleotide repeat sites of 
the androgen receptor (AR) gene (Ferlin et al., 2005) were identified and excluded from 
further analysis. The result of incorporating these exclusion criteria and cancer focus 
was a list of more confident variants with presumptive oncogenic contributions. All 355 
post-filtering variants were visually validated in IGV. 
IHC analysis 
IHC staining and scoring of markers were performed using the previously 
constructed TMA (Riazy et al., 2015; Tessier-Cloutier et al., 2017). Briefly, for each case, 
an epithelial rich area of an FFPE tissue specimen was cored twice with a 0.6 mm 
needle and inserted into a recipient block generating a duplicate 0.6 mm core TMA. For 
staining, 4 µm sections were mounted onto slides and used for IHC staining. IHC 
staining of CD31 and CD34 was performed using the Dako Omnis (Agilent 
Technologies, Inc.) and DAXX and ATRX using the Discovery XT (Ventana Medical 
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Systems, Inc.) automated staining platforms following manufactuers’ recommendations. 
For CD31, slides were incubated with the JC70A clone (Agilent Technologies, Inc.) 
without dilution for 15 minutes at room temperature, then washed and incubated with 
mouse linker (Agilent Technologies, Inc.) for 10 minutes followed by polymer (Agilent 
Technologies, Inc.) for 15 minutes. For CD34, slides were incubated with the QBEnd/10 
clone (Agilent Technologies, Inc.) without dilution for 25 minutes at room temperature, 
then washed and incubated with polymer for 25 minutes. For DAXX and ATRX, slides 
were incubated with rabbit polyclonal antibodies (Sigma-Aldrich) at a dilution of 1:50 
(DAXX) or 1:100 (ATRX) for 60 minutes at room temperature, then washed and 
incubated with Universal Secondary antibody (Ventana Medical Systems, Inc.) for 32 
minutes at room temperature. 
CD31 and CD34 were quantified according to methods developed by Weidner 
(1995). DAXX and ATRX were quantified by H-Score which represents the product of 
percent (0-100) of epithelial cells staining positive and a subjective assessment of 
staining intensity (0-3) which yields a range of 0-300. 
 Data deposition and access 
The sequencing datasets generated during this study are available at the 
European Genome-phenome Archive (EGA; EGAS00001005024). The mass 
spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with the 
dataset identifier PXD024175. Derivative datasets directly referred to in this study are 
provided as supplemental tables. No new software or algorithms were used during the 
study. Public datasets and software downloaded and used during the study are listed in 
the Key Resources Table. 
 Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
CD31, clone JC70A Agilent Technologies, 
Inc. 
Cat# GA610 




REAGENT or RESOURCE SOURCE IDENTIFIER 
DAXX, polyclonal Sigma-Aldrich Cat# HPA008736 
ATRX, polyclonal Sigma-Aldrich Cat# HPA001906 
Biological Samples   











Chemicals, Peptides, and Recombinant Proteins 
USERTM Enzyme New England Biolabs Cat# M5508 
PhusionTM High-Fidelity DNA Polymerase Thermo Scientific Cat# F-530XL 
Trypsin/LysC Promega Cat# V5071 
Critical Commercial Assays 
Agencourt® FFPE FormaPure Kit Beckman Coulter Cat# A33343 
EvoPure RNA Tissue Isolation kit Aline Biosciences SKU R-907T 
NEBNext® rRNA Depletion Kit New England Biolabs Cat# E6310X 
RNA MagClean DX beads Aline Biosciences SKU C-1005 
Maxima H Minus First Strand cDNA Synthesis Kit Thermo Scientific Cat# K1652 
PCRClean Dx beads Aline Biosciences SKU C-1003 
NEBNext® UltraTM Directional RNA Second Strand 
Synthesis Module 
New England Biolabs Cat# E7550 
DNA High Sensitivity Reagent Kit PerkinElmer Part# CLS760672 
Quant-iTTM dsDNA Assay Kit, high sensitivity Thermo Scientific Cat# Q33120 
TMT10plex labeling kit Pierce Cat# 90406 
Sera-Mag Speed beads, carboxylate modified GE Life Sciences Cat# 
45152105050350 
NEBNext® FFPE End Repair Kit GSC New England Biolabs Cat# E6615B-GSC 
NEB Paired-End Sample Prep Premix Kit – A Tail New England Biolabs Cat# E6876B-GSC 
NEB Paired-End Sample Prep Premix Kit – Ligation New England Biolabs Cat# E6877B-GSC 
xGen® Exome Research Panel v1.0 Integrated DNA 
Technologies 
Cat# 1056115 
Dynabeads™ M-270 Streptavidin Thermo Scientific Cat# 65305 
Deposited Data 




REAGENT or RESOURCE SOURCE IDENTIFIER 









COSMIC Coding Mutation Data Tate et al., 2018 https://cancer.sange
r.ac.uk/cosmic 
COSMIC Cancer Gene Census Sondka et al., 2018 https://cancer.sange
r.ac.uk/census 








Mass spectrometry proteomics files This paper PXD024175 at 
https://www.ebi.ac.u
k/pride/ 
Experimental Models: Cell Lines 
BON-1 Drs. Courtney 
Townsend and Mark 
Hellmich, University of 
Texas Medical Branch 
N/A 
NT-3 Benten et al., 2018 N/A 
QGP-1 Japanese Cancer 
Resource Bank 
Cat# JCRB0183 
Software and Algorithms 
STAR v2.6.0c Dobin et al., 2012 https://github.com/al
exdobin/STAR 
Subread v1.6.0 Liao et al., 2013 http://subread.sourc
eforge.net/ 
Picard v2.22.0 Broad Institute https://broadinstitute.
github.io/picard/ 
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REAGENT or RESOURCE SOURCE IDENTIFIER 



























R v3.6.3 R Core Team, 2020 https://www.r-
project.org/ 
limma v3.42.2 Ritchie et al., 2015; 





edgeR v3.28.1 Robinson et al., 2010; 





estimate v1.0.13 Yoshihara et al., 2013 https://bioinformatics
.mdanderson.org/est
imate/rpackage.html 
GSVA v1.34.0 Hänzelmann et al., 






CIBERSORT v1.04   







REAGENT or RESOURCE SOURCE IDENTIFIER 
BWA-MEM v0.7.6a Li and Durbin, 2009 http://bio-
bwa.sourceforge.net
/ 
sambamba v0.5.5 Tarasov et al., 2015 https://github.com/bi
od/sambamba 
JAGuaR v1.7.5 Butterfield et al., 2014 https://www.bcgsc.c
a/resources/software
/jaguar 









LoFreq v2.1.3.1 Wilm et al., 2012 https://csb5.github.io
/lofreq/ 
Pisces v5.2.10.49 Dunn et al., 2019 https://github.com/Ill
umina/Pisces 




SAMtools v0.1.19 Li et al., 2009 http://www.htslib.org/ 
SnpEff v4.1 Cingolani et al., 2012 https://pcingola.githu
b.io/SnpEff/ 



















REAGENT or RESOURCE SOURCE IDENTIFIER 






biomaRt v2.42.1 Durinck et al., 2005, 












Chapter 3.  
 
Whole-genome and transcriptome analyses of 
metastatic PNENs 
This chapter is modified and expanded from a published report describing 
PNENs enrolled in the Personalized OncoGenomics (POG) program at BC Cancer 
(ClincalTrials.gov; NCT02155621). The individuals who contributed to this study and 
their specific contributions are outlined in the Acknowledgements. The first portion of the 
results in this chapter is adapted from the published report describing the whole-genome 
and whole-transcriptome characterization of five metastatic PNENs (Wong et al., 2018). 
A few updates to the published manuscript are implemented in this chapter to reflect 
advances in the field over the past 3 years. My specific roles in the published report 
included data curation and analysis, results interpretation, and preparation of the 
submitted manuscript. Later in this chapter, I expand the initial cohort of five metastatic 
PNENs to include four more recent PNEN cases enrolled in the POG program and 
compare them to the four proteotranscriptomic subgroups identified and characterized in 
Chapter 2. 
3.1. Introduction 
PNENs are rare pancreatic neoplasms commonly diagnosed at an advanced 
stage at which point distant metastases are evident or eventually ensue (Hallet et al., 
2015; Niederle et al., 2010). The molecular landscape of PNETs was initially described 
in a seminal paper by Jiao et al. (2011), in which WES identified recurrent somatic 
mutations in MEN1, DAXX/ATRX, and PI3K/AKT/mTOR pathway genes, most 
commonly PTEN, TSC2, and PIK3CA. Mutations in these and other genes may occur in 
hereditary cancer syndromes, including MEN1 syndrome, TSC, NF1 disorder, and VHL 
syndrome, that increase susceptibility to PNEN development (Jensen et al., 2008). The 
recurrent somatic mutations in MEN1, DAXX/ATRX and the PI3K/AKT/mTOR pathway 
genes were subsequently confirmed in a WGS study by Scarpa et al. (2017), who 
categorized somatically altered genes into those involved in chromatin remodeling, DNA 
damage repair, PI3K/AKT/mTOR pathway activation, and telomere maintenance. 
Additionally, 17% of the patients were found to harbour germline mutations not only in 
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previously described MEN1 and VHL but also in tumor suppressor genes CHEK2, 
MUTYH, and CDKN1B (Scarpa et al., 2017). PNECs, in contrast, often harbour 
alterations in TP53, RB1 and KRAS (Yachida et al., 2012). Aside from sequence 
variants, recurrent chromosomal anomalies have been described and associated with 
mutational frequencies of MEN1 and DAXX/ATRX in PNETs (Hong et al., 2020; 
Lawrence et al., 2018). Wide variations in CNV events have been observed between 
PNENs, and recurrent LOH in chromosomes 1, 2, 3, 6, 8, 10, 11, 16, 22 were observed 
in subsets of PNENs (Hong et al., 2020; Lawrence et al., 2018; Yao et al., 2019). 
Most molecular profiling studies of PNENs to date, however, have focused on 
primary tumours. Despite the important implications of distant metastases in PNENs for 
prognosis and treatment (Kunz, 2015), the molecular characteristics of PNEN 
metastases are rarely reported and the existing studies only examined genomic 
aberrations or metastasis-associated genes (Raj et al., 2018; Scott et al., 2020). The 
whole-genome and whole-transcriptome landscapes of PNEN metastases have not 
been reported. In this chapter, I describe the whole-genome and whole-transcriptome 
profiles for five patients with metastatic PNENs who underwent sequencing analyses as 
part of an ongoing clinical trial – the POG program at BC Cancer (ClincalTrials.gov; 
NCT02155621). Together with Drs. Hui-Li Wong (former medical oncology resident at 
BC Cancer) and Yaoqing Shen (analyst in the POG program), we identified notable 
genomic and transcriptomic characteristics of each of the five POG PNENs, which are 
presented here along with their clinical histories. In addition to previously described 
recurrently altered genes and chromosomes with recurrent LOH, two cases were found 
with molecular aberrations novel to PNENs. One case harboured focal amplification of 
MYCN (MYCN proto-oncogene, bHLH transcription factor) concomitant with loss of APC 
(APC regulator of WNT signaling pathway) and TP53 with wildtype MEN1 and DAXX, 
while another case harboured a germline fusion gene involving the nth like DNA 
glycosylate (NTHL1) gene. Lastly, I correlate these 5 cases plus 4 more recent PNEN 




 Clinical Presentation and Treatment Outcomes 
Clinical vignettes are described for each case below and summarized in Table 
3.1 and Figure 3.1. Radiological responses are defined per RECIST (Response 
Evaluation Criteria in Solid Tumors) version 1.1 (Eisenhauer et al., 2009). 
Table 3.1. Baseline characteristics of the five patients with metastatic PNENs. 
 Case 1 Case 2 Case 3 Case 4 Case 5 
Age (Year) 69 52 46 36 67 
Gender Male Female Female Male Male 






Functional Nonfunctional Nonfunctional Nonfunctional Nonfunctional 
Histological 
differentiation 
Well Well Well Well Poor; LC 
Ki67 indexa < 2% 10-15% 15% 20% > 70% 
Baseline 
chromogranin Ab 




Yes Yes Not done Yes Not done 
aKi67 index was categorized according to the criteria of the WHO 2010 classification system, but the grades remain the 




Figure 3.1. Clinical evolution and treatment of the five patients with metastatic 
PNENs. 
Cap/Tem: capecitabine with temozolomide; Cis/Etop: cisplatin with etoposide; Carbo/Iri: 
carboplatin with irinotecan; Y-90: yttrium90 radioembolization. 
Case 1 
A 69 year-old man presented with hypercalcemia and was found on computed 
tomography (CT) imaging to have a pancreatic mass and liver lesions. Pathology 
examination of the pancreatic mass obtained under endoscopic ultrasound guidance 
confirmed a PNET-G1. Serum chromogranin A (CgA) was slightly elevated at 110 µg/L 
(normal range of < 94 µg/L), and the liver and pancreatic lesions were intensely avid on 
octreotide scan. He commenced treatment with everolimus and underwent core biopsy 
of a liver metastasis for molecular analyses after 7 weeks of therapy. He had 
radiologically stable disease, but treatment was discontinued after 4 months because of 
grade 2 pneumonitis. Second-line systemic therapy with sunitinib was initiated but also 
discontinued early because of congestive heart failure. He eventually received 90yttrium 
(Y-90) radioembolization therapy to his liver metastases and had a partial radiological 
response. His hypercalcemia, which was initially refractory to bisphosphonates and 
required several hospital admissions for management, normalized and remained stable 
5 months after Y-90 therapy. At the study cut-off time (20 months after diagnosis), he 
remained well on maintenance monthly long-acting octreotide. 
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Case 2 
A 52 year-old female presented with several years of abdominal pain, which 
eventually led to abdominal ultrasound and CT that showed a pancreatic tail mass and 
multiple liver lesions. Pathological examination of the liver core biopsy showed a PNET-
G2. CgA was slightly elevated at 92 U/L (normal range of < 40 U/L) and imaging with 
111Indium-labeled octreotide showed uptake in her known disease sites. She 
commenced treatment with sunitinib but required several dose reductions for grade 2 
hand-foot syndrome. She had a brief trial of everolimus but switched back to sunitinib 
after 3 weeks because of mucositis and pneumonitis. She had a symptomatic response 
and radiologically stable disease that was sustained for 15 months before developing 
progressive liver metastases, which did not accumulate 18F-DOPA. She underwent a 
liver biopsy for genomic analysis prior to starting second-line systemic therapy with 
Cap/Tem. She achieved a partial radiographic response and, after 20 months of 
chemotherapy, proceeded to resection of her pancreatic primary along with 
radiofrequency ablation of the liver metastases. Pathologic review of the resected 
pancreatic primary again confirmed a PNET-G2. Three of nine lymph nodes were 
involved. At the study cut-off time (43 months after diagnosis), she remained well with 
disease stability off chemotherapy. 
Case 3 
A 46 year-old female with a prior history of TSC, resected renal angiomyolipoma, 
and childhood epilepsy was noted to have liver masses on routine surveillance imaging. 
Due to progressive fatigue, leg edema, and abdominal discomfort related to massive 
hepatomegaly, a liver biopsy 9 months after initial presentation was done. IHC of the 
liver biopsy did not support metastatic angiomyolipoma but confirmed expression of 
paired box 8 (PAX8) in favour of a pancreatic origin (Sangoi et al., 2011), suggesting a 
PNET-G2 pathology. CgA was markedly elevated at 5200 µg/L. She commenced 
treatment with everolimus and underwent biopsy of a liver metastasis for molecular 
analyses after 16 weeks of therapy. She had an early symptomatic and marker 
response, where CgA decreased to 3780 µg/L from a peak of 8200 µg/L. Interestingly, 
her TSC-associated skin lesions (presumed facial angiofibromas), also improved on 
everolimus treatment. Radiological response could not be accurately assessed, as 
pretreatment imaging was performed 8 months prior to the start of the treatment. 
However, her treatment course was complicated by recurrent anemia, diarrhea, and 
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renal impairment. After nearly 7 months of everolimus treatment, she developed clinical 
progression and died 8 months after initial pathologic diagnosis. Referral to the 
Hereditary Cancer Program for clinical genetic testing had been discussed but was not 
pursued due to absence of significant family history, so this was not pursued. 
Case 4 
A 36 year-old man presented with a short history of right shoulder and chest pain 
was found on CT to have multiple liver lesions and a pancreatic tail mass. Pathological 
examination of the core liver biopsy suggested a PNET, both morphologically and on 
immunoprofile, with positive staining for synaptophysin and cytokeratin AE1/AE3. 
Although the tumor had < 2 mitotic rate (mitoses/10 HPF), the Ki67 index was up to 20% 
in some areas; hence this was classified as a PNET-G2. Octreotide scan identified 
additional disease within the retroperitoneal and supraclavicular lymph nodes, and CgA 
was modestly elevated at 250 µg/L. He commenced first-line systemic therapy with 
Cap/Tem, but the disease progressed after three cycles. He then received Y-90 
radioembolization to the liver but progressed within 3 months. Prior to starting second-
line systemic therapy with everolimus, he underwent liver biopsy for genomic analysis. 
He was also referred for PRRT, but his clinical status declined rapidly. He died 10 days 
after commencing everolimus, 8.4 months after initial diagnosis. 
Case 5 
A 67 year-old male presented with a short history of diarrhea and constitutional 
symptoms and was found on CT to have multiple liver masses and a pancreatic tail solid 
lesion that appeared suspicious for pancreatic ductal adenocarcinoma. He consented for 
genomic analysis at the time of his diagnostic liver biopsy, which showed a NEC-LC with 
positive staining for synaptophysin, chromogranin, and cytokeratin 19. The Ki67 index 
was > 70%. CgA was markedly elevated at 4920 µg/L. He received treatment with 
cisplatin and etoposide for four cycles before developing disease progression. He then 
received four cycles of carboplatin and irinotecan but also had upfront disease 
progression. He had ongoing clinical deterioration and died 9 months after initial 
diagnosis. 
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 Genomic analyses 
WGS of liver metastases and blood from the five patients was performed to 
identify somatic genomic alterations including chromosomal aberrations (Figure 3.2) and 
sequence variants (Figure 3.3A; Supplemental Table 9). Germline alterations in 98 
cancer susceptibility genes were evaluated, as approved by the research ethics board. 
RNA-seq was performed to identify alterations in gene expression and molecular 
pathways. For comparison of gene expression levels, the expression levels of select 
genes were converted into percentile ranks against a collection of tumor transcriptomes 
from The Cancer Genome Atlas (TCGA) project (https://portal.gdc.cancer.gov/) (Figure 
3.3A) or to a compendium of 16 normal tissue transcriptomes from the Illumina Human 
BodyMap 2.0 project (https://www.ebi.ac.uk/gxa/experiments/E-MTAB-513/Results) 
(Supplemental Table 11). The latter comparison provided a coarse list of putative 
disease-specific genes for each case and was used to identify prospective upstream 
regulators (Figure 3.3B) and pathways affected (Supplemental Table 10). Hereafter, 
description of individual gene expression level specifically refers to comparison with the 
TCGA tumor compendium unless otherwise noted. 
The approved therapeutic drugs for the treatment of PNETs in Canada include 
everolimus, sunitinib, SSAs, and chemotherapy with Cap/Tem, whereas platinum-based 
chemotherapy is typically reserved for PNECs. I retrieved the list of proteins targeted by 
the aforementioned approved therapeutic agents from Santos et al. (2017) and 
examined the status of their gene and gene expression in addition to genes previously 
implicated in PNENs (Figure 3.3A). 
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Figure 3.2. Genome-wide copy-number architectures across the five cases. 
(A) Chromosomal regions with loss of heterozygosity events are depicted in green. The zygosity 
states at these regions are not discriminated. (B) Copy number deviations from the estimated 
ploidy in protein-coding regions are depicted in red (copy gain) or blue (copy loss). The 
magnitude of copy gains is capped at +4. Aside from Case 4 in which the estimated ploidy was 4, 





Figure 3.3. Key molecular alterations and predicted upstream regulators across 
the five cases. 
(A) An OncoPrint depicting alterations in genes that have either been implicated in PNETs or are 
targets of conventional therapeutic agents used to treat PNETs. All alterations described here are 
somatic, aside from Case 3, which had germline one copy loss of TSC2. “Set A” contains genes 
recurrently mutated in sporadic PNETs (Jiao et al., 2011). “Set B” contains genes in which 
germline mutations were recently reported in PNET patients (Scarpa et al., 2017). “Others” 
contains genes of interest in this study. “Drugs” contains genes with protein products that are the 
molecular targets (color-coded) of the indicated therapeutic agents used to treat PNETs. 
Nonsynonymous mutations (black bar), copy-number aberrations (red/blue shade), and up- or 
down-regulated expressions (red/blue edge) of these genes are shown. All genes have gray 
background by default to facilitate visualization. Shallow and deep deletions refer to one- or two-
copy losses, respectively. Up-regulated genes are defined as those expressed at levels > 90% of 
TCGA tumor compendium, and down-regulated genes as those expressed at levels < 10% of 
TCGA tumor compendium. (B) Using the Upstream Regulator Analysis tool from Ingenuity 
Pathway Analysis software, the activation states of prospective upstream regulators in each 
sample were predicted based on differentially regulated genes. Only upstream regulators with 
activation score of > 3 or < -3 were selected. Color and intensity indicate the predicted activation 
state and effect size, respectively. The overlap p-value of each prediction is also indicated. *: p < 
0.05; **: p < 0.01; ***: p< 0.001; ****: p < 0.0001. 
A B
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 Shared molecular alterations 
Several genomic alterations were shared within the cohort. LOH events were 
frequently observed in Cases 1, 2, 3, and 5, with chromosomes 1, 2, 3, 6, 11, 16, 21, 
and 22 largely affected. These include regions encoding for MEN1 (11q13.1), DAXX 
(6p21.32), and TSC2 (16p13.3) (Figure 3.2A). Frequent copy number gains were 
observed in Cases 1 and 5, whereas copy number losses, most of which were likely due 
to LOH, were more frequent in Cases 2 and 3. Gene amplification events, defined as the 
ploidy-corrected copy number gain being greater than the ploidy, were absent in Cases 
1, 2, and 3 but were observed in Case 5 and more frequently in Case 4 (Figure 3.2B). 
Consistent with the reported low mutation burden in PNETs (Jiao et al., 2011), less than 
50 nonsynonymous mutations in protein-coding genes were identified in three of the five 
cases (median = 39; range = 21~170; Supplemental Table 9). Somatic mutations in 
MEN1 and DAXX were found in Cases 1, 2, 3, and 5. These comprised nonsense, 
frameshift, and splice site mutations as well as in-frame deletion or missense mutations 
predicted to be deleterious (Table 3.2). In conjunction with LOH events or copy number 
losses, these mutations resulted in biallelic loss of MEN1 and DAXX in the four cases. 
The expression levels of both MEN1 and DAXX were low across all five cases, whereas 
TSC2 expression was low in Cases 1, 2, 3, and 4. Tumor suppressor gene CHEK2 also 
had low expression in Cases 1, 2, 3, and 5 (Figure 3.3A). 
The gene expression levels of the drug molecular targets varied across all five 
cases, but similar trends were observed in a few of the genes. All five cases had high 
expression of SSTR1/2, consistent with their neuroendocrine diagnosis and 111In-labeled 
octreotide scan avidity. The gene encoding the core kinase of the mTOR pathway 
MTOR was expressed at low levels in cases 1, 2 and 4. Low expression of O-6-
Methylguanine-DNA methyltransferase (MGMT), which indicates sensitivity to 
temozolomide in glioblastoma (Hegi et al., 2005), was observed in Cases 1, 2, 3 and 5 
(Figure 3.3A). 
High expression of neuroendocrine markers and pancreas-specific transcription 
factors confirmed the pancreatic origin of the metastases. In all five cases, high 
expression levels of the chromogranin A (CHGA) and the synaptophysin (SYP) genes 
were observed, and neuronal differentiation 1 (NEUROD1) and PDX1 were expressed at 
high levels in four cases. In addition, each case exhibited increased expression of at 
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least one of the INS, glucagon (GCG), gastrin (GAST), SST or vasoactive intestinal 
peptide (VIP) genes, favouring a pancreatic endocrine cell origin (Supplemental Table 
11). 
Table 3.2. Sequence variants in genes previously implicated in PNENs. 
Case Gene Chr HGVS DNA HGVS protein Predicted effect Genotype 
Case 1 MEN1 1 c.1579C>T p.R527* Stop gain Hom 
















Case 2 ATRX X c.1558G>T p.V520F Missense variant Hom 
Case 2 MTOR 1 c.6625C>G p.L2209V Missense variant Hom 
Case 2 BRCA2 13 c.3504G>T p.M1168I Missense variant Het 





Case 3 DAXX 6 c.850C>T p.Pr284S Missense variant Hom 
Case 4 TP53 17 c.818G>T p.R273L Missense variant Hom 
















Chr: chromosome; Hom: homozygous; Het: heterozygous. 
 Case-specific molecular alterations of interest 
Case 1 
In addition to many of the shared molecular alterations, low expression levels of 
tumour suppressor genes TP53 and VHL were observed in this case. Several receptor 
tyrosine kinases (RTKs) and targets of sunitinib including fms related receptor tyrosine 
kinase 1 (FLT1) and kinase insert domain receptor (KDR) that encode for vascular 
endothelial growth factor receptors 1 and 2, respectively, were expressed at high levels 
(Figure 3.3A). Moreover, several MAPK pathway genes including MAP3K10, MAP3K12 
and MAP2K2 were highly expressed suggesting up-regulated activity of MAPK pathways 
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(Supplementary Table 11). The use of sunitinib as second-line therapy was supported by 
the high expression of several RTKs; however, treatment response was not assessable 
due to early discontinuation of therapy. 
Case 2 
Contrary to the other four cases where somatic mutations were only identified in 
MEN1 and DAXX, additional somatic mutations in genes associated with PNENs were 
identified in Case 2. These include a heterozygous missense mutation in BRCA2 and a 
homozygous missense mutation in ATRX, both of unknown significance (Table 3.2). 
Prediction of the damaging effects of the missense mutations using Polyphen-2 
(Adzhubei et al., 2010) indicated that the BRCA2 variant was likely benign (score = 
0.000) while the ATRX variant p.V520F was likely damaging (score = 0.999). In addition, 
missense mutations resulting in amino acid substitutions adjacent to the identified ATRX 
variant (p.S519 and p.P521) had been reported and predicted to be pathogenic 
(http://cancer.sanger.ac.uk; COSM5878330, COSM5878331, COSM4993581, 
COSM4993582; Forbes et al., 2015). Collectively, these predictions suggested that the 
identified mutation in ATRX likely affected its protein functions. Mutations in DAXX and 
ATRX are typically mutually exclusive, and this case was the first reported instance of a 
PNEN with concurrent homozygous DAXX and ATRX loss. Examination of allelic 
frequencies of the DAXX and ATRX variants suggested that both were present in all 
tumour cells (Supplemental Table 9). The identified missense mutation in MTOR, which 
resulted p.L2209V, affected its kinase domain and had been previously characterised as 
an activating mutation that results in constitutively active mTOR signalling (Yamaguchi et 
al., 2015). 
Case 3 
In keeping with the clinical history of TSC in this case, one allele of TSC2 was 
found altered in the germline. Combined with a somatic loss of the remaining copy, the 
biallelic loss of TSC2 accompanied its very low expression (0 percentile) in the tumour. 
The germline inactivation of TSC2 was due to structural variants in chromosome 16, 
which included a large deletion spanning TSC2 and the base-excision repair gene 
NTHL1, and an inversion that caused a fusion between NTHL1 and the TNF receptor 
associated factor 7 (TRAF7) gene (Figure 3.4), predicted to be non-functional. 
Comparison to previously described COSMIC mutational signatures (Alexandrov et al., 
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2013) showed an unusually high contribution of Signature 30, characterized by a high 
proportion of C>T transitions (Figure 3.5). Similar mutational profiles were reported in 
NTHL1-mutated tumours related to polyposis syndromes (Rivera et al., 2015; Weren et 
al., 2015) and in NTHL1 knock-out human colon organoids (Drost et al., 2017), but have 
not previously been described in PNENs. The TMB of this case was the highest among 
the PNETs in this cohort, with 7.47 somatic mutations per megabase vs. 1.17-2.17, with 
C>T transition accounting for 45% (77/170) of the coding variants.  
 
Figure 3.4. Illustration of the two structural variants involving TSC2 identified in 
Case 3. 
Only part of the chromosome 16 that is affected is shown. The lengths of the arrows shown are 
not to scale. 
 
Figure 3.5. Comparison of mutation signature of case 3 to signature 30. 
The base substitutions at all possible trinucleotide contexts are colour-coded as depicted on the 
right. 
Breakpoints of Deletion 1: 16:2093920, 16:2126780
Breakpoints of Deletion 2: 16:2212355, 16:2214166
Breakpoints of Inversion 1: 16:2093920, 16:2212355
Breakpoints of Inversion 2: 16:2126780, 16:2214166
NTHL1 TSC2 TRAF7
Inversion 1
Resulting in NTHL1-TRAF7 fusion
where the fusion product is expressed 
Inversion 2
Resulting in TSC2-TRAF7 antisense 
fusion where the fusion product 
is not expressed
Chr16 (part)
Deletion 1 Deletion 2
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Case 4 
Unlike the other cases in this cohort, CNV events were infrequent in Case 4 
(Figure 3.2). Moreover, no mutations were observed in MEN1, DAXX and ATRX. 
Instead, the key genomic aberrations included a homozygous pathogenic TP53 mutation 
(COSM10779), copy number loss and a gene fusion event involving the APC, and 
amplification of MYCN. Consistent with the observed genomic aberrations, both TP53 
and APC were expressed at low levels. MYCN had a 38-copy gain and was 
overexpressed (99 percentile; 48 fold-change relative to the BodyMap compendium 
expression) (Figure 3.3A). Gene expression analyses predicted activation of MYCN 
(Figure 3.3B) and identified enrichment of genes encoding ribosomal proteins 
(Supplemental Table 10), which are known to be regulated by MYCN (Boon et al., 2001). 
Together, these results suggested MYCN-driven transcriptomic changes in this case. 
In view of the unusual genomic findings, pathology review was undertaken and 
confirmed the diagnosis of PNET-G2 in the liver biopsy samples taken at diagnosis and 
after progression on chemotherapy and Y-90. In particular, there was no evidence of 
transformation to a PNEC, or evidence of glandular or acinar components that may 
suggest an alternate diagnosis. 
Case 5 
Although Case 5 was histologically diagnosed as a PNEC, its genomic landscape 
was similar to that of PNETs as in Cases 1, 2 and 3. These include similar regions with 
LOH events (Figure 3.2A) and copy number aberrations (Figure 3.2B), as well as 
biallelic loss of MEN1 and DAXX (Figure 3.3A). Gene expression analyses suggested a 
number of transcription factors and receptors were uniquely affected in this case. The 
cell cycle regulator cyclin D1 was predicted to be activated (Figure 3.3B), consistent with 
enrichment of genes involved in cell cycle pathway (Supplemental Table 10). 
 Proteotranscriptomic subgroup of metastatic PNENs 
Having examined the whole-genome and whole-transcriptome landscapes of the 
PNEN metastases along with their clinical progression, I was interested in whether these 
metastases could be categorized into one of the four proteotranscriptomic subgroups 
described in Chapter 2. To determine the possible subgroup for each of the metastases, 
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I compared the transcriptomes of the PNENs from the POG program to the sequenced 
specimens from Chapter 2. Additional metastatic PNEN cases had been enrolled in the 
POG program since the publication of the report on the five cases described earlier in 
this chapter, so I expanded my POG PNEN cohort to include these four additional 
metastatic PNEN cases (available up to March 2021) for the comparisons. One of these 
newer cases was a PNET-G3 without alterations in MEN1 and DAXX/ATRX and was 
described previously in a case report (Williamson et al., 2019). The inclusion of these 
more recent POG PNENs resulted in a total of 9 metastatic PNENs from which WGS 
and WTS data were available (Table 3.3). 
Table 3.3. All metastatic PNENs enrolled in the POG program up to March 
2021. 
Study IDa Differentiation status Ki67 index Biopsy site Tumour contentb 
PN2 (Case 3) Well 3-20 Liver 0.77 
PN4 (Case 5) Poor; LC > 55 Liver 0.86 
PN6 (Case 2) Well 3-20 Liver 0.79 
PN12 (Case 1) Well < 3 Liver 0.79 
PN14 (Case 4) Well 3-20 Liver 0.79 
PN18 Mixed; Well > 55 Pancreas 0.64 
PN23 Well 21-55 Liver 0.95 
PN25 Well 3-20 Liver 0.36 
PN27 Well 3-20 Liver 0.30 
aCase numbers were previously assigned arbitrarily based on Ki67 index-based grades for publication purposes. 
Instead of the case numbers, a Study ID was assigned to each NEN enrolled in POG in sequential order. The case 
numbers referred to in the 2018 publication are included in the brackets. bTumour contents were estimated based on 
WGS data. 
I first examined the global transcriptomic correlation of the 9 POG PNENs to the 
sequenced samples from Chapter 2. The samples from Chapter 2 used in this 
comparison included the 84 primary PNEN specimens with subgroup assignments, with 
the 10 normal islet and the 4 cell line samples serving as biological references. As 
expected, and similar to the unsupervised cluster analysis results showing normal islet 
and some of the cell line samples clustering away from PNEN specimens (Figures 2.1A 
and 2.5), the POG PNENs generally had lower transcriptomic correlation to normal islet 
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and cell line samples. On the contrary, greater correlations to primary PNENs of the 
Alpha cell-like subgroup were observed (p = 0.00042; Figure 3.6). 
 
Figure 3.6 Correlation of POG PNENs to each of the proteotranscriptomic 
PNEN subgroups. 
Transcriptomic correlation between the 9 analyzed POG PNENs and a total of 98 sequenced 
samples from Chapter 2 was evaluated using Spearman’s rank correlation. The distributions of 
the correlations between the POG PNENs to PDX1-high subgroup (n = 20), 
Stromal/Mesenchymal subgroup (n = 25), Alpha cell-like subgroup (n = 28), Proliferative 
subgroup (n = 11), normal islet (n = 10) or cell line (n = 4) samples are shown. The dashed line 
denotes the median correlation for all comparisons. The statistical significance was computed 
using Kruskal-Wallis test to determine differences between the subgroups or using Wilcoxon test 
to compare between each subgroup/specimen type to the rest. 
I next explored whether each of the POG PNENs could fit in any of the four 
proteotranscriptomic subgroups that I had identified. This entailed examining the 9 POG 
PNENs on an individual basis and evaluating their transcriptomic similarities to each of 
the subgroups. For this, I adapted the GSVA-based approach that I had employed in 
Chapter 2 for use with subgroup-specific genes. Here, subgroup-specific genes were 
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defined as DEGs exclusively up-regulated in a subgroup, and together represents the 
reference gene signature for the subgroup. Using GSVA against the reference gene 
signature from each of the four proteotranscriptomic subgroups enumerated an 
enrichment score that reflects the subgroup enrichment scores for a target GEP. Using 
the average score as the baseline for each subgroup enrichment, a higher transcriptomic 
similarity to the Alpha cell-like subgroup specimens was observed in 4 of the POG 
PNENs: PN2, PN4, PN6 and PN12 (Figure 3.7), corresponding to Cases 3, 5, 2 and 1 
that had been previously characterized (Table 3.3). In addition, the mRNA expression of 
ARX was relatively high in these four cases, in keeping with their higher similarities to 
the Alpha cell-like subgroup specimens (Figure 3.8). These cases were also the only 4 
POG PNENs among the cohort with concurrent mutations in MEN1 and DAXX (Table 
3.4), consistent with my previous observation of the Alpha cell-like subgroup enriched in 
specimens with mutant MEN1 and DAXX (Figure 2.15). 
Various combinations of subgroup signatures were observed in the POG PNENs. 
PN14 (previously referred to as Case 4), which had only been characterized with MYCN 
amplification and alterations in APC and TP53, had a GEP with a mixed signature of 
PDX1-high and Proliferative subgroups. PN18, a MiNEN, also displayed a mixed 
signature, but was of Stromal/Mesenchymal and Proliferative subgroups (Figure 3.7). 
Consistent with PN18 exhibiting the most pronounced Stromal/Mesenchymal subgroup 
signature among all POG PNENs, the mRNA expression of both YAP1 and WWTR1 
were considerably higher in this PNEN. The only other POG PNEN also demonstrating a 
substantial Stromal/Mesenchymal subgroup signature, PN2, had a high WWTR1 
expression (Figure 3.8). Further, four POG PNENs displayed a pronounced Proliferative 
subgroup signature, either alone or in combination with another subgroup signature. 
These four cases: PN4, PN14, PN18 and PN23 exhibited various histology (including a 
PNEC-LC, a PNET-G2, a PNET-G3 and a MiNEN) but shared a common characteristic 
of high Ki67 indices (Table 3.3). This was consistent with my previous finding of the 
Proliferative subgroup associated with PNENs of higher Ki67 indices irrespective of 
histological differentiation (Table 2.2). 
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Figure 3.7. Transcriptomic similarity of each POG PNEN to the four 
proteotranscriptomic subgroups. 
GSVA was used to evaluate the transcriptomic similarity of each POG PNEN to the four 
proteotranscriptomic subgroups using subgroup gene signatures. Each panel shows the 
enrichment results for a POG PNEN. The average enrichment score from all POG PNENs is 
indicated as a bold vertical line for each subgroup. Ph: PDX1-high; S: Stromal/Mesenchymal; A: 
Alpha cell-like; P: Proliferative. 
Table 3.4. Mutational status of MEN1, DAXX and ATRX in the 9 POG PNENs. 
Study ID MEN1 DAXX ATRX 
PN2 (Case 3) g.64575023C>T (splice variant) p.P284S - 
PN4 (Case 5) p.Tyr327fs p.N268_I275del - 
PN6 (Case 2) p.D82_I86del p.S110fs p.V520F 
PN12 (Case 1) p.R527* p.K393fs - 
PN14 (Case 4) - - - 
PN18 p.D501fs - - 
PN23 p.R420* - - 
PN25 - - p.K1274* 
PN27 - - - 




Figure 3.8. mRNA expression levels of ARX, PDX1, YAP1 and WWTR1 in the 9 
POG PNENs. 
The TPM value for each indicated gene from each of the 9 POG PNENs is shown. Aside from 
ARX, the y-axis is kept consistent across the genes. 
3.3. Discussion 
In the case series study in the earlier part of this chapter, the whole-genome and 
whole-transcriptome landscapes of liver metastases from five patients with metastatic 
PNENs were described. Previous studies on primary PNETs have identified recurrent 
somatic mutations in MEN1, DAXX/ATRX and mTOR pathway genes and germline 
mutations in genes involved in chromatin remodelling, DNA damage repair, mTOR 
signalling and telomere maintenance (Jiao et al., 2011; Scarpa et al., 2017). Consistent 
with these reports, we identified biallelic loss of MEN1 and DAXX (due to deleterious 
mutations, copy number losses and/or LOH events) in three of the four PNETs 
characterized. Low mRNA expression of MEN1, DAXX and TSC2 were observed in all 
five PNENs. These likely contributed to tumour development and progression. In 
addition, one or more cases exhibited low expression levels of tumour suppressor genes 
CHEK2, CDKN1B, NF1 and VHL, in which germline mutations had been reported in 

















































































TSC2 within our cohort (Case 3), the reduced expression of these genes likely also 
augmented disease development and progression. 
Previous studies suggest that loss of nuclear DAXX/ATRX staining is associated 
with metastases, poor prognostic features and shorter survival (Marinoni et al., 2014; 
Singhi et al., 2017). While we are unable to make any definite conclusions about the 
prognostic impact of DAXX/ATRX in our cohort, it is clear that treatment and survival 
outcomes in PNENs were highly variable, and other drivers likely contributed to disease 
progression and treatment response. 
For example, a liver metastasis (Case 4) with typical pathologic features of a 
PNET-G2 was characterized with unique genomic characteristics previously unreported 
in PNENs. The MYCN amplification and expression signature observed in this case had 
not previously been described in human PNENs, although ectopic targeted expression of 
MYCN in pancreatic islets or neural progenitor cells was shown sufficient to induce 
PNEN development in zebrafish and mice, respectively (Fielitz et al., 2016; Yang et al., 
2004). MYCN promotes cell proliferation, and MYCN amplification was correlated with 
poor prognosis, particularly in neuroblastomas (Huang and Weiss, 2013). Similarly, the 
clinical picture for this case was characterized by treatment resistance and poor survival 
that may have been compounded by TP53 loss, which may have negated the pro-
apoptotic signals elicited by MYCN and augmented its oncogenic potential (Chen et al., 
2010; Gamble et al., 2012). Of interest, a small interfering RNA targeting MYC (MYC 
proto-oncogene, bHLH transcription factor) was investigated as a potential therapeutic 
strategy in solid tumours including PNETs, where treatment responses observed in a 
phase I trial (Tolcher et al., 2015) have led to cohort expansion in this tumour type 
(ClinicalTrials.gov; NCT02110563) (Dicerna Pharmaceuticals Inc., 2015). The trial was 
unfortunately terminated as the pharmaceutical sponsor discontinued the program to 
focus on other candidates (Dicerna Pharmaceuticals Inc., 2016). However, given 
demonstrated anti-tumour activity of targeting MYC in PNENs, it would be important to 
explore any underlying molecular characteristics that may predict benefit to MYC-
targeted therapy and regimens that target MYCN. 
Conversely, another PNET within the cohort (Case 2) had relatively good 
treatment outcomes, with prolonged responses to sunitinib (15 months) and Cap/Tem 
(no progression after 20 months). We observed low expression of MGMT in the tumor, 
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which has previously been described and correlated with better responses to 
temozolomide in small PNET cohorts (Cros et al., 2016; Kulke et al., 2009). 
Alterations and aberrant expression of PI3K/AKT/mTOR pathway genes have 
been frequently reported in PNETs (Jiao et al., 2011; Missiaglia et al., 2010), and the 
mTOR inhibitor everolimus is well-established as effective therapy in PNETs-G1/2 (Yao 
et al., 2011). However, no biomarkers that may predict for response to everolimus have 
yet been validated. Within our cohort, three patients received everolimus, and Case 3 
had an early and sustained response to treatment, which would be supported by 
genomic evidence of biallelic TSC2 inactivation. Decreased expression of TSC2 and/or 
PTEN was observed in the other two patients (Cases 1 and 4); however, no conclusions 
can be made regarding the impact of these findings on response to everolimus 
treatment. 
Previous study reported genomically distinct findings that differentiate pancreatic 
NETs from poorly differentiated NECs, with the latter frequently associated with TP53 
and RB1 alterations and rarely with DAXX or ATRX loss (Yachida et al., 2012). 
Conversely, in a study comparing genomic characteristics of NECs from different 
primary sites, the majority PNECs did not harbour alterations in TP53 or RB1, whereas 
33% and 20% of the sequenced PNECs harboured genomic alterations (due to SNVs, 
SVs or CNVs) in MEN1 and DAXX, respectively (Bergsland et al., 2016). The only PNEC 
in this study (Case 5) did not have TP53 or RB1 alterations but retained the 
pathognomonic mutations commonly observed in PNETs. Other genomic features in this 
case included a higher mutation burden and gene expression profile indicative of cell 
cycle activation that was not seen in the other cases (Figure 3.3B; Supplemental Table 
10). The unusual observation of PNET-associated but not PNEC-associated genomic 
alterations in this PNEC-LC raises the hypothesis that it may have evolved from a PNET 
or that some PNECs may share genomic characteristics of PNETs. Either way, this 
suggested the patient would have been a candidate for therapy with targeted molecular 
therapy or temozolomide typically administered to PNETs rather than platinum therapy 
given for PNECs, which did not induce a response. This indicates an inadequacy of the 
conventional approach of treating PNETs and PNECs as distinct entities. 
Of interest, the higher than expected TMB in a PNET-G2 (Case 3), coupled with 
an unusual mutational signature, drew our attention to the germline fusion event causing 
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NTHL1 loss. Germline mutations in NTHL1 had been described in the context of 
polyposis syndromes (Rivera et al., 2015; Weren et al., 2015), similar to those 
associated with MUTYH loss, another base-excision repair gene (Al-Tassan et al., 2002; 
Shinmura et al., 2000). Analogous to Case 3, MUTYH loss was associated with a novel 
mutational signature in PNETs (Scarpa et al., 2017). While loss of the two base-excision 
repair genes resulted in different mutational patterns (C>T for NTHL1 and C>A for 
MUTYH), the physiological similarities between the loss of these two genes highlight the 
potential utility of examining mutational signatures to determine mechanisms of 
tumorigenesis in PNETs. To our knowledge, this was the first reported PNET case 
associated with NTHL1 loss and a somatic mutation pattern that resembles signature 30. 
This was also the first study correlating response to systemic therapy with whole-
genome and transcriptome analyses in PNEN patients and preceded many of the 
sequencing studies involving PNENs to date (Cejas et al., 2019; Chan et al., 2018; Hong 
et al., 2020; Lawrence et al., 2018; Raj et al., 2018). Notably, three of the PNENs in this 
study harboured LOH affecting chromosomes 1, 2, 3, 6, 11, 16, 21, and 22 (Figure 
3.2A). Subsequent studies examining chromosomal aberrations in PNETs similarly 
identified recurrent LOH events in these chromosomes, concurrent with MEN1 
mutations. However, one study found the recurrent LOH events associated with 
lymphovascular invasion (Lawrence et al., 2018) while another observed association 
with a better overall survival probability (Yao et al., 2019). As we and others analogously 
found a subset of PNENs with recurrent LOH affecting chromosomes 1, 2, 3, 6, 11, 16, 
21 and 22 coupled with MEN1 mutations, the clinical outcomes between the affected 
PNET subsets varied and warrant further investigation using a bigger cohort of PNENs 
at various stages. 
The clinical significance of the molecular changes identified among the PNENs 
sequenced in this study remains poorly understood, and to date, there are no known 
predictive biomarkers that are currently applicable in clinical practice. Aside from one 
case in which high expression of several RTKs and components of the MAPK pathway 
supported the use of sunitinib, genomic findings generally did not inform therapy 
decisions in real time. This was partly due to biopsy timing and relatively short disease 
course in three of the patients, as retrospective review suggested that the genomic 
results could potentially have informed treatment decisions. For the two patients who 
remained on follow-up at the completion of this study, high expression of SSTR2 would 
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support the use of PRRT with radiolabeled somatostatin analogs (Hicks et al., 2017). 
Alternatively, four of the PNENs in this cohort had low expression of MGMT which may 
suggest their sensitivity to temozolomide-based regimens (Cros et al., 2016; Kulke et al., 
2009). One of these cases (Case 2) indeed demonstrated exceptional response to 
Cap/Tem. The other three cases, however, were not treated with temozolomide, but the 
one case with normal MGMT expression (Case 4) did not respond to temozolomide. 
Comparisons of the initial five and four additional POG PNENs to primary PNEN 
specimens from Chapter 2 showed stronger correlations with the Alpha cell-like 
subgroup. As mentioned in Chapter 2, the Alpha cell-like subgroup shared molecular 
characteristics of the A-D-M mutant and the Type A subtypes of PNETs with high ARX 
expression and/or transcriptomic similarity to pancreatic α-cells. These two subtypes 
were associated with a reduced recurrence-free or relapse-free survival rate (Cejas et 
al., 2019; Chan et al., 2018) and therefore a higher chance of refractory or metastatic 
disease. While I could not compare the recurrence-free or relapse-free survival rates 
between different PNEN subgroups in Chapter 2 due to limitations in available clinical 
data, the POG program generally enrolls metastatic, treatment-refractory cancer 
patients. Consequently, the POG PNENs may be inherently associated with a greater 
relapse rate explaining the higher correlation to the Alpha cell-like subgroup and in line 
with previous reports associating ARX-high PNETs with greater disease recurrence or 
relapse. 
Four of the POG PNENs characterized with MEN1 and DAXX alterations as well 
as high ARX expression demonstrated considerably higher transcriptomic similarity to 
the Alpha cell-like subgroup specimens. In all of these cases, recurrent LOH or loss 
could be observed in chromosomes 1, 2, 6, 10, 16 and 22 (Figure 3.2) as in the 
previously reported Group 1 subtype, T2 subtype and Subtype A (Boons et al., 2020; 
Lakis et al., 2021; Lawrence et al., 2018). Therefore, there is a possible relationship 
between concurrent MEN1 and DAXX alterations, a pancreatic α-cell-like GEP including 
elevated expression of ARX, and recurrent LOH or loss of chromosomes 1, 2, 6, 10, 16 
and 22. While further analysis combining specimens across studies for comparison is 
needed, the similar features shared by one subtype/subgroup across studies provides 
strong evidence that these studies have descended on the same subtype/subgroup of 
PNENs. 
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PNENs are associated with highly heterogeneous clinical outcomes and 
treatment sensitivities. The in-depth whole-genome and transcriptome analyses of the 
initial five cases demonstrated a number of shared and unique molecular aberrations 
that contribute to this observed heterogeneity. Transcriptomic comparisons with the 
primary PNENs suggested that the molecular characteristics observed in the four 
proteotranscriptomic subgroups were, at least partially, evident in PNEN metastases. 
And, the gene signatures from the proteotranscriptomic subgroups could be potentially 
employed to infer the molecular characteristics of a given PNEN. It is also worth 
mentioning that all 9 cases displayed an unique enrichment profile emphasizing the 
molecular heterogeneity of PNENs. Interestingly, a few of the POG PNENs adopted 
GEPs of hybrid subgroup gene signatures. This could point to a limitation in my 
subgrouping system due to the absence of metastasis specimens in the initial 
proteotranscriptomic subgroup identification process, or due to PNEN metastases 
embracing more composite GEPs. Further molecular analyses of metastatic PNENs with 
associated treatment and outcome information will be critical to improve our 
understanding of the prognostic and predictive implications of the various molecular 
features. 
3.4. Methods 
 Sample collection and processing 
Patients provided written informed consent for metastatic biopsies, sequencing, 
and publication of results as part of the POG program at BC Cancer (ClincalTrials.gov; 
NCT02155621). This study was approved by the UBC Clinical Research Ethics Board 
(H12-00137). 
Following informed consent, patients underwent image-guided metastatic 
biopsies as part of the POG program at BC Cancer (ClincalTrials.gov; NCT02155621). 
As per protocol, biopsies could be undertaken at any time up to disease progression on 
first-line systemic therapy. Up to five biopsy cores were obtained using 18~22G biopsy 
needles and embedded in optimal cutting temperature compound. Tumour sections were 
reviewed by a pathologist to confirm the diagnosis, evaluate tumor content and 
cellularity, and select areas most suitable for DNA and RNA extraction. Peripheral 
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venous blood samples were obtained at the time of biopsy and leukocytes isolated for 
use as a germline reference. 
 Sequencing and Bioinformatics 
DNA and RNA were extracted for genomic and transcriptomic library 
construction, which has been previously described in detail (Sheffield et al., 2015). 
Paired-end reads of 125 bp in length were generated on an Illumina HiSeq2500 
sequencer and aligned to the human reference genome (GSCh37, available from 
http://www.bcgsc.ca/downloads/genomes/9606/hg19/1000genomes/bwa_ind/genome) 
by the BWA aligner (v0.5.7) (Li and Durbin, 2009). Somatic SNVs and Indels were 
processed using SAMtools (Li et al., 2009) and Strelka (v0.4.6.2) (Saunders et al., 
2012). Regions of copy-number variations (CNV) were determined using CNASeq 
(v0.0.6) and LOH by APOLLOH (v0.1.1) (Ha et al., 2012). Tumour content and ploidy 
models were estimated from sequencing data through analysis of the CNV ratios and 
allelic frequencies of each chromosome. This was then compared to in-house theoretical 
models for different ploidy at various tumour contents. Tumour content and sequencing 
coverage as well as the estimated ploidy for each case are provided in Table 3.5. SVs 
were detected by de novo assembly of tumour reads using ABySS and Trans-ABySS 
(Robertson et al., 2010), followed by variant discovery using DELLY (Rausch et al., 
2012). RNA-seq reads were processed and gene expression analyzed as previously 
described in (Sheffield et al., 2015). 
Table 3.5. Tumour content and sequencing coverage for the five metastatic 
PNENs. 
Case 
WGS coverage – 
Tumour 
WGS coverage – 
Normal 
RNA-seq coverage 






78X 41X 192M 79% 2 
Case 
2 
94X 47X 246M 79% 2 
Case 
3 
89X 42X 289M 77% 2 
Case 
4 
87X 42X 187M 79% 4 
Case 
5 
91X 43X 116M 86% 2 
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 Gene expression analysis 
In the absence of matched normal transcriptome data, the level of expression of 
each gene was determined as the number of reads per kilobase of transcript per million 
mapped reads (RPKM) and compared to a compendium of 16 normal transcriptomes 
from the Illumina BodyMap 2.0 project (https://www.ebi.ac.uk/gxa/experiments/E-MTAB-
513/Results). Differential expression analysis between tumor and the normal 
compendium was performed as previously described (Sheffield et al., 2015). Up-
regulated genes were defined as those with a fold change (FC) > 4 and a p.FDR < 0.05; 
down-regulated genes were defined as those with FC < −2 and a p-value < 0.1. 
Expression levels of select genes were converted into percentile ranks against a 
compendium of 5976 tumor transcriptomes across 25 cancer types from the TCGA 
project. KEGG signaling pathway gene set enrichment analysis was performed using the 
gage R package (Luo et al., 2009). Upstream regulator analysis was performed using 
Ingenuity Pathway Analysis to predict the activation/inhibition states of G-protein-
coupled receptors, ligand-dependent nuclear receptors, transcription regulators, kinases, 
and phosphatases from the list of differentially expressed genes (Krämer et al., 2014). 
To increase prediction confidence, only candidates with activation scores > 3 or <−3 
were selected. Molecular targets of drugs mentioned in this study were retrieved from 
Santos et al. (2017). 
For comparisons with RNA-seq data from Chapter 2, TPM values from protein-
coding genes were used. Correlation analyses were performed using Spearman’s rho, 
and GSVA analyses were performed using log2-transformed TPM values. DEGs 
exclusively over-expressed in a subgroup (ie. subgroup signature genes) were used to 
construct the reference gene signature for the subgroup. 
 Sequencing result visualization 
LOH events and CNAs were illustrated using the R package GenVisR (Skidmore 
et al., 2016). Heatmaps were generated using the R packages ComplexHeatmap (Gu et 
al., 2016) and gplots. 
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 Data deposition and access 
Sequencing data were deposited in the EGA as part of the study 
EGAS00001001159, accession IDs EGAD00001003048, EGAD00001003089, 
EGAD00001002591, EGAD00001003069 and EGAD00001002607. The variants 
reported were deposited in the ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) database 
with the following accession numbers: MEN1 c.1579C>T (SCV000611142), 
c.245_259delACCTGTCTATCATCG (SCV000611144), c.798+1G>A (SCV000611149), 
c.981_1006delCCACTGTCGCAACCGCAATGTGCGGG (SCV000611152); DAXX 
c.1178delA (SCV000611143), c.329_330delCT (SCV000611145), c.850C>T 
(SCV000611150), c.801_824delTAACAGGCGCATTGAGCGGCTCAT 
(SCV000611153); ATRX c.1558G>T (SCV000611146); MTOR c.6625C>G 
(SCV000611147); BRCA2 c.3504G>T (SCV000611148); TP53 c.818G>T 
(SCV000611151). 
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Chapter 4.  
 
Conclusions and future directions 
PNENs are a group of rare pancreatic neoplasms with immense clinical, 
pathological and molecular heterogeneity. Increasing awareness of this disease has led 
to rising research interests in its etiology and pathology, yet the links between their wide-
ranging clinicopathological presentations and diverse molecular characteristics remained 
fragmented. The drivers of PNEN development also remained elusive in some cases. In 
this thesis, I aimed to address these knowledge gaps by identifying potential pathogenic 
alterations in PNENs and elucidating connections between clinicopathological and 
molecular attributes of PNENs. Additionally, I investigated a potential molecular 
classification to help establish the basis for novel therapeutic approaches to better the 
management of this disease. In this concluding chapter, I highlight select key findings on 
PNENs throughout my doctoral study and describe their contributions to the field of 
PNEN research with emphases on their potential clinical utility. In addition, I present my 
insights on current limitations and potential future research directions that will help to 
improve the management of PNENs as well as NENs in general. 
4.1. Novel alterations in PNENs 
Novel dysregulated pathways or processes were found in the PDX1-high, Alpha 
cell-like and Stromal/Mesenchymal subgroups, including potential Ras pathway 
activation, metabolic dysregulation and YAP1/WWTR1 activation, respectively. 
Additionally, a metastatic PNEN carried MYCN alterations that likely contributed to its 
pathogenesis. The specific biological and therapeutic implications of these potential 
oncogenic drivers are described here. 
 Activation of HRAS and NRAS in PDX1-high PNENs 
The RAS family of GTPases promotes oncogenic cellular functions through 
activation of signaling cascades including the mitogen-activated protein kinase (MAPK) 
pathway and the PI3K/AKT/mTOR pathway (Gimple and Wang, 2019). Three members 
of the family, KRAS, NRAS and HRAS, are proto-oncogenes frequently found with 
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activating mutations and promote tumour development in various cancer types (Akbani 
et al., 2015; Collisson et al., 2014; Muzny et al., 2012; Raphael et al., 2017a). From my 
analysis of primary PNENs, 11.4% (4 out of 35) of the specimens harboured genetic 
alterations potentially leading to RAS pathway activation. These included 3 PNETs with 
activating mutations in KRAS, NRAS or HRAS and another with a deleterious NF1 
mutation (Figure 2.15). Mutations in KRAS are rare in PNETs and, to my knowledge, 
there is no report of PNETs with mutant HRAS or NRAS except for a NRAS p.Q61R 
variant in the BON-1 NEN cell line (Vandamme et al., 2015) and a metastatic PNET with 
BRAF p.V600E variant that acquired an NRAS (p.Q61R) mutation after treatment with 
BRAF inhibitor vemurafenib (Raj et al., 2018). Aside from the KRAS-mutant case, all 
affected cases fell in the PDX1-high subgroup (Figure 2.15). Although only three of the 9 
PDX1-high PNENs harboured RAS pathway-activating mutations, gene expression-
based inference analysis identified higher activity of HRAS and NRAS in the PDX1-high 
subgroup suggesting a subgroup-wide dysregulation. This makes the potentially 
elevated RAS pathway activity a characteristic of the PDX1-high subgroup, which 
otherwise lacks obvious oncogenic drivers, and supplies a possible avenue for novel 
therapeutic intervention. Considering other groups had similarly reported PNET subtypes 
with high PDX1 expression, and the PDX1-high subgroup expresses higher levels of 
PDX1, it would be interesting to investigate potential connections between PDX1 and the 
RAS pathway in PNENs. The RAS pathway has been one of the most sought-after 
targets in anti-cancer therapeutics, and multiple inhibitors that have been approved for 
other indications or in clinical trials can be exploited to curb the activity of specific RAS 
protein variants, the MAPK pathway or the PI3K/AKT pathway (Moore et al., 2020). The 
identification of a subgroup of PNENs with elevated RAS pathway activity and high 
PDX1 expression carries potential classification and therapeutic utility. A validated 
connection between PDX1 expression, RAS pathway activation and possible 
susceptibility to RAS pathway inhibition could be explored to facilitate selection of 
patients with PNEN for RAS-targeting therapeutic options. 
 Activation of Hippo signaling pathway effectors in 
Stromal/Mesenchymal PNENs 
The Hippo signaling pathway elicits downstream effects through transcription 
coactivators YAP1 and WWTR1. In mammals, a kinase module comprising 
serine/threonine kinase 3/4 (STK3/4) and large tumor suppressor kinase 1/2 (LATS1/2) 
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acts downstream of NF2 and phosphorylates YAP1 and WWTR1 for cytoplasmic 
retention and degradation thereby inhibiting the transcription of genes mediated by 
YAP1/WWTR1 (Hansen et al., 2015). The Hippo signaling pathway is an emerging 
subject in cancer research, but its roles and implications in PNENs have never been 
described. Known mechanisms leading to dysregulation of YAP1/WWTR1 include 
mutations in upstream regulators such as LATS1/2 and NF2 in mesothelioma and 
amplification of YAP1 and WWTR1 in squamous cell carcinomas (Wang et al., 2018). 
Mutations in YAP1 or WWTR1 are rare (≤ 3% of all cancers) and include inactivating as 
well as activating mutations across cancers (Wang et al., 2018). IHC analyses revealed 
elevated YAP1/WWTR1 nuclear staining in cancer cells across multiple cancer types, 
suggesting YAP1/WWTR1 activation is not uncommon in cancer (Zanconato et al., 
2016).  
My identification of a Stromal/Mesenchymal subgroup of PNENs with the first 
molecular evidence of aberrant activation of YAP1/WWTR1 will hopefully spur interest in 
further investigating the roles of the Hippo signaling pathway in the context of PNENs. 
Also, the upstream alterations leading to YAP1/WWTR1 activation in PNENs remain 
elusive, and understanding the mechanisms by which YAP1 and WWTR1 are aberrantly 
activated in PNENs can provide additional details on PNEN pathogenesis and potential 
means for patient selection for YAP1/WWTR1-targeting therapeutics. Given the 
Stromal/Mesenchymal subgroup of PNENs demonstrated higher activity of 
YAP1/WWTR1, inhibiting the downstream function of these transcription coactivators 
may achieve anti-tumour effects and become an additional targeted therapeutic option 
for PNENs with evidence of aberrant YAP1/WWTR1 activation. The Hippo signaling 
pathway regulates angiogenesis, and YAP1/WWTR1 expression promote endothelial 
cell proliferation and arrangements (Choi et al., 2015; Neto et al., 2018). Cell-type 
analysis suggested a higher endothelial cell proportion in the Stromal/Mesenchymal 
subgroup specimens which may have contributed to their elevated expression levels of 
YAP1/WWTR1. While it remains to be confirmed whether the higher expression and 
aberrant activation of YAP1/WWTR1 were restricted to tumour cells or due to endothelial 
cells, sunitinib, an existing agent that targets angiogenesis, achieves therapeutic 
benefits in PNETs (Raymond et al., 2011). Thus, suppressing the aberrant activities of 
YAP1/WWTR1 in either tumour or endothelial cells may be potentially effective in 
achieving anti-tumour effects in PNENs. Aberrant activation of YAP1/WWTR1 can lead 
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to dysregulated expression of genes associated with oncogenesis, including the target 
genes of the TEAD family of transcription factors (Liu-Chittenden et al., 2012; Ota and 
Sasaki, 2008; Zhao et al., 2008). As such, the YAP1/WWTR1-TEAD axis has gained 
enormous interest as a target to inhibit YAP1/WWTR1 function in cancer cells (Calses et 
al., 2019; Crawford et al., 2018). Although existing agents targeting the YAP1/WWTR1-
TEAD interaction either lack clear mechanism of action or lead to off-target effects such 
as oligomerization of proteins involved in other cellular processes (Calses et al., 2019), 
the interaction axis itself remains a potential target to inhibit YAP1/WWTR1 activity, and 
such a strategy could be similarly employed to target PNENs with evidence of elevated 
YAP1/WWTR1 activity. 
 Dysregulated metabolism involving arginine and glutamine in 
Alpha cell-like PNENs 
Metabolism represents one of the enabling cancer hallmarks in which cancer 
cells reprogram cellular energetics to sustain cell growth and proliferation (Hanahan and 
Weinberg, 2011). Interests in the field have led to explosive growth in our understanding 
and culminated in hallmarks of cancer metabolism including “deregulated uptake of 
glucose and amino acids” and “increased demand for nitrogen” (Pavlova and Thompson, 
2016). Yet, there is virtually no published work on the possible metabolic dysregulation 
in PNENs nor metabolic variations between PNENs. The Alpha cell-like subgroup of 
PNENs that I identified showcased enrichment of OxPhos genes on both mRNA and 
protein levels (Figure 2.10) and had higher abundance of proteins involved in arginine 
and glutamine/glutamate metabolism (Supplemental Table 2). The OxPhos process is 
tightly connected to the tricarboxylic acid (TCA) cycle, and the two modules act in a 
feedback loop that ultimately produces ATP (Martínez-Reyes and Chandel, 2020). 
Glutamine is a major anaplerotic substrate in cancer cells that fuels the TCA cycle and 
supplies nitrogen for biosynthesis required during cancer cell growth (Hensley et al., 
2013). Interestingly, glutaminolysis, the conversion of glutamine into α-ketoglutarate that 
involves GLS, is required for mTOR complex 1 (mTORC1) activation and downstream 
signaling that promotes cell growth (Durán et al., 2012; Jewell et al., 2015; Nicklin et al., 
2009). In the context of glutamine deficit, arginine can sufficiently activate mTORC1 
downstream signaling, though the activation mechanism remains to be investigated 
(Lowman et al., 2019). Given the Alpha cell-like subgroup exhibited higher abundance of 
glutamine/glutamate and arginine metabolic enzymes, the PNENs of this subgroup likely 
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had higher demands for these amino acids, and as such, may have higher mTORC1 
activation. In line with this hypothesis, the Alpha cell-like subgroup was the only 
subgroup with PNENs in which deleterious mutations were found in TSC1/2, upstream 
negative regulators of mTORC1 (Huang and Manning, 2008). 
A literature search identified only one conference abstract that describes 
metabolism-related work in PNENs. In that study, fresh tissue slices from 15 PNENs 
were treated with everolimus and subjected to transcriptomic profiling to identify potential 
molecular features of everolimus sensitivity/resistance. Apoptosis activation was 
evaluated based on IHC of caspase 3 (CASP3) for determining sensitivity or resistance 
to everolimus. Transcriptomic analysis identified enrichment of glycolytic signatures in 
the everolimus-resistant PNENs while everolimus-sensitive PNENs exhibited enrichment 
of OxPhos signatures. IHC analysis confirmed increased abundance of solute carrier 
family 2 member 1 (SLC2A1) and hypoxia inducible factor 1 subunit alpha (HIF1A) in the 
resistant specimens and mitochondrial respiratory chain components in the sensitive 
specimens (Cros et al., 2018). While the described work from this abstract is yet to be 
published (as of April 2021), the increased abundance of mitochondrial respiratory chain 
components and enrichment of OxPhos gene signature observed in their everolimus-
sensitive PNENs match the characteristics of the Alpha cell-like PNENs. Further, two of 
the four patients from the analyzed POG PNENs exhibiting substantial Alpha cell-like 
subgroup signatures, PN2 (Case 3) and PN12 (Case 1), were treated and their 
neoplasms responded to everolimus during their clinical course. Future research is 
needed to confirm whether the Alpha cell-like subgroup of PNENs indeed exhibits higher 
mTORC1 signaling and is sensitive to everolimus treatment. 
 Focal amplification of MYCN concomitant with a MCYN-driven 
transcriptomic signature in a metastatic PNEN 
The MYC family of transcription factors, including MYC, MYCN and MYCL 
(MYCL proto-oncogene, bHLH transcription factor), regulates the expression of a broad 
range of genes involved in a myriad of cellular processes, including ribosome 
biogenesis, DNA replication and inhibition of apoptosis, that contribute to cancer 
development (Dang, 2012). All three MYC family genes are proto-oncogenes. Myc 
overexpression promotes tumourigenesis in murine models (Dang, 2012), and MYC is 
frequently amplified across cancer types in human (Beroukhim et al., 2010). MYCN and 
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MYCL have tissue-specific expression patterns (Zimmerman et al., 1986) and are 
frequently amplified in neuroblastoma and small cell lung cancer, respectively (Huang 
and Weiss, 2013; Kim et al., 2016; Nau et al., 1985). Forced expression of Mycn and 
constitutively active Akt1 transforms prostate epithelial cells into metastatic 
neuroendocrine prostate cancer (Lee et al., 2016). In the context of PNENs, ectopically 
expressed MYCN induced PNEN development in animal models (Fielitz et al., 2016; 
Yang et al., 2004), but whether MYCN dysregulation contributes to PNEN development 
in human is unknown. The PNET-G2 with focally amplified MYCN from the POG 
program was the first instance of a human PNEN with evidence of MYCN amplification 
and resultant gene expression changes (Figure 3.3). While it is not possible to confirm 
the pathogenic roles of MYCN in this PNET, the absence of aberrations in PNET-
associated genes or other obvious genomic alterations sufficient to induce neoplastic 
transformation (Figures 3.2~3.3) suggested a potential oncogenic contribution from the 
MYCN amplification in this case. In addition, this particular case of PNET was found in a 
relative young individual (< 50 year-old; Dasari et al., 2017) with rapid disease 
progression (Figure 3.1). This rather aggressive disease course may be related to its 
MYCN-driven nature. Although the aggressive clinical course of this PNET was unlike 
the most PNETs, pathology reviews confirmed its PNET diagnosis. Experimental 
assessments are needed to ascertain whether MYCN serves as a proto-oncogene in the 
context of pancreatic islets and promotes tumour aggressiveness in PNENs. 
Murine studies showed MYC and MYCN are partially compensatory in functions 
yet are both required during development (Huang and Weiss, 2013) suggesting they 
have shared but also distinct transcriptional targets. In NEN-related studies, MYC has 
shown context-dependent roles. MYC promotes neuroendocrine marker expression and 
drug resistance in murine PDACs (Farrell et al., 2017) but induces neuroendocrine de-
differentiation in a Notch pathway-dependent manner in small cell lung cancer (Ireland et 
al., 2020). Similar to MYCN, the oncogenic roles of MYC in PNENs are largely unknown, 
but 81% of 21 PNETs in a study were found with moderate to high MYC IHC score 
despite lack of association with clinicopathological characteristics (Chang et al., 2017). 
MYC overexpression confers resistance to everolimus, and pharmacological inhibition of 
MYC reduced the viability of everolimus-resistant PNEN cells (Terracciano et al., 2020). 
This provides a potential therapeutic avenue to target PNENs intrinsically resistant to 
everolimus by interfering with MYC. It is therefore important to elucidate the functional 
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roles and potential differences between MYC and MYCN in PNENs as well as their 
possible contributions to treatment sensitivity and resistance. It had been recognized 
that MYC-induced transcriptional activation is facilitated by members of the 
bromodomain and extra-terminal (BET) subfamily of proteins, and inhibition of BET 
proteins down-regulate the expression of MYC as well as MYC and MYCN target genes 
providing anti-tumour effects in vivo (Delmore et al., 2011; Puissant et al., 2013). Several 
phase 1/2 clinical trials are currently in progress to investigate the anti-cancer effects of 
BET inhibitors (Shorstova et al., 2021). While the functional roles of the MYC family in 
the context of PNENs are yet to be elucidated, the lessons to be learned from the BET 
inhibitor trials could be exploited to potentially repurpose those agents for PNENs with 
molecular evidence of MYC contribution. 
4.2. Emerging molecularly based classifications 
Traditional cancer classification systems such as the WHO Classification of 
Tumours project (Kleihues and Sobin, 2000) build upon clinical observations and 
experience of a given cancer type to guide the management of newly diagnosed patients 
with the same cancer type. This typically involves histopathological assessments of the 
tumours and has been the standard approach to classify tumours in order to facilitate 
clinical management of cancer patients, including those with PNENs (Kulke et al., 
2010b; Nagtegaal et al., 2020). However, this traditional classification approach for 
PNENs is becoming insufficient as we begin to appreciate the vast clinical and 
pathological heterogeneity of these neoplasms. This problem is particularly evident from 
the generally poor responses to treatments observed in patients with PNENs despite 
basing treatment decisions on the recommendations surrounding the WHO classification 
of PNENs (Kunz et al., 2018; Li et al., 2020; Raymond et al., 2011; Sorbye et al., 2013; 
Yao et al., 2011). In conjunction with the lack of predictive biomarkers for PNENs to 
inform possible therapeutic regimens, a new approach to classify PNENs is imperative. 
With an increasing number of molecular studies as well as targeted therapeutic 
agents surfacing over recent years, a new era of a molecularly guided classification 
approach to achieve more effective and precise management regimens for cancer 
patients seems imminent. In fact, clinical practices or ongoing initiatives have been 
harnessing the predictive utility of validated biomarkers or molecular data to inform 
therapeutic regimens. These include using single gene biomarkers such as MGMT, in 
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which promoter methylation or low expression confers sensitivity to temozolomide (Cros 
et al., 2016; Hegi et al., 2005; Kulke et al., 2009) and BRCA1/2, in which mutations 
confer sensitivity to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition 
(Golan et al., 2019; Robson et al., 2017), to identify therapeutic agents that are likely to 
result in a tumour response. A number of ongoing projects adopt a precision medicine 
approach which utilizes a tumour’s unique sequencing data to identify its therapeutic 
vulnerabilities. Examples of such strategies include the POG program at BC Cancer 
(Laskin et al., 2015), the CAPTUR trial taking place across Canada (Skamene et al., 
2018), the OncoTreat platform at Columbia University Irving Medical Center (Alvarez et 
al., 2018) and the MSK-IMPACT test at Memorial Sloan Kettering Cancer Center (Cheng 
et al., 2015). While these projects adopt different methodologies, they all engage a 
basket trial approach which sanctions the use of targeted therapeutic agents based on 
molecular evidence of treatment susceptibility, irrespective of the type of cancer in 
question. This transition towards using molecular evidence to support and inform 
treatment decisions can be similarly exploited for the classification and management of 
PNENs. The addition of molecular level data to cancer classification indirectly addresses 
the issues surrounding the clinicopathological heterogeneity of PNENs by identifying 
shared molecular characteristics and molecular aberrations suitable as therapeutic 
targets in PNENs regardless of their clinicopathological characteristics. 
In Chapter 2, I used an unbiased approach to identify four subgroups of PNENs 
with distinct transcriptomic and proteomic profiles. The proteotranscriptomic subgroups 
demonstrated different mutational frequencies in genes associated with PNENs and 
variations in GEPs suggestive of different oncogenic drivers. Previous studies had 
attempted to classify PNENs using miRNA expression profiles, GEPs, CNVs and/or 
epigenomics, but the identified subtypes were limited to having prognostic significance 
and were either largely inconsistent or not comparable between studies. By coupling 
transcriptomic and proteomic variations, I confirmed an Alpha cell-like and a PDX1-high 
PNEN subgroup sharing features with previously described subtypes (Boons et al., 
2020; Cejas et al., 2019; Chan et al., 2018; Di Domenico et al., 2020; Lakis et al., 2021; 
Lawrence et al., 2018). Moreover, I identified a Proliferative subgroup comprising 
PNENs with molecular characteristics suggestive of a higher proliferation (Figures 
2.10~13 and 2.15; Table 2.2) and a Stromal/Mesenchymal subgroup of PNENs with 
novel implication of the Hippo signaling pathway (Figure 2.16). Applying my subgroup 
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classification to PNEN metastases confirmed select subgroup molecular characteristics 
but also reaffirmed the molecular heterogeneity of PNENs. Most notably, three of the 
subgroups that I identified exhibited certain dysregulated pathways or processes that 
may be exploited for novel therapeutic interventions, as discussed above. 
Among the four proteotranscriptomic subgroups, the Proliferative subgroup was 
the only subgroup associated with known clinicopathological characteristics, including 
enrichment of PNECs. However, roughly half of the subgroup was PNETs. The 
conventional belief dictates that PNECs and PNETs are two independent entities and 
should be considered and managed differently (Kulke et al., 2010b; Kunz, 2015; 
Strosberg et al., 2010). My observation of a molecular subgroup comprising both PNETs 
and PNECs raises an important question surrounding this assumption. If a small subset 
of PNETs is genuinely more similar to PNECs than other PNETs on the molecular level, 
should PNETs and PNECs truly be considered distinct simply based on their differences 
in histological differentiation? While genetic differences between PNETs and PNECs had 
been previously reported (Yachida et al., 2012), and PNECs are more likely to respond 
to platinum-based therapy (Moertel et al., 1991), some PNETs were also found to 
harbour mutations in PNEC-associated genes: KRAS, TP53 and RB1, albeit at lower 
frequencies (Vijayvergia et al., 2016). Similarly, the only PNEC (PN4; Case 5) among 
the 9 POG PNENs that I examined in Chapter 3 harboured mutations in PNET-
associated genes, MEN1 and DAXX, but not in PNEC-associated genes, TP53, KRAS 
or RB1 (Table 3.5; Supplemental Table 9). These findings suggest some PNENs share 
molecular characteristics despite histological differences. In line with this argument, four 
of the POG PNENs analyzed in Chapter 3 presented with different histopathological 
characteristics yet all elicited a substantial degree of the Proliferative subgroup signature 
(Table 3.4; Figure 3.7). The addition of molecular evidence could augment 
histopathological assessments to better classify PNENs and predict whether a given 
neoplasm is likely to respond to a certain treatment. 
4.3. Expanding to other NENs 
NENs can arise from neuroendocrine cells found in most tissues and are 
categorized based on their organ of origin. However, NENs are perceived as distinct 
entities from their non-neuroendocrine counterparts arising from the same organ. Such 
distinction is reflected in the most recent WHO classification system which distinguishes 
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NENs in each organ-specific chapter (Nagtegaal et al., 2020). The current official 
nomenclatures for NENs in each primary anatomical site (PAS) differ due to historical 
conventions, and terminologies like “carcinoid” are still being used to refer to well-
differentiated pulmonary NENs. That being said, clinically relevant features such as 
histological differentiation and proliferative indices are similarly used in NENs across 
different PASs for prognostic and therapeutic utility (Nagtegaal et al., 2020; Raphael et 
al., 2017b). An example of this is the use of platinum-based therapy for NECs of GI, 
pancreas and lung origin (Evans et al., 1985; Moertel et al., 1991). Generally, tumour 
grades based on proliferative indices are highly prognostic, but the presence of distant 
metastases remains the top contributor to inferior survival outcomes for patients with 
NENs (Dasari et al., 2017). 
A recent initiative by international NEN experts proposed a consensus 
classification framework for NENs across different PASs (Rindi et al., 2018). This 
suggestion came in the wake of the various terminologies adopted for NENs of different 
PASs that are potentially confusing for interdisciplinary communication. The proposed 
consensus classification system largely resembled the current WHO classification for 
PNENs where a dichotomized histological definition distinguishes NETs from NECs. 
Similar to those of pancreatic origin, NETs were further classified into G1-3 based on 
proliferative index, and NECs may be of SC or LC type (Rindi et al., 2018). The 
nomenclatures from this proposed classification system is adopted hereafter for 
convenience. 
Despite the initiative to consolidate and standardize the terminologies and some 
shared management regimens already in clinical practice for NENs across PASs, the 
vast majority of molecular studies to date have focused on primary NENs of certain 
PASs. Further, organ-specific NEN studies have identified molecular subtypes among 
NENs of pancreatic origin (as described in Chapter 2 and summarized in Section 1.4.4), 
pulmonary origin (Ireland et al., 2020) and the small intestine (Karpathakis et al., 2016). 
Yet, similar genetic alterations have been observed in NENs of different PASs. PNENs 
and pulmonary NENs, for example, share several mutational characteristics. MEN1, 
which is recurrently mutated in up to 56% of PNETs and rarely altered in PNECs, was 
found mutated in 13.6% of pulmonary NETs but not in pulmonary NECs. Similarly, 
tumour suppressors TP53 and RB1 that are frequently altered in PNECs were found 
recurrently altered in pulmonary NECs (26~98%) but rare in pulmonary NETs (< 5%) 
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(Fernandez-Cuesta et al., 2014; George et al., 2015; Jiao et al., 2011; Miyoshi et al., 
2017; Scarpa et al., 2017; Yachida et al., 2012). In addition to genetic alterations, 
aberrations that affect signaling pathways such as the PI3K/AKT/mTOR pathway have 
been identified in both small intestinal NENs and pulmonary NECs-LC (Karpathakis et 
al., 2016; Miyoshi et al., 2017). Together, these observations suggest that despite vast 
heterogeneities among NENs of the same PASs, some NENs of different PASs share 
molecular features. 
To explore potential commonalities and distinctions in the molecular profiles of 
NENs originating from different PASs, I conducted a preliminary analysis utilizing 
existing molecular data available from the POG program. I identified a total of 29 NENs 
(including the 9 PNENs explored in Section 3.5) enrolled in the POG programs with 
available WGS and WTS data. A consensus hierarchical cluster analysis, using 
Spearman’s correlation calculated from the top 25% variably expressed RNAs between 
the samples, identified 3 hierarchical clusters, one of which may be further divided into 
two or three subclusters (Figure 4.1; green, red and orange at k = 5). One cluster 
consisted exclusively of pulmonary and thyroid NENs, and another contained mostly 
NECs or MiNENs with or without high Ki67 indices. The third cluster consisted of mostly 
NETs of pancreas or small intestine origin but also a few pulmonary/thyroid NETs and a 
NET originated from neck (Figure 4.1). For the majority of the cohort, biopsies from 
distant metastases were sequenced, and NENs of different PASs have distinct 
metastatic patterns (Hermans et al., 2020), so the biopsy sites were correlative with the 
PASs. Overall, the results suggest the clustering structure was largely associated with 
PASs/biopsy sites and grade or histological differentiation status. However, it is also 
evident that there are potential transcriptomic features not reflected in the 
clinicopathological characteristics as a few of the samples clustered away from others 
sharing the same PASs, grades or histological differentiation status. While this is a 
preliminary piece of data, it highlights the importance of elucidating potential 
commonalities and distinctions on the molecular level between NENs of different PASs. 
A comprehensive analysis of a large cohort with NENs of different PASs and various 
clinicopathological characteristics would provide valuable knowledge to better assess 
the adequacies of the current organ-specific practice in NEN management. 
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Figure 4.1. Consensus hierarchical clustering result of the POG NENs. 
Consensus hierarchical cluster analysis was performed using Spearman’s correlation for 1000 
iterations. An optimal cluster solution was achieved at k = 3 (top dendrogram), after which there 
were relatively smaller changes in area under the consensus distribution function curves. The 
cluster solutions at k = 4 and 5 are shown for comparison. Where available, the available 
clinicopathological data and estimated tumour content are shown as coloured boxes with legends 
at the bottom. White boxes denote missing information. 
4.4. Concluding remarks 
Considerable clinical, translational and basic research advances in PNENs have 
led to improved detection, increased number of therapeutic options and better molecular 
understanding of this disease. However, the current cancer classification system and 
effective treatment regimens are still inadequate as demonstrated by the low treatment 
response rates and the lack of predictive markers to facilitate therapeutic decisions. In 
addition, putative drivers of PNEN development are unknown in a substantial number of 
cases. In Chapter 2, I show that PNENs can be stratified into four molecular subgroups 
characterized by mutational, transcriptomic and proteomic distinctions. Whereas other 
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therapeutic vulnerabilities suitable for clinical interventions in my subgroups. Due to the 
rarity of PNENs and heterogeneous nature of the disease, additional validation analyses 
using larger and international patient specimen cohorts are needed to affirm the 
applicability of my subgroup stratification system. Also, functional validation of subgroup-
specific features, such as arginine/glutamine metabolism and YAP1/WWTR1 activity, 
could provide preclinical evidence for establishing novel therapeutic avenues for PNENs. 
This may entail genetic and pharmacological modulation of key factors of a cellular 
pathway/process of interest in cell line, patient-derived spheroids/organoids and 
genetically engineered mice. Experimental studies investigating select subgroup 
molecular characteristics are in the works. 
Throughout Chapters 2 and 3, novel oncogenic events were identified in genes 
or pathways already implicated or utilized as therapeutic targets in other cancer types. 
The discoveries of these oncogenic contributors provide additional insights into the 
pathogenesis of PNENs and suggest potential for repurposing therapeutic agents 
approved for other cancers to be used for PNENs. This argument advocates the 
emerging precision medicine initiatives that leverage molecular evidence to aid 
therapeutic decision-making for patients with PNENs. 
PNENs are heterogeneous yet may share molecular features with 
extrapancreatic NENs. The data and results from this thesis may help to foster the 
molecular understanding and clinical management of NENs in general. My findings 
herein provide a sizable contribution to the NEN field towards better clinical outcomes for 
patients with NENs. 
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Supplemental Data File 
The following files can be found in the Appendix file “Supplemental Data File.xlsx”. 
Supplemental Table 1. Clinicopathological and subgroup information for each of the 84 
PNENs in the Discovery and Validation cohorts. List of sample identifiers, clinical and 
pathological characteristics, and the cohort and subgroup assignment for each of the 84 
cases of PNENs included in this study. 
Supplemental Table 2. The list of DEGs and DAPs and their differential expression or 
abundance analysis statistics. The Accession column refers to the Ensembl Gene ID (for 
mRNAs) or the UniProt Accession ID (for proteins) of each gene entry. 
Supplemental Table 3. The mRNA- and protein- based gene set enrichment results for 
the complete list of MSigDB Hallmark gene sets. Includes mRNA-based results from the 
Discovery and Validation cohort specimens, and protein-based results from the 
Discovery cohort specimens. 
Supplemental Table 4. Significantly over-represented pathways from SPIA results. Only 
over-represented pathways with adjusted p-value less than 0.05 are shown, and the 
status of a pathway is indicated as activated or inhibited based on topology score and p-
value threshold of 0.05. 
Supplemental Table 5. The mRNA- and protein- based gene set enrichment results for 
the cellular components gene ontologies. Only ontologies with an FDR-adjusted p-value 
less than 0.05 in either mRNA- or protein- based analysis are included. 
Supplemental Table 6. TFEA results from ChEA3Only the top 10% ranked transcription 
factors are included. 
Supplemental Table 7. Filtered variants in cancer-related genes identified from each of 
the Discovery cohort specimens. 
Supplemental Table 8. VIPER results. Only regulators with an FDR-adjusted p-value 
less than 0.05 in at least one subgroup are shown. 
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Supplemental Table 9. Somatic sequence variants identified from each of the five 
metastatic PNEN cases. 
Supplemental Table 10. KEGG pathway enrichment results for each of the five 
metastatic PNEN cases. 
Supplemental Table 11. RNA expression and comparison of select genes of interest for 
each of the five metastatic PNEN cases. 
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